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Alzheimer's Disease (AD) is a progressive, age-related disease that is positively
characterised by the post-mortem presence of neurofibrillary tangles and amyloid plaques.
At present ~ 5 % of those aged over 65 years are diagnosed with AD, with this figure
increasing to ~ 20 % for those aged over 75 years. It is nearly 100 years since AD was first
characterised in 1907, however the exact cause has yet to be determined with the cholinergic
and beta-amyloid (Ap) hypotheses remaining central to the aetiology. The cholingergic
hypothesis suggests that loss of the cholinergic pathways precedes that of any other
neurotransmitter making it a primary target in AD and predating the amyloid hypothesis
which itself postulates that deposition of Ap is primarily responsible for the
neurodegeneration in AD. Until recently, these two hypotheses have been almost
exclusively studied in separation. However, recent studies suggest that the two major CNS
cholinergic nicotinic acetylcholine receptor subtypes a4p2 and a7 may interact directly with
Ap and therefore, a multidisciplinary approach has been used to evaluate the reported
interaction.
Radioligand binding was used to characterise the a4p2 nAChR ([3H]-epibatidine
and [3H]-cytisine) and a7 nAChR ([3H]-methyllycaconitine ([3H]-MLA) and [3H]-
aBungarotoxin ([3H]-aBgTx)) in rat and mouse brain tissue and in SH-EP1 cell lines
overexpressing human forms of the a4p2 or a7 nAChRs. No species difference in ligand
affinities were observed for the a4p2 nAChR. In contrast, nicotinic agonists exhibited
significantly higher affinity (-100 fold) for human a7 nAChRs compared to their rat
counterparts with no change in antagonist affinity. Interestingly, evaluation of [3H]-MLA
and [3H]-aBgTx binding indicated the latter ligand bound to a restricted number of sites on
the a7 nAChR. Furthermore, neither human nor rat Ap,.42 inhibited [3H]-cytisine or [3H]-
MLA binding to nAChRs. In parallel to behavioural studies, these binding assays were also
employed to assess nAChR pharmacology in transgenic a7 knockout mice. With no
alteration in a4p2 nAChR pharmacology, the deficit in sustained attention exhibited by these
a7-KO mice is probably due to loss of the a7 nAChR.
Finally, a series of studies was performed to examine the functional interaction
between APi_42 and nAChRs. (-)Nicotine evoked changes in calcium flux or membrane
potential in SH-EPl-ha4p2 cells were not inhibited by soluble or insoluble human AP]_42.
Even whole cell patch clamp analysis of single cells showed no direct interaction between
the a4p2 nAChR and APi_42. The examination of the functional interaction between a7
nAChRs and APi_42 using whole cell patch clamp or fluorescence based assays was
compromised by a lack of consistent expression of functional human a7 nAChRs in the SH-
EP1 cell line. In addition, neither human a4p2 nor a7 nAChRs co-immunoprecipitated with
human ApM2.
In conclusion, using a systematic multidisciplinary approach incorporating
functional and non-functional assays the following major observations were made (1)
species differences in a7 but not a4p2 nAChR pharmacology, (2) the two a7 nAChR
antagonists MLA and aBgTx differ in their ability to bind the a7 homopentamer, (3)
removal of the a7 nAChR does not alter a4p2 nAChR pharmacology in transgenic mice (4)
neither soluble or insoluble APi_42 interacted in pharmacological, functional, or biochemical
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Alzheimer's Disease (AD) was first characterised by Alois Alzheimer in 1907 and
it is estimated that there are more than 25 million suffers worldwide (Wimo et al., 2003).
With the growing tendency towards an aging demographic, it appears likely that these
figures will rise in the near future. At present approximately 5 % of those aged over 65 years
are diagnosed with AD, with this figure increasing to approximately 20 % for those aged
over 75 years. Consequently, AD is a serious problem for healthcare authorities worldwide
(Sloane et al., 2002; Leung et al., 2003; Sadik et al., 2003).
1.1.1 Familial and Sporadic Alzheimer's Disease
Alzheimer's disease is routinely divided into two distinct types based upon age of
onset. Familial AD (FAD, or early onset AD) is classified on the basis of age, with onset
generally being less than 65 years of age and with family history being a distinct risk factor
(Hirst et al., 1994). In contrast, the vast majority are late-onset cases (over 65 years of age at
time of onset) and are classified as sporadic AD (Ling et al., 2003). With the exception of
the earlier onset (and for some patients a shorter disease duration), FAD is pathologically
indistinguishable from sporadic or non-FAD.
FAD is transmitted as an autosomal-dominant trait with at least 3 recognised
genetic loci (Bertram et al., 2004). The first gene mutation identified was at position 717 on
the amyloid precursor protein (APP), occurring as a consequence of a substitution of a valine
for an isoleucine (Goate et al., 1991). Further mutations within the APP gene have also been
reported including but not limited to APP717vai-giy, APP717vai.phc, and the APP67o/67i (APPswe)
mutations, with the latter identified in a Swedish family which resulted in a double mutation
at residues 670 and 671 of the APP gene (Chartier-Harlin et al., 1991; Mullan et al., 1992).
Despite the number of mutations identified in APP, these account for only 5-10
% of FAD pedigrees (Strittmatter et al., 1996; Lendon et al., 1997). The more common
FAD mutations are linked to the presenilins (PS), transmembrane proteins primarily
localised to the endoplasmic reticulum of cells throughout the body with Schellenberg and
colleagues (1992) finding many early onset pedigrees mapped to chromosome 14. The
causative genes, PS1 and PS2, were subsequently cloned and the PS1 gene is now known to
have in excess of 45 individual mutations while at least 2 mutations have been identified for
PS2 (Levy-Lahad et al., 1995; Schellenberg, 1995; Cruts et al., 1996; Dewji, 2005). A
fourth gene locus, the e4 allele of apolipoprotein E (ApoE), has also been identified as
having a causal link in AD (Strittmatter et al., 1996; Poirier, 2005). Apolipoprotein E has 3
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naturally occurring alleles, s2, e3, and e4 which differ from each other by a single codon
(Strittmatter et al., 1996). Interestingly, the e4 allele is substantially overexpressed in AD
patients when compared to control subjects and as such is associated with an increased risk
of both familial and sporadic AD (Strittmatter et al., 1996; Farrer et al., 1997; Horsburgh et
al., 2000).
1.1.2 Clinical Characteristics of Alzheimer's Disease
Alzheimer's Disease is characterised by an irreversible, progressive
neurodegeneration of the central nervous system (CNS), that is associated with a gradual
decline in cognitive function (Selkoe, 1990; Teplow, 1998). Clinically, AD is difficult to
truly define as patients in the early stages of the disease often present with only slight
problematic memory loss, (usually manifesting as an inability to recall recent events or
encode some (but not all) new memories), but have otherwise normal neurological function
(Rossor et al., 1996; Backman et al., 2004). Typically, over a period of months sufferers
continue to lose short-term (working) memory and then gradually episodic (memory for past
and personally experienced events) and semantic memory (knowledge for the meaning of
words and how to apply them) (Tulving et al., 1990; Rossor et al., 1996).
In the late stages of AD, multiple cognitive and behavioural symptoms are
observed including sudden involuntary jerking movements as well as orientation and
language difficulties (Romanelli et al., 1990; Morris et al., 1991; Rossor et al., 1996). The
average lifespan from time of AD diagnosis is 7 - 10 years making it a long process for both
the patient and their family (Australian Alzheimers Association, 2000).
Clinical heterogeneity is a common feature of neurological disease in general and
as such, a positive AD diagnosis can only be determined at autopsy (Dickson, 1997a).
Neurodegeneration and synaptic loss, activation of microglia and astrocytes, and increased
levels of inflammatory mediators are all observed in the AD brain (Akiyama et al., 2000a,b).
In addition, AD patients have an increased incidence of cerebro-vasculature disease, possibly
related to the deposition of amyloid protein on the vasculature walls (Ray et al., 1998).
However, the AD brain has two distinguishing pathological features; neurofibrillary tangles
and neuritic (senile) plaques (Katzman, 1986; Dickson, 1997a), which are discussed in more
detail below.
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1.1.3 Histopathological Characterisation of Alzheimer's Disease
1.1.3.1 Neurofibrillary Tangles
Neurofibrillary tangles (NFTs) are composed primarily of microtubule associated
protein (MAP) tau and constitute intracellular deposits within the cell bodies of neurons
and/or glia (Iqbal et al., 2005). Tau, MAPI, and MAP2, the major microtubule associated
proteins in the normal mature neuron, promote the assembly and stability of microtubules
(Weingarten et al., 1975; Lindwall et al., 1984; Iqbal et al., 2005). Microtubules themselves
are essential for axonal transport and consequently neuronal activity (Iqbal et al., 2005). In
the human brain, there are six known isoforms of tau, generated from a single gene by
alternative mRNA splicing (Goedert et al., 1989). These isoforms differ by the presence or
absence of a 29 or 58 amino acid (aa) insert in the amino terminal and by the presence or
absence of a 31 aa repeat that is encoded by exon 10 in the carboxy terminus (Himmler et
al., 1989; Goedert et al., 2005). The biological activity of tau is regulated by its degree of
phosphorylation, with normal tau requiring 2-3 mol of phosphate per mol of protein for
optimal activity (Kopke et al., 1993).
Hyperphosphorylation (at ~4-6 mol phosphate per mol of tau protein) depresses its
ability to assemble and stabilise microtubules (Lindwall et al., 1984; Alonso et al., 2004). In
AD brain tissue, tau is found to be abnormally hyperphosphorylated in two subcellular pools;
(1) polymerised into intraneuronal tangles of paired helical filaments (PHFs) mixed with
straight filaments or (2) in a non-fibrilised form in the cytosol (Iqbal et al., 1986; Bancher et
al., 1989; Kopke et al., 1993). The tau observed in NFTs appears inert until enzymatic
degradation takes place allowing promotion of microtubule assembly. In contrast, when
examined in vitro cytosolic tau sequesters normal tau (in addition to other MAP isoforms)
causing inhibition and disassembly of microtubules (Kopke et al., 1993; Alonso et al., 1994,
1996, 1997; Iqbal el al., 1994).
To form the PHFs so frequently observed in AD neurons, tau undergoes a series of
seemingly ordered events. In its random coil configuration tau in pretangle neurons becomes
progressively truncated at both its amino- and carboxy-terminals (Braak et al., 1994). This is
followed by truncation of both termini to a Tau-66 state and further cleavage in the NFTs
(Binder et al., 2005). The critical problem with tau is that it may be phosphorylated at over
30 serine/threonine sites in the AD brain (Alonso et al., 1997; Hanger et al., 1998). For
example, phosphorylation at ser-262 or thr-231 has been shown to inhibit tau binding to
microtubules (Sengupta et al., 1998). Although there is still some debate as to whether
NFTs or plaques occur first, the majority of evidence now suggests NFTs occur secondary to
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plaque fbrmalion (Games et al., 1995; Hsaio et al., 1996; Oddo et al., 2003, 2004; Gotz et
al., 2004; Bloom et al., 2005).
1.1.3.2 Amyloid Plaques
The 'neuritic' or 'senile' plaques, which are characteristic of AD, are primarily
composed of beta-amyloid (AP) protein. Initially identified in the meningeal blood vessels
of AD patients, Ap was found to be the primary component of the plaques observed in AD
brain tissue (Glenner et al., 1984; Masters et al., 1985; Kang et al., 1987). Two forms of
plaque, diffuse and neuritic, may be present in the AD brain with much debate as to which is
the more toxic form (Dickson, 1997b; Dickson et al., 2001). Diffuse plaques are generally
composed of shapeless, loosely aggregated Ap and typically not associated with the
dystrophic neurons and neuronal degeneration observed in AD patient brains (Ray et al.,
1998). In contrast, the cluster core of neuritic plaques contain extracellular densely
aggregated fibrillar Ap and are generally associated with degeneration and neuronal cell loss
(Ray et al., 1998; Velez-Pardo et al., 1998). Much of the recent progress in elucidating AD
pathogenesis has centred on the apparent role of amyloidi.40 (APi.40) and APi.42 as the
unifying pathological features of all forms of AD, which will be discussed more extensively
in Section 1.3.
1.2 The Cholinergic Hypothesis of AD
It has long been accepted that AD is associated with a severe loss of neurons and
associated neurotransmitter systems (Perry et al., 1978; Whitehouse et al., 1981, 1982).
These neurotransmitter systems include the cholinergic, glutamatergic, and gamma
aminobutyric acid (GABA)ergic pathways, effectively encompassing all three of the major
neurotransmitter systems in the body (Rossor et al., 1982; Lowe et al., 1990; Francis et al.,
1993). Until recently the influence of these neurotransmitter systems on AD aetiology have
been (almost exclusively) investigated separately. However, it is the degeneration of the
cholinergic system that has historically been shown to be pivotal in AD aetiology and, until
recently, was the only target of marketed drug treatments.
The most severe neuronal loss in AD brain tissue occurs in the nucleus basalis of
Meynert, an area of the brain that provides the major source of cortical cholinergic
innervation (Shute & Lewis, 1967; Mesulam & Van Hoesen, 1976; Wenk et al., 1980;
Whitehouse et al., 1981, 1982). Initial biochemical studies conducted using AD brain tissue
indicated substantial neocortical deficits in choline acetyltransferase (ChAT) and
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acetylcholinesterase (AChE), the enzymes responsible for regulation of the main cholinergic
neurotransmitter acetylcholine (ACh) (Davies & Mahoney, 1976; Perry et al., 1977, 1978b;
Bowen & Davison, 1980; Whitehouse et al., 1982; Prado et al., 2002). The reduction in
these presynaptic ACh markers was found to correlate well with the degree of cognitive
impairment observed in AD patients when compared to age-matched control subjects (Perry
et al., 1978a,b; Sugaya et al., 1990; Rinne et al., 1991). Loss of these connections is clearly
detrimental as the basal and rostral forebrain cholinergic pathways serve important
functional roles in memory processes such as attention and working memory, facets which
are impaired in AD patients (Perry et al., 1999; Stolerman et al., 2000; Levin et al., 2002;
Singer et al., 2004; Young et al., 2004). In addition to the components highlighted above, a
loss of high affinity nicotinic acetylcholine receptors (nAChRs e.g. a4p2) is consistently
observed in cortical post-mortem brain tissue relative to age-matched controls (Flynn &
Mash, 1986; Nordberg & Winblad, 1986; Perry et al., 1990, 1995; Sugaya et al., 1990;
Schroder et al., 1991; Sabbagh et al., 2001). This reduction in nAChR number is not only
over and above that observed in nonnal aging, but the apparent loss in receptor number
correlates significantly with the level of cognitive impairment in AD patients (Nordberg et
al, 1995, 1997).
The predominant high affinity nAChR (> 80 %) in the central nervous system is
the a4p2 nAChR yet surprisingly limited research has assessed its role in AD progression
(Flores et al., 1992; Paterson et al., 2000; Dani, 2001; Drago et al., 2003). Positron emission
tomography studies utilizing (5)(-)[uC]nicotine have demonstrated nicotine binding deficits
in the temporal and frontal cortices of AD patients in vivo while an array of in vitro binding
and autographical assays utilizing [3H]-epibatidine, [3H]-cytisine, and [3F1]-nicotine have
been used to determine the number of high affinity nAChR binding sites and their
subsequent reduction in AD brain tissue (Nordberg & Winblad, 1986; Whitehouse et al.,
1986; Nordberg et al., 1988, 1990, 1995; Perry et al., 1995; Marutle et al., 1999; Sihver et
al., 1999). Although the majority of studies have identified a reduction in a4p2 nAChR
density, it would appear that this loss is a result of a reduction in a4 subunit expression only
as, somewhat surprisingly, the expression of the p2 subunit appears to remain intact (Guan et
al., 2000).
The recent availability of transgenic animals that model some aspects of AD, has
facilitated the largest advances in the understanding of an interaction between nAChRs and
Ap. Mice expressing the APPSWC mutation exhibit some degeneration of ChAT-
immunoreactive fibres, reduced high affinity choline uptake, decreased cortical nicotinic
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ligand binding, as well as a deficit in learning and memory trials (Wong et al., 1999; Apelt et
al., 2002; Bednar et al., 2002; Boncristiano et al., 2002; Dineley et al., 2002a; Luth et al.,
2003). Furthermore, treatment of APPswe mice with nicotine has been shown to reduce A|3
deposition in the brain and cerebral blood vessels (Nordberg et al., 2002; Hellstrom-Lindahl
et al., 2004) and to exacerbate tau pathology in the new triple transgenic mice that express
mutations in presenilin I, human APPswe, and human tau (Oddo et al., 2005). The role of
altered AChE in AD aetiology has been further strengthed by observations that glycosylation
of AChE (increasing AChE levels) is altered in mice expressing APPswe prior to Ap plaque
deposition and that expression of the human AChE gene in mice already expressing APPswe
leads to shortening of the time frame over which Ap plaques normally develop (Fodero et
al., 2002; Rees et al., 2003). Observations from studies utilizing bigenic mice have also
endorsed a direct association between the cholinergic system and AP in AD. Mice
expressing both the APPswe and PSIMi46l FAD mutations develop age-related dense and
diffuse amyloid plaques in conjunction with a decreased density of cholinergic boutons (Hu
et al., 2003). Interestingly, an increase in cholinergic bouton number was observed in mice
expressing the APPswe mutation alone, with no change observed in mice expressing only the
PSIm,46l mutation (Wong et al., 1999; Wengenack et al., 2000). Decreased cholinergic fibre
length and small cholinergic neurons are also common in mice expressing the APPswe
mutation (Boncristiano et al., 2002; Klingner et al., 2003). Finally, until the NMDA
antagonist memantine received market approval, the only registered pharmacological
interventions for AD were the AChE inhibitors such as tacrine, donepezil, and galanthamine
(Palmer, 2003). These ACh-mimetics, although initially associated with significant side-
effects and short plasma half-lives, do not cure the disease but do significantly delay the
onset ofmany AD symptoms (Palmer, 2003). With the other major neurotransmitter systems
seemingly unaffected in the early stages of AD, it was this wealth of evidence highlighting a
central role for the cholinergic system in AD aetiology, has underlain the so-called
"cholinergic hypothesis" ofAD.
First postulated nearly 30 years ago, the cholinergic hypothesis suggested that the
loss of cholinergic pathways precedes that of other neurotransmitter systems making it
central to AD (Bowen et al., 1976; Davies et al., 1976; Perry et al., 1977). The cholinergic
neuron degeneration in the basal forebrain and associated loss of cholinergic
neurotransmission in the cerebral cortex was thought to contribute significantly to the
deterioration in cognitive function observed in AD patients (Bartus et al., 1982).
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The endogenous neurotransmitter of the cholinergic system is acetylcholine (ACh)
and, in a reaction catalysed by choline acetyltransferase (ChAT), ACh is produced in the
presynaptic terminal by the interaction of choline and acetyl-coenzyme A (CoA; Figure 1.1).
Following release of ACh into the synaptic cleft, ACh binds to receptors on both the pre- and
postsynaptic membranes while the remainder is broken down by AChE to choline and CoA.
Choline itself then undergoes reuptake into the presynaptic terminal via a choline transporter
protein (Dani, 2001). This endogenous neurotransmitter can act at both muscarinic
(metabotropic) and nicotinic (ionotropic) acetylcholine receptors. Because they are not
central to this thesis, only a brief overview of muscarinic AChRs will be presented, prior to a
more in-depth look as the nicotinic AChR sutype.
1.2.1 The Neuronal AChR Family
The ACh receptor (AChR) gene family is divided into muscarinic and nicotinic
AChRs, the latter of which may be subdivided further into nicotinic AChRs that bind or do
not bind the snake toxin aBungarotoxin (aBgTx).
1.2.1.1 The Muscarinic AChR
Muscarinic AChRs (mAChRs) are members of the 7 transmembrane-spanning
receptor superfamily and are widely distributed throughout the central (CNS) and peripheral
(PNS) nervous system (Paterson et al., 2000; Dani, 2001). In addition to having 7
transmembrane domains and conserved regions characteristic of G-protein linked receptors,
mAChRs also share conserved tyrosine and threonine residues thought to be critical in
forming the agonist binding site (Figure 1.2; Wess, 1993). A total of five different subtypes,
(Mi, M2, M3, M4, and M5), have been cloned from both human and rat tissue (Volpicelli et
al., 2004). The first mAChR cDNA was cloned approximately 20 years ago with this
achievement closely followed by the cloning of other related receptor subtypes (Kubo et al.,
1986; Bonner et al., 1987, 1988; Peralta et al., 1987). The muscarinic receptor subtypes M|,
M3, and M5 are coupled to the Gq protein which activates phospholipase C, whilst the M2 and
M4 receptors couple to the Gj/0 protein, which results in inhibition of adenylate cyclase
(Figure 1.2; Eglen et al., 2001).
A number of studies have implicated muscarinic receptors (in particular M,) in AD
aetiology as they appear to undergo a preferential loss in the brains of AD patients (Flynn et










Synthesis of the Endogenous Cholinergic Neurotransmitter Acetylcholine, in a
reaction catalysed by choline acetyltransferase (ChAT), acetylcholine (ACh) is produced from the
interaction between choline and acetyl coenzyme A (acetyl CoA). On release into the synaptic cleft,
ACh can interact with its receptors (AChRs) on either the pre- or postsynaptic membranes. Any
excess ACh is degraded by acetylcholinesterase (AChE) to form acetate and choline. Choline itself
undergoes reuptake into the synapse via a choline transporter protein.
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all muscarinic Mi agonists that have entered clinical trial have experienced problems due to
the lack of specific agonists and antagonists, unacceptable side effects, low efficacy, and
poor plasma pharmacokinetics (Eglen et al., 2001). The problems associated with
muscarinic ligands in clinical trials and the vast body of experimental evidence on neuronal
nicotinic AChRs (nAChRs) means the majority of studies continue to focus on the role of
these latter subtypes in AD.
1.2.1.2 Nicotinic AChR Stoichiometry
In contrast to the five mAChRs, there are 12 nAChR genes encoding for the
ionotropic nAChRs characterized in humans, rodents, and chickens (Paterson et al., 2000;
Drago et al., 2003). The a2 - a7, a9, ai0 and (32 - Pr subunits have been cloned from human
tissue with an additional a subunit (a8) found in avians (Elgoyhen et al., 1994, 2001; Le
Novere & Changeux, 1995). The nAChR subunits form either functional heterozygous or
homozygous pentameric receptors, with heterozygous receptors generally assembling
according to a 2a3p stoichiometry using a combination of a2-a6 and p2-p4 subunits (Figure
1.3). However, growing evidence suggests more than one type of a or p subunit may be
used in the pentameric structure giving rise to the so-called "triplet" receptor subunit
configuration (Ramirez-Latorre et al., 1996; Wang et al., 1996; Boorman et al., 2000; Groot-
Kormelink et al., 2001). Indeed, a5 and a6 nAChR subunits have been observed to form
functional receptors in "triplet" formations with a4p2 (Conroy et al., 1992; Ramirez-Latorre
et al., 1996; Wang et al., 1996; Groot-Kormelink et al., 1998, 2001; Boorman et al., 2000,
Champtiaux et al., 2003). In contrast, the a7, a8, and ct9 nicotinic subunits form homomeric
receptors in mammalian tissue (Paterson et al., 2000; Dani, 2001) with the latest addition to
the nAChR subunit family (aio) only forming functional receptors when co-expressed with
a9 (Elgoyhen et al., 2001). The two predominant nAChRs in the CNS are the a4p2 and the
a7 nAChR (Paterson et al., 2000; Dani, 2001). The pharmacology and functional roles of
these two receptors is discussed more extensively below.
1.2.1.2A The a4p2 nAChR
The a4p2 nAChR is the predominant nAChR in the CNS, comprising > 80 % of all
high affinity nAChR binding sites (Paterson et al., 2000; Dani, 2001; Drago et al., 2003).
The gene encoding the human p2 subunit was cloned almost 15 years ago and exhibits a high
degree of homology with the p2 subunits cloned from rat (97 %) and chick
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Figure 1.2








Muscarinic Acetylcholine Receptor G-protein Coupled Signalling Pathways. The
stimulatory pathway (depicted on the left) is composed of receptors containing muscarinic subunits
Mi, M3, or M5. ACh is released from the presynaptic terminal by depolarisation, and travels across
the cleft to bind to the mAChR, thereby activating phospholipase-C (PLC) via a G-protein dependent
mechanism. Activation of PLC stimulates phosphatidylinositol-4,5-bisphophate (PIP2) hydrolysis
generating the second messengers inositol (1,4,5-trisphosphate (IP3) and diacylglycerol (DAG)
resulting in intracellular calcium release and protein kinase C activation. The inhibitory pathway
(depicted on the right) is composed of receptors containing the muscarinic subunits M2 or M4. The
binding of ACh to the mAChR activates an inhibitory G,-protein pathway that inhibits
phosphorylation of adenylate cyclase. Consequently, the generation of adenosine 3',5'-cyclic


















Schematic Representation of the Neuronal Nicotinic Acetylcholine Receptor
Stoichiometry. Heterozygous nAChRs generally assemble according to a 2a3(3 stoichiometry
using a combination of a2-a6 and P2-P4 subunits while a7, ag, and a9 nAChR generally form
homomeric nAChRs. However, recent evidence suggests the existance of "triplet" receptors that
contain 1 or more different a or p subunits. The red dots depicted in the nicotinic AChR diagrams
represent potential agonist binding sites. Figure adapted from (Sharpies et al., 2004).
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(90 %) (Deneris et al., 1988; Schoepfer et al., 1988; Anand et al., 1990). In contrast, the
human a4 subunit was not cloned until 1995, and only then was it co-expressed in human
embryonic kidney cells (HEK 293) with the human p2 subunit (Monteggia et al., 1995). The
human a4 cDNA again has a high degree of homology to rat (84 %) and chick (76 %),
although less than the p2 subunit, with phosphorylation sites differing between species as a
consequence of base changes in the cytoplasmic domain (Goldman et al., 1987; Nef et al.,
1988; Monteggia et al., 1995). The a4p2 nAChR is widely expressed in all forebrain regions
where it has a primary confonnation of 2 identical a and 3 identical P subunits (Paterson et
al., 2000; Dani, 2001). However, as discussed above, functional a4p2 receptors comprised of
two or more different a and P subunits have been observed (Conroy et al., 1992; Wang et
al., 1996; Nelson et al., 2003). Furthermore, the a4 subunit has itself been shown to exist in
two isoforms although incorporation of the p2 subunit means the two a4 isoforms are
indistinguishable on a pharmacological basis (Connolly et al., 1992).
1.2.1.2B The a7 nAChR
The other principal nicotinic acetylcholine receptor in the CNS is the homomeric
a7 receptor (Paterson et al., 2000; Dani, 2001). Initially cloned from chick brain, the a7
nAChR was subsequently cloned from rat and human brain (Couturier et al., 1990;
Schoepfer et al., 1990; Seguela et al., 1993; Peng et al., 1994b). Sequence homology is
again high between the species with the human a7 nAChR having a 94 % and 92 % sequence
identity to the rat and the chick a7 nAChRs, respectively (Peng et al., 1994b). Until the
cloning of the a7 nAChR, controversy surrounded its existance, although it is now generally
agreed that the a7 nAChR can be identified on the basis of its pharmacological interaction
with aBgTx (Paterson et al., 2000; Dani, 2001). The a7 nAChR exhibits high calcium
permeability, is rapidly desensitised, and it appears early in development (Role et al., 1996;
Albuquerque et al., 1998; Agulhon et al., 1999; Adams et al., 2002). Recently, two isofonns
of the a7 nAChR were identified in rat intracardiac neurons, however they differ in their
desensitisation properties, and in their sensitivity to aBgTx (Severance el al., 2004). When
expressed in X. Laevis oocytes, the a7-2 nAChR was found to reversibly bind aBgTx and
slower desensitisation properties when compared to the a7-l nAChR (Severance et al.,
2004).
Like the a8 and a9 subunits, a7 nAChRs generally form functional homomeric
receptors, however a variability in sensitivity to aBgTx and MLA has been demonstrated,
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which has led to some evidence suggesting that heteromeric cx.7 nAChRs may be found in
some cellular systems (Yum et al., 1996; Guo et al., 1998; Yu & Role, 1998a,b). While the
majority of studies support a homomeric structure, data from some, but limited, biochemical,
pharmacological, and biophysical studies favour a heteromeric structure (Quik et al., 1996;
Yu et al., 1998; Girod et al., 1999; Palma et al., 1999; Rakhilin et al., 1999; Drisdel et al.,
2000; Ferreira et al., 2001). Therefore, it is probable that the composition of the a7 nAChR
is species and/or region-specific. Indeed, a7 and p2 nAChR subunits have been observed to
coassemble in rat hippocampal neurons and subsequent studies have shown that these
subunits form functional receptors when expressed in Xenopus oocytes (Sudweeks et al.,
2000; Khiroug et al., 2002). Moreover, the a7 subunit has also been observed to fonn
heteromers with the a8 subunit in chick brain and may combine with other subunits in chick
sympathetic neurons (Couturier et al., 1990; Elgoyhen et al., 1994; Gotti et al., 1994).
1.2.2 Structure of nAChR
Despite the wide variety of potential nAChR subtypes conferred by the numerous
individual subunits the general receptor structure remains the same for all (Dani, 2001). The
neuronal nAChR receptor is a water filled pentamer with each individual subunit having a
tetrameric structure (Figure 1.4, upper) (Paterson et al., 2000; Dani, 2001). The general
receptor structure comprises of a large hydrophilic amino terminus that faces the synaptic
cleft and contains the ACh binding site, several glycosylation sites and a 15 residue cysteine
loop between amino acids 128-142 (Devillers-Thiery et al., 1993; Corringer et al., 2000;
Brejc et al., 2001). Secondly, it has a compact hydrophobic region that may be further
subdivided into 3 transmembrane segments (Ml, M2, and M3) composed of 19-28
uncharged amino acids, separated from each other by short hydrophilic sections (Drago et
al., 2003). The hydrophilic components of the five M2 subunit segments fonn the wall of
the ion channel and allow the flow of the cations, sodium (Na+), potassium (K+), and calcium
(Ca2+) (Leonard et al., 1988; Akabas et al., 1994; Corringer et al., 2000). The third domain
is a hydrophilic cytoplasmic loop (M4) of variable length that contains phosphorylation sites
and like the N-terminus, M4 is exposed to the synaptic cleft where it plays a role in ligand
binding (Paterson et al., 2000; Dani, 2001). Finally, there is a short hydrophobic carboxyl
tenninus of approximately 20 aa which is exposed to the cytoplasm and contains further
glycosylation sites (Paterson et al., 2000; Dani, 2001), with all neuronal nAChRs possessing
adjacent cytseine residues (analogous to cysteines 192 - 193 on the a,) subunit of the AChR)
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(Arias, 2000; Brejc et al., 2001). The known ligand binding sites on the nAChR are
illustrated in Figure 1.4 {lower) and are discussed in greater detail below.
1.2.2.1 Activation and Conformational Changes of the nAChR
The neuronal nAChR exists in one of four functionally distinct conformations
(Paterson et al., 2000; Dani, 2001). When an agonist binds to the receptor it undergoes an
allosteric transition from the resting (closed) state, to an active (open) state, in which cations
can permeate through the channel (Changeux et al., 1998). In this latter state the channel
opens on a micro- to millisecond time scale, binding agonists with low affinity (Galzi et al.,
1995). Continued presence of the agonist leads to closure of the channel and receptor
desensitisation, with multiple desensitisation states postulated to exist (Changeux et al.,
1998). In the desensitized state the closed receptor channel has a refractory period to allow
for re-activation and it becomes sensitive to high affinity ligand binding thereby promoting
the active receptor confonnation once more. Prolonged exposure of nAChRs to agonists is
thought (although still controversially) to primarily result in an increase in receptor number,
rather than the down regulation which is observed for many other ion channels (Kem, 2000).
Of all the nAChRs, the a4p2 and a7 are thought to be the most sensitive to upregulation (Hsu
et al., 1996; Olale et al., 1997) with a number of laboratories demonstrating that chronic
nicotine exposure causes upregulation of both receptor subtypes when expressed in Xenopus
oocytes (Peng et al., 1994a), HEK293 (Gopalakrishnan et al., 1996; Eilers et al., 1997;
Molinari et al., 1998), and M10 cell lines (Peng et al., 1994a) as well as an increase in the
number of nAChR binding sites in human brain (Benwell et al., 1988; Breese et al., 1997;
Court et al., 1998). This effect has also been observed in vivo following chronic exposure of
both rats and mice to cigarette smoke (Yates et al., 1995; Pietila et al., 1998; Nuutinen et al.,
2005). It is thought that the observed increase in receptor number in chronic exposure studies
is not from increased receptor trafficking but because the nAChR undergoes a structural
conformational change stabilising its expression at the cell surface (Peng et al., 1994a).
1.2.2.2 Ligand Binding Sites on the nAChR
A number of binding domains have been identified within the structure of the
neuronal nAChR, that encompasses sites for agonists, antagonists, allosteric modulators, and













Schematic Representation of Neuronal Acetylcholine Receptor Structure and Ligand Binding
Site Locations. The upper panel illustrates the proposed subunit structure, comprising of 4 prinicipal
domains, adjacent cysteine residues, glycosylation and phosphorylation sites. The lower panel
illustrates the proposed ligand binding sites on the nAChR with the inset on the lower diagram
showing the agonist binding pocket loops. Loops A-C are on the a subunit and fonn the principal
component while loops D-F form the complementary component on the adjacent a or p subunit.
Figure adapted from Sharpies & Wonnacott, 2004).
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1.2.2.2A Agonist Binding Site on the nAChR
Until recently, the location of the agonist binding site on the nAChR had remained
the subject of much debate (Brejc et al., 2001). A great deal of research had focused binding
primarily on techniques such as photoaffmity labeling (Chiara et al., 2003a,b), mutagenesis
(Sullivan et al., 2000; Wilson et al., 2001; Yassin et al., 2002), and computer modeling of
the nAChR (Sansom et al., 1998) in an attempt to elucidate the location of the agonist
binding site. However, in 2001, Brejc and colleagues described a 210aa acetylcholine
binding protein (AChBP) that they had isolated from the fresh water snail Lymnaea
stagnalis. ACh bound to this protein and these authors showed it was analogous to the a
subunit of the nAChR. The determination of the AChBP crystalline structure provided
confirmation that the agonist binding site lay on the a subunit interface adjacent to the other
a and/or p subunits of the nAChR. Both the principal (located on the a subunit) and the
complementary components (located on the adjacent a or p subunit) are required for a
functional binding site. Indeed, all the nAChR agonist binding sites must be occupied for
channel activation to occur (Colquhoun & Sakmann, 1985; Hess et al., 1987; Udgaonkar &
Hess 1987a,b; Keleshian et al., 2000; Dajas-Bailador et al., 2003).
In general, and as discussed earlier, the heteromeric nAChR (e.g. a4p2) is
composed of 2a and 3P subunits, and therefore it contains 2 agonist binding sites located at
the interface between the a subunits and their adjacent p subunit (Alkondon et al., 1993). In
contrast, homomeric nAChRs (e.g. a-;) are comprised of 5a subunits giving rise to 5
potential binding sites, located at the interface between all 5 individual a subunits (Corringer
et al., 1995; Palma et al., 1996; Wang et al., 1996). Further site-directed mutagenesis
studies identified the existence of six loops labeled A-F that participated in the formation of
the agonist binding site (Figure 1.4 lower, Corringer et al., 2000). The a subunit which
harbours the principal component of the binding sites contains loops A, B, and C while the
complementary component contains loops D, E, and F (Figure 1.4, lower).
1.2.2.2B Antagonist Binding Sites on the nAChR
Competitive antagonists such as <7-tubocurarine (c/-TC) interact reversibly with the
nAChR, at or in close proximity to the agonist binding site (Figure 1.4; Arias, 2000). On
binding to the receptor antagonists stabilise the receptor in the closed conformation,
effectively blocking agonist access to the binding site. In contrast, non-competitive
antagonists (e.g. mecamylamine) interact at a site distinct from the agonist binding site
which is potentially located within or near the entrance of the ion channel (Figure 1.4). In
16
order for the non-competitive antagonists to interact with their binding site on the nAChR, it
must first undergo activation prior to inhibition (Arias, 2000).
1.2.2.2C Allosteric Modulation of the Neuronal AChR
In addition to inhibiting the breakdown of ACh, acetylcholinesterase inhibitors can
also function as non-competitive positive allosteric modulators of the neuronal nAChR by
enhancing channel opening and consequently ion conductance (Pereira et al., 1993). The
competitive allosteric activator site was found to be located on the a subunit of the receptor,
however it is again distinct from the agonist binding site (Figure 1.4, lower, Pereira et al., 1993;
Storch et al., 1995).
Non-competitive negative allosteric modulators such as barbiturates and ethanol
inhibit ion channel function without directly affecting ACh binding, with both high and low
affinity sites identified (Dodson et al., 1987; Lena et al., 1993; Yost et al., 1993). The high
affinity site is believed to bind ligands in the nanomolar range and is located within the ion
channel. Once the channel is activated, the negative allosteric modulator can bind to the high
affinity site on the channel causing a rapid but reversible channel block (Valenzuela et al., 1994).
In contrast the low affinity site is thought to be located between the receptor protein and lipid
membrane where the binding of ligands accelerates desensitisation. In addition to positive and
negative allosteric modulation, the neuronal nAChR may also undergo modulation by
phosphorylation via a number of different kinases that include protein kinases A and C, both of
which can cause desensitisation of the receptor (Huganir et al., 1990).
1.2.2.2D Steroid and Dihydropyrridine Binding to the Neuronal AChR
Recent studies have shown that neurosteroids are potential endogenous regulators of
nAChR activity (Paradiso et al., 2001; Curtis et al., 2002). Indeed, non-endogenous steriods have
been shown to bind to the extracellular hydrophilic domain of the nAChR at a site distinct from
the agonist binding site, causing desensitisation of the receptor (Figure 1.4; Bertrand et al., 1991;
Inoue & Kuriyama, 1991). Furthermore, a number of dihydropyridine binding sites are also
proposed to exist within the ion channel structure, with these thought to accommodate binding
sites for L-type Ca2+ channel antagonists such as nifedipine and nimodipine (Lopez et al., 1993).
1.3 The Amyloid Hypothesis of Alzheimer's Disease
Following on from the "cholinergic" hypothesis, the amyloid hypothesis of AD
emerged in the mid-1980's and postulated that Ap deposition was responsible for the
17
neurodegeneration observed in AD brains (Glenner et al., 1984). As a degradation product
of amyloid precursor protein (APP) metabolism, a role for AP in AD pathogenesis emerged
when APP was found to be localised to chromosome 21 (Goldgaber el al., 1987a,b; Kang et
al., 1987; Robakis et al., 1987; Tanzi et al., 1987). This was considered significant as those
with trisomy 21 (Down's syndrome) evolved AD pathology in later life (Olson et al., 1969).
These studies led to the development of transgenic mice overexpressing mutant APP which
were shown to have highly elevated Ap levels, and extensive plaque deposition in the same
regions as those observed in human AD patients (Sturchler-Pierrat et al., 2000).
To thoroughly understand the complex role that Ap plays in AD, its processing
from the amyloid precursor protein must first be described.
1.3.1 Amyloid Precursor Protein
Amyloid precursor protein (APP), a normal constituent of the human brain and
blood vessels, is an integral membrane protein with a large extracellular domain, a
membrane anchoring domain, and a short intracellular C-terminal tail. Initially cloned and
expressed in 1987, APP exists in multiple isoforms generated as a consequence of alternative
splicing of APP mRNA with each variant named according to their amino acid (aa) length
(e.g. APP695, APP77o) (Goldgaber et al., 1987a,b; Kang et al., 1987; Robakis et al., 1987;
Tanzi et al., 1987). The longer forms of the amyloid precursor protein are 751 and 770 aa in
length and contain a 56 aa domain with homology to the Kunitz family of serine proteases
inhibitors (Ponte et al., 1988).
The immature form of APP can undergo several post-translational modifications
including N- and O-glycosylation, and Tyr-sulphation to reach maturity (Hardy et al., 2002).
Following these initial modifications, APP is then subject to proteolytic processing by at
least 3 individual proteolytic enzymes (a, |3, and y secretases) producing at least two
different forms of p-amyloid. The most common peptides are 39-43 aa in length and are
composed of a transmembrane domain of 11-15 aa and a 28 aa peptide generated from the
extracellular domain of APP (Figure 1.5; Glenner & Wong, 1984; Masters et al., 1985). As
described below, these secretases are central to amyloidgenic and non-amyloidgenic
processing of APP with the nonnal regulation of APP metabolism involving a contribution
from a number of intracellular second messenger systems. The protein kinase C (PKC)
pathway was the first APP-linked signal transduction system described, with increased PKC
activity consistently observed in AD brain tissue (Gillespie et al., 1992; Buxbaum et al.,
1993; Caporaso et al., 1994). PKC has several calcium-dependent and independent
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isoforms, although it is not known which isoform triggers soluble APP (sAPPa) secretion,
however PKC is believed to target a-secretase, rather than APP itself (Sinha et al., 1999b).
Other studies utilising thapsigargin, an irreversible calcium reuptake inhibitor in the
endoplasmic reticulum have implicated a Tyr-kinase dependent pathway, effectively
bypassing the PKC pathway, and indicating an alternative target for therapeutic intervention
(Buxbaum et al., 1994; Petryniak et al., 1996). Furthermore, downstream messengers such
as nVkinase have also been shown to stimulate sAPPa release (Solano et al., 2000).
However, because proteolysis of APP by the a, P, and y secretases are central to AD
pathology, these are described in more detail.
1.3.1.1 a-secretase Processing of APP (The Non-Amyloidogenic Pathway)
The non-amyloidogenic, and putatively non-toxic pathway of APP processing, so-
called as full length Ap is not formed, involves proteolytic cleavage of APP by a-secretase
(Figure 1.5). a-secretase cleaves APP in the extracellular domain near the middle of the Ap
sequence at residues Lysl6 and Leu 17 (Esch et al., 1990; Sisodia, 1992). The soluble
ectodomain (sAPPa) is released into the extracellular space while the 83 aa residue C-
terminal fragment (C83) remains membrane anchored (Weidemann et al., 1989; Haass et al.,
1992a; Sisodia, 1992). C83, a substrate for y-secretase, undergoes further proteolysis in the
transmembrane domain releasing a 3 kDa peptide p3 (AP17.43) or AP17.40 while the C-terminal
fragment remains membrane bound. The p3 product is a significant component of diffuse
amyloid plaques (Gowing et al., 1994). APP cleavage by a-secretase is determined by the
distance of the hydrolysed bond from the membrane (12-13 aa) and a local helical
conformation rather than by specific residues (Sisodia, 1992). Although it is likely
processing events occur in the trans-Golgi network, the exact subcellular localisation of a-
secretase remains unclear (Kuentzel et al., 1993).
Members of the disintergin and metalloprotease (ADAM) family, ADAM9,
ADAM 10, and ADAM17 (also known as tumour necrosis factor alpha converting enzyme,
TACE) are believed to constitute a-secretase (Buxbaum et al., 1998; Koike et al., 1999;
Lammich et al., 1999). These proteases are implicated in both the constitutive and PKC
regulated a-secretase pathways (Buxbaum et al., 1998; Lammich et al., 1999). Indeed it
should be noted that while all cells contain a basal level of a-secretase activity, a-secretase
proteolysis of APP may also be stimulated by phorbol esters (increasing PKC activity) or by







Proteolytic Processing of APP. APP, an integral membrane protein undergoes proteolytic cleavage
by at least 3 enzymes to produce ApM0/i-42- Cleavage by a-secretase results in an 83 aa C-terminal
peptide (C83) and soluble APP (sAPPa). Subsequent C83 cleavage by y-secretase produces the small
3 kDa peptide p3 and a membrane bound C-terminus. Cleavage by p-secretase results in a 99 aa C-
terminal peptide (C99) and soluble APP (sAPPP). Further proteolytic cleavage of C99 by y-secretase
results in the release of either Ap^o or APi_42. The postulated neurotoxic pathway is illustrated in red.
Numbered points represent where the following mutations are believed to occur: (1) Swedish APP (2)
presenilin I & II and APP transmembrane (3) Flemish/Dutch and artic mutations. Apolipoprotein E
(ApoE) is believed to exert its influence following the release of AP1.42.
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serotonergic neurons (Buxbaum et al., 1990, 1993; Nitsch et al., 1992; Caporaso et al., 1994;
Lee et al., 1995).
1.3.1.2 P-secretase Processing of APP (The Amyloidogenic Pathway)
The amyloidogenic and putatively toxic pathway of APP processing results in the
formation of full length Ap and involves proteolytic cleavage of APP by P-secretase (Figure
1.5; Hardy & Selkoe, 2002). APP undergoes proteolysis at the NH2-terminus by P-secretase
to produce a truncated form of sAPP (sAPPp) and a membrane bound 12 kDa C-terminal
fragment (C99) that acts as a substrate for y-secretase. C99 undergoes further heterogeneous
proteolysis by y-secretase in the transmembrane domain releasing a 4 kDa full length Ap
fragment. The majority of the Ap species produced is a 40 aa peptide (APi.40), while a small
proportion is a 42 aa C-terminal variant (APi_42; Esler & Wolfe, 2001). Traditionally it has
been thought that this latter form, ApM2, is the toxic component of Ap plaque formations.
The identification and cloning of the p-secretase enzyme (also known as beta-site
APP cleaving enzyme, BACE), has demonstrated that p-secretase consists of a single
transmembrane domain that contains two active site motifs and a conserved sequence
(Hussain et al., 1999; Sinha et al., 1999a; Vassar et al., 1999; Yan et al., 1999; Lin et al.,
2000). Consistent with findings that Ap is produced by a number of difference cell types, p-
secretase mRNA is highly expressed in brain and in a variety of other tissues (Haass et al.,
1992a; Haass et al., 1992b; Seubert et al., 1992; Shoji et al., 1992; Busciglio et al., 1993;
Vassar et al., 1999; Yan et al., 1999; Lin et al., 2000). Cleavage by P-secretase has
generally been considered to occur in the endosomal/lysosomal pathway, although there are
reports of the potential involvement of the endoplasmic reticulum and Golgi apparatus
(Chyung et al., 1997; Sinha et al., 1999a; Vassar et al., 1999; Yan et al., 1999; Lin et al.,
2000).
Targeting the accumulation of Ap in brain tissue is being actively pursued in the
search for a new treatment for AD, however, Ap plaques may also accumulate in vascular
tissue (Castellani et al., 2004). Studies using transgenic mice have already demonstrated
some potential side effects of vascular Ap accumulation including haemorrhage and
neuroinflammation (Winkler et al., 2001; Herzig et al., 2004). However, it is interesting to
note that the P-secretase homolog BACE2 is found in highly vascularised systemic tissues
such as the heart, kidney, placenta (Yan et al., 1999; Farzan et al., 2000), and therefore
inhibitors of BACE 1 may yet be beneficial in AD.
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1.3.1.3 y-secretase Processing of APP
The third secretase involved in APP proteolysis is y-secretase and it exhibits some
rather unusual characteristics. Firstly, before proteolysis of APP by y-secretase may take
place, the target protein must first be cleaved within its ectodomain (Figure 1.5; Struhl &
Adachi, 2000; Esler et al., 2001). Secondly, although proteolytic cleavage of proteins
normally takes place under hydrophilic conditions (e.g. in the cytoplasm or extracellular
space), due to the need for water, y-secretase cleaves APP in the hydrophobic lipid bilayer
(Struhl et al., 2000; Esler et al., 2001). Finally, cleavage by y-secretase can produce not one
but two different C-terminal peptides, A(3i.40 or APi_42, making it the rate-limiting step in
APP proteolysis. Of the Ap species produced, APi.40 constitutes approximately 90% of
secreted Ap while the majority of the remaining 10% in non-Alzheimer's Disease brains is
composed of ApM2 (Mattson, 1997; Mills et al., 1999). As suggested earlier, it is this latter
peptide, APi_42, that is ultimately thought to be responsible for the insoluble Ap plaques that
accumulate in AD.
Until recently, there was considerable debate over the identity of y-secretase, with
the majority of evidence suggesting that y-secretase was comprised of the integral membrane
proteins presenilin I and presenilin II. However, very recent studies have shown that the
complex contains four proteins; presenilin, nicastrin, aph-l, and pen-2 (for reviews see
Steiner, 2004; Tomita & Iwatsubo, 2004). Whilst a full description of the role of these
proteins is beyond the scope of this thesis, it is believed that presenilin carries the active site
of y-secretase while the other components are required for assembly, stabilisation, and
maturation of the complex (Prokop et al., 2004; Shirotani et al., 2004; De Strooper, 2005).
To date, many pharmaceutical companies are pursuing a-secretase activation and
inhibition of P- and y-secretases in order to identify new therapies that could potentially treat
AD (Chang et al., 2004; Cumming et al., 2004; Tomita et al., 2004; Minter et al., 2005).
1.3.2 Controversies Surrounding the Amyloid Hypothesis
Despite extensive research, there is still debate over the role of amyloid in AD, not
least because it remains unknown how y-secretase cleavage results in one predominant form
of Ap species (Pollack et al., 2005). However, the major criticisms and concerns regarding
this hypothesis can be generally subdivided into two areas; (1) a lack of plaque and symptom
correlation (including the tau and amyloid time debate) and (2) the identity of the neurotoxic
Ap species. Ultimately on-going clinical trials which target the amyloid protein, such as
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vaccines (e.g. Llan Pharmaceuticals, Inc.) or [3-sheet breakers (Sereno Pharmaceuticals Inc.)
will prove or disprove the role of Ap in AD.
1.3.2.1 Amyloid Plaques and Symptom Correlation
To date, it is still true that diagnosis of AD can only be conclusively defined by the
presence of neuritic plaques and neurofibrillary tangles after a post-mortem (Alzheimer,
1907). However, the number of plaques does not correlate well with the degree of
impairment seen in patients (Wang et al., 1999), and over 20% of elderly humans with AD-
like dementia fail to meet pathological criteria (Lue et al., 1999). In addition, some
cognitively normal patients do meet pathological criteria and are referred to in studies as
having "preclinical AD" (Lue et al., 1999; Wang et al., 1999). Part of the diagnosis problem
probably arises from the way AD is clinically classified. Most humans over 60 years of age
will experience some form of dementia, with symptom classification similar for all forms of
dementia. Age and genetic variability affect the susceptibility to such diseases, and the
degree to which a person is affected; this problem is not confined to humans. For example,
although a number of APP-transgenic mice have been generated, the majority of mice fail to
show clear-cut neuronal loss (Irizarry et al., 1997a,b). However, a recent biochemical study
of human AD brain tissue showed a better correlation between Ap^ levels and cognitive
decline (Naslund et al., 2000).
The literature discussing plaque and symptom correlation is associated with a large
body of publications addressing whether Ap or tau pathology is the underlying cause of AD,
or to be more precise, whether plaques or tangles occur first. The belief tau pathology
preceded that of Ap primarily rested on a pivotal paper by Braak and Braak in 1991. In it
they observed that the neurofibrillary degeneration of cell bodies gradually increased with
age, and most importantly, they showed that this increase in tangle formation appeared to
predate morphologically detectable Ap plaques (Braak et al., 1991). However, as the so-
called "Braak Stage I" neuropathology was based on non-demented elders, it is impossible to
know whether the neurofibrillary tangles observed were a result of AD (Hardy et al., 2002).
Indeed, other human studies contradict the Braak and Braak study, demonstrating Ap
pathology prior to tangle formation not only in AD patients but in those suffering Down's
Syndrome (Mann et al., 1986; Lemere et al., 1996). In addition, a study following the fate of
an Australian family with a variant form of FAD, showed that a member of that family who
died from unrelated causes prior to the onset of dementia exhibited plaques but no tangles
(Smith et al., 2001).
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Critically, there is now evidence from studies using double and triple transgenic
mice which support the view that Ap deposition occurs prior to tangle formation.
Transgenic mice overexpressing both human APP and human tau produce increased tau-
positive tangles when compared to mice expressing tau alone (Lewis et al., 2001; Oddo et
al., 2003, 2004; Billings et al., 2005). Importantly, the structure and number of Ap plaques
remained the same suggesting alterations in APP processing occurred prior to changes in tau
metabolism. Transgenic mice overexpressing human APP alone experience a time-
dependent increase in Ap deposition and certain neuropathological and behavioural
alterations that are comparable to those observed in AD, although they fail to show clear cut
neuronal loss (Irizarry et al., 1997a,b; Hsia et al., 1999; Moechars et al., 1999). In contrast,
mice expressing both PS1 and human APP experience an acceleration in Ap pathology
(Borchelt et al., 1996, 2002; Scheuner et al., 1996; Citron et al., 1997) and finally, as
discussed earlier, inheritance of one or two s4 alleles of apolipoprotein E (ApoE) is a strong
genetic risk factor for AD (Corder et al., 1993; Saunders et al., 1993). When mice
overexpressing APP are crossed with mice deficient for apoE, cerebral Ap deposition is
significantly decreased in the offspring supporting the evidence that apoE genotype is likely
to influence Ap metabolism (Bales et al., 1999).
However, care must be taken when interpreting transgenic data. Indeed, the
degree of pathology seen in APP-transgenics has been shown to be dependent upon the
mouse strain (Hsiao, 1998). For example, mice expressing the Val717-Phe FAD mutation
only express Ap plaques beyond the age of 12 months, however these animals show
cognitive impairment from as young as 3 months of age (Moechars et al., 1999).
1.3.2.2 Determining the Neurotoxic Form of Ap
Which form of Ap is supposedly neurotoxic and what its relationship to neuronal
degeneration continues to remain the subject of much debate. In vitro, Ap spontaneously
aggregates into fibrils that appear to be indistinguishable from those found in vivo (Selkoe,
1994; Lendon et al., 1997; Lamb et al., 1999). However, in all animals, Ap is present in
multiple conformations including monomers, oligomers, protofibrils, and mature fibrils, and
as such it is difficult to define which form causes neurodegeneration (Walsh et al., 1997,
2002a; Teplow el al., 1998; Conway et al., 2000; Bitan et al., 2003). It is over 10 years
since Selkoe (1993) reported that Ap is predominantly found in a fibrillar form in the brains
of AD patients, however, recent studies also show that soluble oligomers of Ap, but not
monomers or fibrils, inhibit long term potentiation (LTP; Walsh et al., 2000a). As LTP is
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thought to be pivotal in the formation of new memories, it is clear that various conformations
of A|3 are likely to modify particular functions in the brain.
To date, the majority of recent AD research has focused on APi_42, the longer of
the two Ap species produced as a consequence of y-secretase cleavage of APP (Ling et al.,
2003). Because of its length, APi_42 is more likely to form fibrils and once formed, these
fibrils are more stable than those of APi_40 (Hardy et al., 2002). Indeed, Api_42 can aggregate
up to 70 times faster in solution than APi_40 (Thunecke et al., 1998). APi_42 is believed to be
a central component of insoluble neuritic plaques, with these plaques being a defining factor
of AD neuropathology. However, recent evidence from a number of laboratories indicates
that soluble rather than insoluble Ap may be the more toxic species, although at present Api_
42 still seems to be crucial in AD neuropathology (Tucker et al., 2002; Walsh et al., 2005).
The situation is constantly evolving with additional questions likely to arise from continuing
research.
Until recently, a central tenet of the amyloid hypothesis has been that Ap exerts its
neurotoxic effects extracellularly, however, new evidence suggests Ap may accummulate
intraneuronally (Blanchard et al., 2003; Oddo et al., 2003; Billings et al., 2005; Crowther et
al., 2005). Although generally ignored, Masters and colleagues (1985) suggested 20 years
ago that Ap plaques form in neurons prior to deposition in the extracellular space. In 2003,
Blanchard and colleagues demonstrated a high level of neuronal loss in their aged mouse,
bigenic for PS1 and APP mutations. Although the neuronal loss did not correlate with
amyloid plaque load, a high level of intraneuronal Ap was observed indicating a possible
involvement of intraneuronal Ap in neurotoxicity (Blanchard et al., 2003). Oddo and
colleagues (2003) simultaneously produced a triple transgenic mouse (PS1, tau, and APP
mutations) that showed synaptic dysfunction and intraneuronal amyloid immunoreactivity,
prior to plaque or tangle deposition (Oddo et al., 2003; Billings et al., 2005). Furthermore,
following expression of the artic APi_42 mutation in Drosphilia melanogaster intraneuronal
AP accumulation was observed and it alone was enough to cause neurotoxicity (Crowther et
al., 2005). Taken together these recent studies indicate intraneuronal Ap accumulation may
not only precede Ap plaque and tangle deposition but could underlie the neurotoxic loss
observed in AD brain tissue. These findings will have a significant impact on future AD
research considering the historical dogma that AP was only found extracellularly.
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1.4 Interaction Between Ap and nAChRs in Alzheimer's Disease
The individual roles of nAChRs and Ap in AD have been well documented and
although the cholinergic and amyloid hypotheses have been developed in parallel, both have
been treated as almost distinct entities. Indeed, until recently, studies examining the
interaction between Ap and nAChRs were almost exclusively confined to the preservation or
loss of cholinergic receptors in AD (Flynn & Mash, 1986; Nordberg & Winblad, 1986; Perry
et al., 1990, 1995; Sugaya et al., 1990; Schroder et al., 1991; Sabbagh et al., 2001). For
example, while the 0.4p2 nAChR appears to be the predominant nAChR lost in AD, the 0.7
nAChR is in fact quite well preserved, although there is some region-specific loss (Sugaya et
al., 1990; Perry et al., 1995; Martin-Ruiz et al., 1999; Guan et al., 2000).
It is only in the last 5 years that evidence was provided to support a direct
pharmacological interaction between nAChRs and Ap in AD pathology. Wang and
colleagues (2000a) showed that the a7 nAChR and APi_42 could be co-immunoprecipitated in
samples from human AD brain tissue and in cell lines transfected with the human a7 nAChR
and spiked with Ap. Furthermore, radioligand binding studies using the a7 nAChR
antagonists [3H]-aBgTx and [3H]-MLA indicated that picomolar concentrations of Ap1_42
could inhibit binding to the a7 nAChR (Wang et al., 2000a). These initial findings were
closely followed by a second study demonstrating that APi.42 exhibited > 5,000-fold higher
affinity for the a7 nAChR compared with the a4p2 nAChR (Wang et al., 2000b). Subsequent
electrophysiological studies have indicated that nanomolar concentrations of Ap inhibit
nicotine-evoked currents in rat hippocampal slices, cultured neurons, and at a4p2 and a7
nAChRs expressed mXenopus laevis oocytes (Dineley et al., 2001, 2002a; Liu et al., 2001;
Pettit et al., 2001; Tozaki et al., 2002; Grassi et al., 2003; Wu et al., 2004). These papers
generated considerable interest and there is now an emerging body of research that has
shown a direct interaction between Ap and, in particular, the a7 nAChR (Kihara et al., 1997,
1998, 2001; Dineley et al., 2001, 2002b; Guan et al., 2001; Liu et al., 2001; Pettit et al.,
2001; Tozaki et al., 2002; Fu & Jhamandas, 2003; Grassi et al., 2003; Fodero et al., 2004;
Wu et al., 2004; Xiao & Kellar, 2004). In addition, nicotine, a well characterized high
affinity nAChR ligand, has been shown to breakdown fresh and preformed AP fibrils in
vitro, slow Ap fibril formation in vivo, as well as exerting neuroprotective properties by
inhibiting Ap-induced neuronal cell death in a range of standard cell and primary neuronal
cultures (Hunter et al., 1994; Salomon et al., 1996; Kihara et al., 1997; Zamani et al., 1997;
Kihara et al., 1998; Kihara et al., 2001; Shimohama et al., 2001; Ono et al., 2002; Grassi et
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al., 2003; Martin et al., 2004). Furthermore, a significant reduction in APi.42 deposition was
observed when mice expressing the APPSWC mutation were treated (acutely and chronically)
with nicotine (Nordberg et al., -2002; Hellstrom-Lindahl et al., 2004). .
One of the principal obsevations of the cholinergic hypothesis of AD was a
general loss in AChE levels, and this was the primary driving force in the development of a
number of ACh-mimetics that now include compounds such as tacrine, donepezil and
galanthamine, with yet more still under clinical development (Yamada et al., 2002; Palmer,
2003; Francotte et al., 2004). Nevertheless, whilst the overall level of AChE is decreased in
AD brain tissue, the concentration of the enzyme is increased around A|3 plaques and in
neurofibrillary tangle-bearing neurons early in the Ap deposition process (Atack et al., 1983;
Fishman et al., 1986; Mesulam et al., 1986; Geula et al., 1989). Fodero and colleagues
(2004) showed that this increase was mediated via the interaction of AP1.42 with the 017
nAChRs. In addition to the role of ACh itself, it is clear that the a7 nACliR in particular
plays an important role in learning and memory perhaps through modification of the MAP
kinase pathway (Figure 1.6; Dineley et al., 2001). Indeed, as in humans, deficits in attention
and in learning and memory are observed in transgenic mouse models of AD (Tulving et al.,
1990; FIsiao et al., 1996; Rossor et al., 1996; Gordon et al., 2001; Savonenko et al., 2005).
Importantly, the a7 nAChR was found to be upregulated in a number of AD transgenic
mouse models (Bednar et al., 2002; Dineley et al., 2002a). Furthermore, using the 5-CSR
task, our group have shown that a7 nAChR knockout mice exhibit deficits in sustained
attention in comparison to their age-matched wildtype littermates and that the administration
of nicotine significantly reversed this effect (Young et al., 2004). However, care must be
taken when interpreting data from mouse to human. Indeed, although the a7 nAChR was
found to be upregulated in transgenic models of AD, studies of human AD brain tissue
indicate the a7 nAChR is either lost or unchanged (Sugaya et al., 1990; Martin-Ruiz et al.,
1999; Guan et al., 2000).
Although a growing body of evidence now supports a direct interaction between
APi-42 and nAChRs, controversy exists over the nature of this interaction and indeed the type
of nAChR involved. Whilst Wang and colleagues (2000a,b) showed Ap^ inhibited
[l25I]aBgTx binding at picomolar concentrations, other groups have failed to replicate this
results despite the use of APi_42 concentrations ranging from femtomolar to nanomolar (de
Fiebre et al., 2005). Furthermore, although some functional studies suggest APi_42 is able to
directly activate a7 nAChRs this finding remains controversial with some studies showing
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Figure 1.6
Effect of ACh and P-amyloid on the a7 nAChR. A(3 is thought to alter calcium (Ca2+)
concentrations by binding directly to a7 nAChRs or by interacting directly or indirectly with L-type
voltage-gated Ca2+ channels (L-VGCC). Raising intraneuronal Ca2+ levels could influence long tenn
potentiation (LTP) and thereby learning and memory processes directly or indirectly via the mitogen-
activated protein kinase (MAPK) pathway. MAPK stimulates p90 Rsk which renders cAMP response
element binding (CREB) protein transciptionally incompetent through phosphorylation of its
serine 133 residue leading to changes in LTP.
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the a4p2 nAChR may be the primary target of Ap (Guan et al., 2001; Liu et al., 2001; Tozaki
et al., 2002; Dineley et al., 2002b; Fu et al., 2003; Grassi et al., 2003). For example, Fu and
Jhamandas (2003) demonstrated Ap was able to evoke a concentration-dependent increase in
inward current in rat basal forebrain neurons, however, this effect on single channel and
whole cell currents was blocked by the general nicotinic antagonists mecamylamine and
dihydro-P-erthroidine but not by a7-specific antagonist MLA. In contrast, Tozaki and
colleagues (2002) found Ap^ and APi_40 significantly inhibited the rat a4p2 nAChR but not
the a7 nAChR when both were expressed inXenopus oocytes (Tozaki et al., 2002).
The possibility of a direct interaction between Ap and nAChRs enables new
pharmaceutical interventions to be developed for AD, and as such, it is important to fully
investigate these potential interactions between Ap and nAChRs. Therefore, in late 2001
following the publication of the Wang papers (2000a,b) I began to examine the interaction
between the human a4p2 and a7 nAChRs and human APi_42. A comprehensive approach was
taken incorporating pharmacological, functional, and biochemical techniques. It should be
noted that my Ph.D. programme at the University of Edinburgh was sponsored by Fujisawa
Pharmaceuticals Ltd. and that this has influenced the design of the radioligand binding
assays. In particular these binding assays have been designed to not only assess nAChR
pharmacology but so that they might be used in high-throughput screening (e.g. small
volume design). Furthermore, this approach influenced the choice of tissue used in these
experiments. Ideally, a species comparison of rat and human nAChRs would be carried out
using brain tissue from rodents and human autopsy tissue. However, human brain tissue is
not only a precious resource but presents many difficulties in terms of health and safety
issues (e.g. separate equipment due to potential pathogen contamination). Therefore, I chose
to work with a human cell line in which the human a4p2 or a7 nAChR was over-expressed.
As this cell line does not natively express these receptors it has the added advantage of
allowing the researcher to fully assess each individual receptor.
It should also be noted that the a7 nAChR knockout mouse data presented in my
thesis represents the initial data from an on-going collaborative study with other members of
our Institute (Fujisawa Institute for Neuroscience in Edinburgh now Astellas Centre for
Neuroscience in Edinburgh). This project involves cross-breeding the a7 nAChR-knockout
mouse with another mouse in which the human APPSWC gene has been over-expressed.
Ultimately, this breeding programme will allow us to study the interaction of ApM2 and the
a7 nAChR in vivo. At the completion ofmy thesis only the a7 nAChR-knockout mouse had
been breed to sufficient levels to enable binding studies to be performed.
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1.5 Hypothesis and Aims
I hypothesized that APi_42 interacts both pharmacologically and functionally with
the a4p2 and a7 nAChRs. As such, the aims ofmy thesis were as follows:
(1) To establish a number of radioligand binding assays ([3H]-epibatidine, [3H]-cytisine,
[3H]-methyllycaconitine, and [3H]-aBungarotoxin) to characterise the pharmacology
of the rodent and human cc4p2 and a7 nAChRs.
(2) To use the established radioligand binding assays in a collaborative study with other
researchers within our Institute (Fujisawa Institute of Neuroscience in Edinburgh) to
assess the pharmacology (affinity and binding density) of a4p2 and a7 nAChRs in a
transgenic mouse model.
(3) To use the established radioligand binding assays to assess the ability of various forms
of APi_42 to inhibit binding to rat and human a4p2 and a7 nAChRs.
(4) To establish a functional assay (calcium fluorescence, membrane potential
fluorescence, whole cell patch-clamp electrophysiology) to assess the function of the
human a4p2 and a7 nAChRs expressed in a non-native cell line.
(5) To use the established functional assay to determine any functional interaction
between AP].42 and human a4p2 and/or a7 nAChRs.
(6) To determine whether APi_42 and nAChR subunits a4 and/or a7 co-immunoprecipitate.
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2.0 MATERIALS AND METHODS
2.1 Experimental Animals
2.1.1 Rats and Non-Transgenic Mice
Unless otherwise stated, the animals used were either male Sprague Dawley rats
(250-350 g) or male C57 Black 16/J mice (20-25 g) both supplied by Charles River (U.K.).
Prior to tissue removal, animals were given food and water ad libitum and maintained on a
12 hour light/12 hour dark cycle. Studies were performed under licence by United
Kingdom authorities (Scientific Animal Procedures Act, 1986,
http://www.homeoffice.gov.uk), and in accordance with the Guide for the Care and Use of
Laboratory Animals as adapted and promulgated by the National Institute of Health.
2.1.2 Transgenic a7 nAChR Mice
An a7 nAChR-null breeding pair were supplied by Jackson Laboratories
(B6.12957-Chrna7tmlBay/J; Jackson Laboratories, Bar Harbour, U.S.A.) and backcrossed
11 times onto a C57B16/J background to produce litters of wildtype, heterozygous, and
knockout mice. Animals were given food and water ad libitum and maintained on a 12
hour light/12 hour dark cycle. As detailed in Section 2.1.1, studies were performed under
licence by United Kingdom authorities (Scientific Animal Procedures Act, 1986,
http://www.homeoffice.gov.uk), and in accordance with the Guide for the Care and Use of
Laboratory Animals as adapted and promulgated by the National Institute of Health.
To confirm the genotype of the a7 nAChR transgenic mice, animals were tail
tipped under halothane/nitrous oxide anaesthesia and tail DNA obtained by proteinase K
treatment of tail samples (Promega, Southampton, U.K.). Three primer pairs were used
corresponding to both wildtype (forward primer 5'-CCT GGT CCT GCT GTG TAA AAC
TGC TTC-3', reverse primer 5'-CTG CTG GGA AAT CCT AGG CAC ACT TGA G-3',
producing a 440 base pair (bp) product; and disrupted: (same forward primer as for
wildtype, but reverse primer 5'-GAC AAG ACC GCG TTC CAT CC -3', producing a 750
bp product) alleles.
2.2 Maintenance of Cell Lines in Culture
2.2.1 SH-EPl-pCEP4-ha4p2 and SH-EPl-pCEP4-ha7 Cell Lines
SH-EP1 human epithelial cells containing either the cloned human a4p2 nAChR
(SH-EPl-pCEP4-ha4p2; SH-EP-ha4p2) or the cloned human a7 nAChR, were kindly
provided by Dr. R.J. Lukas, and both have been described previously (Pacheco et al., 2001
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and Peng et al., 1999, respectively). Both stable cell lines were grown in Dulbecco's
modified Eagle's medium (DMEM; Sigma, U.K.) 500 ml supplemented with 10 % of heat
inactivated (56°C, 30 min) horse serum (Invitrogen, U.K.) and 5 % ml of foetal bovine
serum (Invitrogen, U.K.). In addition, 5 ml of 100 units/ml penicillin / 100 mg/ml of
streptomycin (Sigma), 4 ml of 50 mg/ml hygromycin (Sigma), 100 pi of 250 pg/ml
amphotericin B (Sigma) and 10 ml of 4 mM glutamate (Sigma). In addition, 3 ml of
lOOmg/ml zeocin (Sigma) was added to SH-EPl-ha7 media. The cells were incubated at
37°C in a humidified atmosphere with 95% air/5% C02 and passaged once per week when
90 % confluent. Media was changed twice weekly.
2.2.2 GH4Cl-ha7 Stable Cell Line
This cell line was transfected by Dr. K. Finlayson. As a component of the
overall a7 nAChR project, a human a7 nAChR cDNA (Genbank Accession No. X70297)
was cloned from an adult brain cDNA library by Cytomyx (Cambridge, U.K.) and ligated
into the pcDNA3.1 expression vector between BamHl and Notl. GEI4C1 cells, a rat
pituitary cell line were obtained from the European Collection of Cell Cultures (ECACC,
U.K.) and stable cell lines generated following transfection with the human a7 nAChR
cDNA (Cytomyx, U.K.). The stably transfected cells were grown in Hams F-10 medium
(500 ml, Sigma, U.K.), supplemented with horse serum (15 % v/v, Invitrogen, U.K.) and
foetal bovine serum (2.5 % v/v, Invitrogen, U.K.). In addition, L-glutamine (2 mM, Sigma,
U.K.), penicillin (100 units/ml, Sigma, U.K.), streptomycin (100 pg/ml, Sigma, U.K.), and
G418 (500 pg/ml, Sigma, U.K.) was added, with the cells subsequently incubated at 37°C
in a humidified atmosphere with 95% air/5% C02. Cells were passaged once a week while
media was changed twice weekly.
2.2.3 Transient Transfection of SH-EP1 Cells with a Human a7 nAChR cDNA
SH-EP1 null cells (a generous gift from Dr. R. Lukas) were transiently-
transfected with the human a7 nAChR cDNA from Cytomyx (U.K.) as described in Section
2.2.2, with cells studied 24-48 h post-transfection. This work was performed by Dr. K.
Finlayson.
2.2.4 CHO-APP Cells
Chinese hamster ovaries (CHO) over-expressing the human amyloid precursor
protein (APP) were obtained from the European Collection of Cell Cultures (ECACC,
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U.K.). The stably expressing cells were maintained in Ham's F12 media with L-glutamate
(500 ml, Invitrogen, U.K.) supplemented with 50 ml foetal bovine serum (Invitrogen,
U.K.). 5 ml gentamicin (Invitrogen, U.K.) was added and cells incubated at 37°C in a
humidified atmosphere with 95% air/5% C02. Cells were passaged once a week while
media was changed twice weekly.
2.3 Radioligand Binding Studies
2.3.1 Membrane Preparation
2.3.1.1 Rodent Brain Membrane Preparation
Animals were sacrificed by Home Office Schedule one procedure, the brains
were removed, and immediately placed in ice-cold saline (0.9% NaCl, Sigma, U.K.). The
whole brain minus the cerebellum (due to the low density of a7 nAChR, Davies et al., 1999)
was used for the P2 synaptosomal membrane preparation. Following dissection, the brain
tissue was rolled on filter paper to remove superficial blood vessels, and weighed. At this
point, tissues were either pooled (in general 30 mouse brains or 10 rat brains) or treated
individually where noted. Brain tissue was homogenised in 15 volumes (15 vol. v/w) of
0.32 M sucrose using a glass/Teflon homogeniser, the homogenate centrifuged at 1,000 g for
10 min (4°C), and the resulting supernatant centrifuged at 17,000 g (20 min, 4°C). The
synaptosomal/mitochondrial P2 pellet was lysed in 30 vol. (v/w) of ice-cold water for 60
min and centrifuged at 50,000 g (10 min, 4°C). The membrane pellet was resuspended in
the appropriate assay buffer (see Section 2.3.2.1), centrifuged at 50,000 g for 10 min (4°C),
resuspended in 5 vol. (v/w) of the appropriate assay buffer and stored in 1.5 or 6 ml aliquots
at -20°C.
On the day of use, frozen membranes were thawed, resuspended in 30 vol. (v/w)
of appropriate assay buffer and the suspension centrifuged at 50,000 g for 10 min at 4°C.
The final pellet was then resuspended in the appropriate assay buffer and kept on ice prior to
use in the binding assay. The protein content of the brain tissue was determined using
Molecular Devices BCA protein assay kit (Molecular Devices, UK; Section 2.3.1.3).
For a7 nAChR transgenic mice experiments, brain membranes were prepared in
the same manner as above. However, for the determination of specific [3H]-
methyllycaconitine or [3H]-cytisine binding in transgenic mice brains, some brain tissue was
initially prepared as individual brains rather than as a pooled group.
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2.3.1.2 SH-EPl-ha7 and SH-EPl-ha4p2 Cell Membrane Preparations
Flasks (175cm2; Corning® Life Sciences, U.K.) containing confluent (90%) cells
were rinsed twice with 10 ml of pre-warmed (37°C) Hanks Balanced Salt Solution (HBSS,
Sigma, U.K.), prior to addition of 15 ml of 5 mM Tris buffer (4°C, pH 7.4). The cells were
dislodged from the flasks using a cell scraper and the suspension then placed on ice for 2 h
to lyse. The lysate was spun at 50,000 g (10 min, 4°C) and the pellet resuspended in a 5x
(v/w) of either 50 mM potassium phosphate buffer (pH 7.4; SH-EPl-ha7) or 15 mM
HEPES buffer (pH 7.4; SH-EPl-a4|32) and stored in 1 ml aliquots at -20°C.
2.3.1.3 BCA Protein Assay
Bovine serum albumin (BSA) standards (BCA Protein Assay Kit, Pierce, U.K.)
were made up in MLA/Cytsine assay buffer at a concentration of 0.03, 0.06, 0.125, 0.25, 0.5,
and 1 mg/ml. In a 96-well flat bottomed clear plate (Corning® Life Sciences, U.K.), 100 pi
of appropriate assay buffer was added into wells A1 and B1 which act as blank wells.
Standards (10 pi) were added in duplicate in rows A2 - A7 and B2 - B7. Samples (10 pi)
were then added to the 96-well plate in triplicate. The BCA reagent was made up to a
dilution of 98 % Reagent A + 2 % Reagent B and 200 pi of BCA reagent added to each well.
The plate was then covered in foil and incubated for 30 min at 37°C, prior to reading on a




The [3H]-epibatidine binding buffer consisted of 50 mM Tris-HCl containing 120
mM NaCl, 5 mM KC1, 1 mM MgCl2.6H20, and 2.5 mM CaCl2.2H20, pH to 7.4 with 5 M
Hydrochloric acid (HC1) at room temperature. The [3H]-epibatidine wash buffer consisted of
25 mM Tris HC1 (pH 7.4).
2.3.2.1 B [3H]-Cytisine Buffer
The assay buffer and wash buffers were identical for the [3H]-cytisine binding
experiments. The buffer consisted of 50 mM Trizma® hydrochloride, 120 mM NaCl, 5 mM
KC1, 1 mM MgCL and 2.5 mM CaCl2, pH to 7.0 with 5 M HC1 at room temperature.
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2.3.2.1C [3H]-Methyllycaconitine and [3H]-aBungarotoxin Buffers
The [3H]-MLA and [3H]-aBgTx assay buffer was a phosphate buffered saline
solution (pH 7.4 with NaOH). One litre of assay buffer was made up using 395 ml of 0.1 M
KH2PO4, 105 ml of 0.1 M K2HPO4 and 500 ml of MilliQ H20 supplemented with 1 mM
EDTA and 0.1 % (w/v) sodium azide. At room temperature this gives the buffer a pH of 7.4.
The [3H]-MLA and [3H]-aBgTx wash buffer consisted of 20 mM Na2HP04, 5
mM KH2P04, 150 mM NaOH, pH to 7.4 with 5 M NaOH.
2.3.2.2 Time Course Experiments
Time course experiments allow determination of when equilibrium of ligands and
receptors has been reached, allowing hot saturation and competitive inhibition binding
studies to be performed correctly. The time course of binding of the different radioligands
was performed using rodent brain, SH-EPl-ha7 or SH-EP1-ha4|32 membranes at a fixed
concentration of radioligand, excess cold inhibitor (non-specific binding (NSB), and
membranes. These assays were terminated by filtration through GF/B glass-fibre filters
(Whatman, U.K.) which had been presoaked (3 h) in [3H]-epibatidine assay buffer, [3H]-
cytisine assay buffer, or 0.3 % polyethylemine ([3H]-MLA and [3H]-aBgTx), using a Brandel
cell harvester (SEMAT Technical (UK) Ltd., U.K.), separating bound from free radioligand.
Concentrations of radioligand, membranes, and non-specific inhibitor are listed in Table 2.1.
Filters were then placed in 6 ml scintillation vials (VWR Scientific Products, U.K.) and 4 ml
of Emulsifier Safe™ scintillation fluid added. Vials were left overnight to equilibrate before
radioactivity was determined in a Packard 2500TR liquid scintillation counter using
automatic quench correction.
2.3.2.3 Hot Saturation Experiments
Radioligand binding levels in a membrane preparation (e.g. tissue or cells) are
dependent upon the protein content of the preparation and the specific activity and
concentration of the chosen radioligand (Bennett, 1985; Keen, 1995; Foreman, 2002).
Parameters measured are total binding, (TB, the amount of binding measured in the absence
of an unlabelled competitor) and non-specific binding (NSB, the amount of binding
measured in the presence of an excess unlabelled competitor). Specific binding (SB) is then
determined by subtracting NSB from TB. By keeping the membrane (receptor) density and
inhibitor concentrations fixed and only varying the radioligand concentration, these
experiments allow the determination of the equilibriation dissociation constant K<| of the
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radioligand and the number of binding sites Bmax it labels. In brief, radioligands (at
concentrations at least 10 (but preferably 100)-fold above and below the estimated KDi, see
Table 2.2, pg 37) were incubated with rat brain, SH-EPl-hcc4p2, or SH-EPl-ha7 cell
membranes for a minimum of 1 h at 22°C in 6 ml polypropylene tubes (12 x 75 mm, VWR).
Following the incubation period, bound radioligand was separated from free by
filtration through GF/B glass-fibre filters using a Brandel harvester and filters treated as
described in Section 2.3.2.2. Exact assay conditions for individual radiolabels are detailed in
Table 2.2.
2.3.2.4 Competitive Inhibition Binding Experiments
In competitive inhibition studies, the incubation time, membrane concentration,
and the radioligand concentration are all kept constant with the concentration of the
competing drug varied. As the concentration of the competing drug is increased the amount
of bound radioligand decreases, allowing determination of the concentration of the ligand
which inhibits 50% of specific radioligand binding (IC50). In brief, the radioligand (at a
fixed concentration) was incubated with membranes and increasing concentrations of
inhibitor for a set time period. Following the incubation period, bound radioligand was
separated as described previously (Section 2.3.2.2). Exact assay conditions for individual
radiolabels are detailed in Table 2.2.
2.3.2.4A [3H]-Epibatidine Competitive Inhibition Experiments
[3H]-Epibatidine (NEN DuPont, U.K., 48 Ci/mmol) competitive binding assays
were carried out by modification of a method described by Floughtling and colleagues
(1995). Epibatidine assay buffer (Section 2.3.2.1A) or test drug was incubated with [3H]-
epibatidine (final concentration 15 pM) and either 3 mg of rat brain membranes or 0.03 mg
of SFI-EP1-ha4p2 cell membranes in a total assay volume of 4 ml for 4 h at 22°C. Non¬
specific binding was determined in the presence of 300 pM (-)nicotine. To reduce NSB, the
glass-fibre filters were pre-soaked in epibatidine assay buffer for 3 hours prior to use.
Binding was terminated as described previously (Section 2.3.2.2). Full assay conditions are
detailed in Table 2.2. This work was performed by Dr. K. Finlayson.
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2.3.2.4B [3H|-Cytisine Competitive Inhibition Experiments
[3H]-Cytisine (NEN®DuPont, U.K., 35.2 Ci/mmol) competitive binding assays
were carried out by modification of a method described by Sabey and colleagues (1998).
Cytisine assay buffer or test drug was incubated with [3H]-cytisine (final concentration 3
nM) and either 400 pg of rat brain membranes or 115 pg of SH-EP1 -ha4p2 cell membranes
in a final assay volume of 250 pi (60 min, 22°C). Non-specific binding was determined in
the presence of 10 pM (-)nicotine with binding terminated as described previously (Section
2.3.2.2). To reduce NSB, GF/B glass fibre filters (Whatman) were pre-soaked in cytisine
assay buffer. Full assay conditions are detailed in Table 2.2.
2.3.2.4C [3H]-Methyllycaconitine Competitive Inhibition Experiments
The [3H]-Methyllycaconitine (([3H]-MLA), Tocris; 19.8 Ci/mmol) competitive
binding assay was carried out by modification of a method described by Davies et al.,
(1999). Assay buffer or test drug was incubated with [3H]-MLA (final assay concentration
of 2 nM) and either 400 pg of rat brain membranes or 150 pg SH-EP l-ha7 cell membranes
in a total assay volume of 250 pi (60 min, 22°C). Non-specific binding was determined in
the presence of 1 mM rZ-tubocurarine. Binding was terminated as previously described
(Section 2.3.2.2) using GF/B glass fibre filters pre-soaked in 0.3 % v/v poly(ethyleneimine).
Full assay conditions are detailed in Table 2.2.
2.3.2.4D [3H]-aBungarotoxin Competitive Inhibition Experiments
The [3H]-aBungarotoxin ([3H]-aBgTx) competitive inhibition experiments were
carried out in the same manner as the [3H]-MLA competitive assay using the same assay
buffer and only the following a small modification in assay protocol. The specific binding
of [3H]-aBgTx (2 nM; NEN®DuPont, U.K., 59 Ci m/mol) was determined by the addition
of 10 pM rZ-tubocurarine to assess NSB. Preliminary studies indicated aBgTx is an
irreversible ligand at a7 nAChRs and does not reach equilibrium. As a consequence, all
studies were terminated following a 6 h incubation period when specific binding
consistently reached 65 % with extended incubation times not producing any further
increase in the level of specific binding. It should be noted that because aBgTx is an
irreversible ligand, KD and K; values calculated for aBgTx are apparent values only and are
dependent upon the length of incubation time. Assay conditions are detailed in Table 2.2.
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2.3.2.4E Data Analysis
(i) Hot Saturation Studies
Data were fitted using a one-site saturation equation in SigmaPlot 2002, version 8
(SPSS UK Ltd., U.K).
y _ ^max ■ "
KD +X
where y is the specific binding (total - non-specific; in fmol/mg protein), x is the
concentration of free ligand, Bmax is the maximum number of binding sites (fmol/mg
protein), and KD is the concentration of ligand to reach halfmaximal binding.
(ii) Competitive Inhibition Studies
Data were fitted using an iterative, non-linear least square curve fitting program
SigmaPlot 2002 (version 8, SPSS UK Ltd., U.K.) to a one-site logistic model:
max - min
y = mm +
1 + 10<*-bgEC50)
where x is the log concentration of drug, y is the total or specific binding, min is the
minimum response plateau, max is the maximum response plateau, log ECS0 is the log of
EC50 or IC50.
The following equation was used for assessing any potential two-site binding;
y = mill + (max - mill)
+ 1 - F,
! + 10U-logEC501) ! + 1O(*-bgEC502)
where x is the log concentration of the inhibitor (cold ligand), y is total or specific binding,
min is non-specific binding, max is maximum binding in the absence of cold ligand, Fj is
the fraction of first class of receptor with the logEC50i being the affinity of the ligand for
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this site, and logEC502 being the affinity of the ligand for the second site. Units for max and
min are identical as those used fory.
When the inhibitor was the unlabelled fonn of the radioligand, the binding site
affinity, (KD) and the binding site density, (Bmax) were calculated using the following
equations;
(A) Kd = IC50 - [[3H]-radioligand]
(B) = (SB/RL,t)
[protein]
where IC50 is the concentration of the cold unlabelled ligand that inhibits 50 % of the
radiolabel binding to the receptor, SB is the specific binding (disintergrations per minute,
d.p.m.), RLSa is the specific activity of the radiolabel, and [protein] is the protein
concentration of tissue sample (mg).
For all other unlabelled competing ligands, Kj values were calculated using the
Cheng-Prusoff approximation (Cheng & Prusoff, 1973).
1 + ([[3H]-radioligand] / KD
2.3.2.4F Preparation of Soluble and Insoluble AP]_42
Human (or rat where stated) APi_42 (Calbiochem, U.K.) was resuspended in the
following manner to make 100 pM stock solutions of soluble amyloid (1) 5 % acetic acid
(Sigma) and MilliQ (MQ) H20 e.g. (Pettit et al., 2001), (2) 100 mM Tris buffer (pH 9.0)
containing 50 % dimethyl sulfoxide (DMSO, Sigma) and giving a final pH 8.0 (e.g. Wang et
al., 2000 personal communication), or (3) 100 mM HEPES (pH 8.5; Sigma, e.g. Dineley et
al., 2001). Likewise, human APi_42 obtained from Rpeptide (U.S.A.) was resuspended to 100
pM in sterile MQ H20.
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A solution of aggregated APi_42 was made in accordance with the instructions
supplied by Calbiochem (U.K.). In brief, 250 pg of APi_42 was dissolved to a concentration
of 6 mg/ml in sterile MQ H20 and then diluted to 1 mg/ml in magnesium-free, calcium-free
phosphate buffered solution (Invitrogen, U.K.). The stock solution was incubated at 37°C for
48 h and, following the incubation period, the solution was diluted to 100 pM in sterile MQ
H20.
All 100 pM Api_42 stock solutions were aliquoted (100 pM) and used fresh, or
frozen following storage at -20°C. On the day of use, Api_42 aliquots were diluted in the
appropriate assay buffer with all frozen aliquots used within 6 weeks.
2.3.2.4G Radioligands and Unlabelled Compounds
[3H]-Epibatidine (48 Ci/mmol) and [JH]-cytisine (35.2 Ci/mmol) were purchased
from NEN®DuPont, (U.K.) with [3H]-aBgTx (59 Ci/mmol) from Amersham Biosciences UK
Ltd. Galantamine hydrobromide, [3H]-MLA (56.17 Ci/mmol), methyllycaconitine citrate,
physostigmine sulphate, and tacrine hydrochloride were purchased from Tocris (Bristol,
U.K.). Acetylcholine, 4-aminopyridine (4-AP), atropine, bicuculline methoiodide, a-
bungarotoxin, choline, cytisine, l,l-dimethyl-4-phenylpiperazinium iodide (DMPP), d-
tubocurarine, epibatidine, methylcarbamylcholine chloride (MCCC), McN-A-343,
mecamylamine, methacholine chloride, (-)nicotine, pilocarpine, RJR2403, scopolamine, and
tetraethylammonium (TEA) were from Sigma (U.K). E2020 was supplied by Fujisawa
Pharmaceuticals Ltd. (Japan). The stereoisomers of the putatively selective a7 nAChR
agonist (-)AR-R17779 and (+)ARR-17779 (Mullen et al., 2000) were custom synthesised by
Tocris Cookson, (U.K.). Stock solutions for all drugs were prepared in distilled H20 and
diluted into the appropriate buffer on the day of the assay. All other standard chemicals were
of research grade.
2.4 Thioflavin T Assay For the Assessment of APm2 Aggregation
Human APi_42 stock solutions were prepared as detailed in Section 2.3.2.4F. The
degree of P-sheet aggregation of the APj.42 solutions was then determined using the
fluorescent dye, thioflavin T (Sigma, U.K.), which specifically binds to fibrous P-sheet
structures (Vassar & Culling, 1959; LeVine, 1993; Yoshiike et al., 2003). For time course
experiments, 40 pi of aggregated APi_42 stock solution (1 mg/ml; final assay concentration,
40 pM) was added to 20 pi of thioflavin T (final assay concentration 10 pM) and 140 pi of
sterile Milli Q water. For all other experiments, 10 pi of APj.42 (final assay concentration, 5
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pM) was added to 20 pi of thiotlavin T (final assay concentration, 10 pM), and 170 pi of
appropriate assay buffer ([3H]-MLA, [3H]-cytisine, or electrophysiology buffers). The assay
was conducted in a 96-well clear flat-bottomed black plates (Corning® Life Sciences, U.K.),
with samples shaken for 10 s prior to each measurement. For time course experiments,
measurements were made every 30 min for 48 h whereas for all other experiments, plates
were read immediately after the addition of thioflavin T.
The relative degree of P-sheet aggregation was assessed in terms of fluorescence
intensity, which was measured at 37°C (time course experiments) or 22°C (all other
experiments) using a Flexstation® Microplate Reader (Molecular Devices, U.K.). These
temperatures were chosen as 37°C is the Calbiochem recommended temperature to aggregate
APi-42 while all other experiments were conducted at 22°C to assess their degree of
aggregation under normal experimental conditions. Measurements were perfonned at an
excitation wavelength of 444 nm and an emission wavelength of 485 nm, resulting in a
maximal detection of bound thioflavin T (Yoshiike et al., 2003). The fluorescence intensity
of control samples containing either dye and cells, or dye, cells, and the control vehicle for
the APi_42 sample of interest were subtracted from that of each Api.42 sample to account for
background fluorescence. Results are presented in the form of mean ± S.E.M. which is an
average of three individual wells.
2.5 Intracellular Calcium and Membrane Potential Experiments
2.5.1 Cell Culture and 96-well Plate Preparation
The SFI-EP1-ha4P2 or SH-EPl-ha,7 cells were maintained in culture as described
in Section 2.2.1 and 2.2.2, respectively. For both fluorescence based assays, cells were
grown in 150 cm2 cell culture (vent cap/canted neck) flasks (Coming® Life Sciences, U.K.).
Two days before the experiment, 100 pi of poly-D-lysine (1 mg/ml, diluted 1:50) was added
to each well of a 96-well clear flat-bottomed black plates (Coming® Life Sciences, U.K.) and
left overnight in a laminar flow hood. The following day, an appropriate number of flasks
containing SH-EPl-ha4p2 or SH-EPl-ha7 cells were removed from the incubator, the waste
media removed using a stripette (Coming® Life Sciences, U.K.) and the cells rinsed twice
with pre-warmed (37°C) Hank's balanced salt solution (HBSS; Invitrogen, U.K.). To
encourage cell dissociation, 2.5 ml of trypsin-EDTA (0.25 % trypsin, 1 mM EDTA.4Na,
Invitrogen, U.K.) was added to the flasks prior to placement in the the incubator. After 5
min, 2.5 ml of the appropriate cell media was then added to neutralise the effects of trypsin
and the cell suspension transferred to a 50 ml centrifugation tube (Corning® Life Sciences,
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U.K.) prior to centrifugation at 150 g for 5 min. The supernatant was then removed and the
cell pellet resuspended in 10 ml of the appropriate cell media, prior to cell counting using a
haemocytometer. The cell suspension was diluted again if required to generate a solution of
approximately 1 million cells / ml. Any excess poly-D-lysine was removed from the 96-well
plate using a sterile yellow pipette tip attached to a vacuum filtration system and 100 pi of
cell suspension added to each well (final cell density was 100,000 cells/well). When higher
cell densities were required, the initial cell dilution was altered, and then the 96-well plates
were returned to the incubator and left overnight at 37°C, prior to use in either the
intracellular calcium or membrane potential assays.
2.5.2 Intracellular Calcium ([Ca2+] j) Assay
On the experimental day, the cell plates were removed from the incubator and the
supernatant removed. Calcium assay buffer (100 pi HBSS with 2 mM HEPES, pH 6.0;
Molecular Devices, U.K.) with an additional 2.5 mM Ca2+ added to the plate followed by
100 pi of calcium assay dye (FLIPR® Calcium Assay Kit, Molecular Devices, U.K.) added.
The plates were then incubated for 1 h at 37°C to facilitate equilibration. Agonist ligands
were made up at 5 x their final concentration in a separate 96-well flat bottomed clear plate
(Corning® Life Sciences, U.K.) and were added to the cell plate by the Flexstation®
fluorescence plate reader (Molecular Devices, U.K.) robotics system. In studies using
antagonists, the ligands (25 pi at 10 x final concentration) were added to the cell plates 50
min into the dye equilibration and preincubated for 10 min. Changes in [Ca2+]j were
measured by a change in fluorescence intensity determined by the Flexstation® plate reader
(Molecular Devices, U.K.) with excitation and emission wavelengths set at 485 and 525 nm,
respectively.
2.5.3 Membrane Potential Assay
Membrane potential assays were performed using a modification of the [Ca2+]j
assay method. On the experimental day, the cell plates were removed from the incubator and
the supernatant removed. Membrane potential assay buffer (100 pi of HBSS with 2 mM
HEPES, pH 6.0; Molecular Devices, U.K.) and 100 pi of membrane potential dye (FLIPR®
Membrane Potential Assay Kit, Molecular Devices, U.K.) were added and the plates were
incubated for 30 min at 25°C to facilitate equilibration. Agonist ligands were made up at 5 x
their final required concentration in a separate 96-well flat bottomed clear plate (Corning®
Life Sciences, U.K.) and were added to the cell plate by the Flexstation® fluorescence plate
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reader (Molecular Devices, U.K.) robotics system. In studies using antagonists, following a
20 min incubation, the ligands (25 pi at 10 x their final required concentration) were added
to the cell plates and preincubated for 10 min. Changes in membrane potential were
assessed by a change in fluorescence intensity determined by the Flexstation® plate reader
(Molecular Devices, U.K.) with excitation and emission wavelengths set at 535 and 560 nm,
respectively.
2.6 Whole-Cell Patch-Clamp Recordings
2.6.1 Preparation of SH-EPI-IUX4P2 and SH-EPl-ha7 Cell Lines
The cell lines used in these studies were the SH-EP1 human neuroblastoma cells
stably transfected with either human a4p2 nAChRs or human a7 nAChRs or GH4C1 cells, a
clonal rat pituitary cell line also stably expressing the human a7 nAChR. Cells were
maintained as previously described in Sections 2.2.1 - 2.2.3. For whole-cell patch-clamp
recordings, cells were plated on 35 mm dishes (Nunc™, U.K.) at a density of 2 x 104 cells/ml
and examined when 80 - 90 % confluent. Prior to electrophysiological recordings, the cell
media was removed, the cells rinsed in the appropriate bath solution, and allowed to
equilibrate at room temperature for 30 min.
2.6.2 Preparation of Recording Electrodes
Glass electrodes for whole-cell patch-clamp electrodes were made from
borosilicate glass (Intracel, U.K.) with glass dimensions of 1.5 mm O.D. x 1.17 mm I.D. and
containing a filament. The glass was mounted onto a Narashige pipette puller (Figure 2.2A)
and pulled, with respect to the ramp value of the glass, into a patch electrode. The electrode
tips were then fire polished using a heated platinum-iridium wire (Goodfellow Metals, U.K.)
to the required 4-6 MQ resistance.
2.6.3 Whole-Cell Patch Clamp Electrophysiology Recording
To reduce ambient noise and vibration, a major problem associated with
electrophysiology, all recordings were conducted in a Faraday cage with the recording
equipment mounted on a pressurised air table. Cells were visualised with a Nikon Diaphot
inverted microscope with Floffman modulation contrast (Modulation Optics Inc., USA) with
plates mounted on the microscope stage (List L/M-PC patch clamp amplifier, List-Medical,
Germany). Borosilicate glass patch electrodes back filled with the appropriate electrode
solution were mounted on a head stage (List L/M-PC patch clamp amplifier, List-Medical,
45
Germany) which was fixed to a micromanipulator (List L/M-PC patch clamp amplifier, List-
Medical, Gennany). After forming a tight seal (>1 GCl) on the cell surface suction was
applied to convert to conventional whole-cell recording. After breakthrough from the cell-
attached configuration to the whole-cell configuration, the cells were clamped at -60 mV by
a List L/M-PC patch clamp amplifier (List- Medical). Drugs were applied to cells using an
eight inlet barrel micromanifold (see Figure 2.3) with a single outlet tube having a diameter
of 200 pm. Drug delivery was controlled electronically using Lee valves and a valve
controller. The outlet tube was positioned close to the cell which was continuously
superfused with bath solution (1 ml/min into a holding chamber with an approximate volume
of 2 ml) via one inlet tube. Switching to other inlet tubes permitted application ofmultiple
drugs or drug concentrations. Suction also occurred at 1 ml/min to allow for circulation of
the recording solution in the holding chamber and the maintenance of a constant volume.
Whole-cell patch experiments were performed using a patch clamp amplifier
(List L/M-PC, Germany). Currents were low pass filtered at 1 kHz, digitised at 5 kHz using
an analogue-to-digital converter (Digitdata 1200A, Axon Instruments, USA) and stored on a
personal computer. Access resistance (Ra) and cell capacitance (Cm) were routinely
compensated, with Ra determined at the start and end of the experiment and data rejected if it
had changed more than 25 % from the initial value of <15 MQ before compensation. Series
resistance (RJ was routinely compensated at 70 %. Voltage commands were generated with
pClamp7 software (Axon Instruments, U.K.).
2.6.3.1 Drug Application Protocols For Electrophysiology
To determine the stability of nAChR responses 10 pM (-)Nicotine was applied for
375 ms every 3 min. Nicotine dose-response curves (0.3 nM - 1 mM) were generated in the
presence and absence of 100 pM d-tubocurarine (d-TC) applied pseudo-randomly as
described above. For studies investigating soluble human Ap,.42, sixteen cells were
randomly allocated into 4 groups of four with (-)nicotine (10 pM) again applied every 3 min
to produce an inward current (In;c). Following the initial application of nicotine, the
perfusing solution was switched from bath solution to one of the following for 6 min before
returning to bath solution; soluble human ApM2 (100 or 300 nM), Hepes vehicle, 5 % acetic
acid vehicle, 50/50 DMSO/Tris vehicle or BS. A delay of ~45 s was observed before the
new solution exited the outlet tube.
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2.6.3.2 Recording Solutions and Drug Dilutions
Whole-cell patch clamp recordings were made from SH-EP1 cell lines
continuously superfused in one of two bath solutions; (1) bath solution one (BSi) comprised
of (mM); 150 NaCl, 2.5 KC1, 2 CaCl2, 1 MgCl2, 10 D-glucose, 0.0005 tetrodotoxin, 10
Hepes, (Liu et al., 2001) or (2) bath solution two (BS2) comprised of (mM);. 120 NaCl, 3
KC1, 2 CaCl2, 2 MgCl2, 25 D-Glucose, 10 Hepes, (Zhao et all, 2003; Wu et al., 2004). Both
solutions were pH balanced to 7.4 with NaOH, and osmolarity maintained between 300 and
310 mOsm
Pipette electrode solutions were matched to the bath solution. BS, pipettes were
filled with (mM); 100 CsCH3S03, 20 CsCl, 2 MgCl2, 2 Mg-ATP, 10 Hepes, 20
phosphocreatine, adjusted to pH 7.2 with CsOH (Liu et al., 2001). In contrast, BS2 pipettes
were filled with a K+-free electrode solution (mM); 110 Tris phosphate dibasic, 28 Tris base,
11 EGTA, 2 MgCl2, 0.1 CaCl2, 4 Na-ATP, pH 7.3 with Tris base (Zhao et al., 2003).
(-)Nicotine was dissolved and serially diluted in the appropriate bath solution, d-
Tubocurarine was dissolved in MilliQ water and serially diluted in bath solution. Human
APi .42 was prepared as previously described in Section 2.3.2.4F (Rpeptide Apt_42 in sterile
water, Calbiochem APi_42 dissolved in Hepes, 5 % acetic acid, or 50/50 DMSO/Tris) and
serially diluted in the BS2. The 100 pM APi_42 stock aliquots were frozen at -20°C and used
fresh or within 6 weeks of reconstitution. On the day of the experiment, ApM2 aliquots were
dissolved in bath solution to a concentration of either 100 or 300 nM.
2.6.3.3 Data Analysis
All inward current responses are based on measurements of peak current
amplitude using pClamp7 software (Axon Instruments, U.K.). Data were exported into
SigmaPlot 2002 (version 8, SPSS UK Ltd., U.K.) for graphing and fitted using an iterative,
non-linear least square curve fitting program to a one-site logistic model as described in
Section 2.3.2.4E.
2.7 Western Blot and Co-Immunoprecipitation Studies of Human a4p2 and a7
nAChRs and Human APi_42
2.7.1 Preparation of SH-EPl-ha4p2 and SH-EPl-ha7 and CHO-APP Cell Lysates
for Western Blot Analysis
SH-EP1 cell lines stably expressing the human a4p2 or a7 nAChRs were
maintained in culture as previously described (Section 2.2.1) with both cell lines plated at a
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density of 5 million/10 cm2 dish (Corning* Life Sciences, U.K.) and left overnight at 37°C.
On the following day, each dish was rinsed three times with 2 ml of warm sodium phosphate
buffer (NP Buffer; 100 mM NaCl, 25 mM NaHiPCfl, pH 7.4), a further 5 ml of NP buffer
added to each dish, the cells scraped and collected in a 50 ml centrifuge tube. Samples were
then spun at 1,000 g for 5 min (22°C) and the supernatant discarded. The pellet was
resuspended in NP buffer (200 pi/confluent plate) containing protease inhibitors (Complete
protease inhibitor cocktail mini tablet, 1 tablet per 10 ml, Roche Diagnostics, U.K.) and
homogenised using a Teflon-glass homogeniser (10 strokes, at 4°C). The resultant solution
was then centrifuged (Biofuge Fresco, Heraceus Instruments, U.K.) at 13,000 r.p.m. for 10
min at 4°C, the supernatant discarded and the pellet resuspended in either NP extraction
buffer (Extraction Buffer 1 (EB|): 200 pl/confluent plate; supplemented with protease
inhibitors and 1 % Triton X-100) or in sodium chloride extraction buffer (Extraction Buffer 2
(EB2): 150 mM NaCl, 10 mM HEPES, 0.01 % CHAPS, 0.001 mM PMSF, 10 pg/ml protease
inhibitor cocktail (Sigma, U.K.), pH 7.4). The tube was secured on a rotating platform at
room temperature (22 - 25°C). After 45 min the tube was centrifuged (Biofuge Fresco,
Heraceus Instruments, U.K.) at 13,000 r.p.m. for 10 min and the supernatant fraction
containing the solubilised membrane protein retained. Total protein concentration was
determined using the BCA protein assay kit (Section, 2.3.1.3; Pierce, UK).
2.7.2 Immunoprecipitation of nAChR
SH-EPI-IKX4P2 and SH-EPl-ha7 cells were maintained in culture as previously
described (Section 2.2.1) with both cell lines plated at a density of 5 million/10 cm2 dish
(Corning® Life Sciences, U.K.) and left overnight at 37°C. On the following day, each dish
was rinsed three times with 2 ml ofwarm NP buffer (see Section 2.7.1), a further 5 ml ofNP
buffer added to each dish, the cells scraped and collected in a 50 ml centrifuge tube.
Samples were then spun at 1,000 g for 5 min (22°C) and the supernatant discarded. The
pellet was resuspended in NP buffer (200 pl/confluent plate) containing protease inhibitors
(Complete protease inhibitor cocktail mini tablet, 1 tablet per 10 ml, Roche Diagnostics,
U.K.) and homogenised using a Teflon-glass homogeniser (10 strokes, at 4°C). The tube was
secured on a rotating platform at room temperature (22 - 25°C). After 45 min the tube was
centrifuged at 13,000 r.p.m. (10 min at 4°C) and the pellet discarded. A small volume of
supernatant was kept and labelled as starting material (SM). The remaining supernatant
fraction (1 mg) was incubated overnight at 4°C with the appropriate antibody (Table 2.3) in
the presence of protein G agarose beads (Sigma, U.K.). Immunoprecipitates were collected
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by centrifugation (13,000 r.p.m., 10 s, 4°C) and washed three times in NPT buffer (NP Buffer
supplemented with 1 % Triton X-100) before resuspension in SDS-PAGE sample buffer
(NuPAGE® sample buffer, Invitrogen, U.K.) containing p-mercaptoethanol (20 pi per
sample, Sigma, U.K.). Samples of supernatant were retained after each wash step and
labelled (in order) Wl, W2, W3 and depleted supernatant (DSn). The immunoprecipitant
and sample buffer mix was heated at 95°C for 10 min before undergoing western analysis.
2.7.3 Western Blot Analysis
Lysates (30 pg protein) prepared in EBi were diluted in Nupage® LDS sample
buffer (Invitrogen, U.K.) containing the reducing agent P-mercaptoethanol (20 pi per
sample) and heated at 95°C for 10 min. Likewise, lysates (30 pg protein) prepared in EB2
were diluted in the same sample buffer but containing the reducing agent DL-Dithreitol (0.1
M) and heated at 95 °C for 10 min. Solubilised protein, regardless of sample buffer utilised,
was collected and subjected to SDS-PAGE separation on pre-cast 4-12% acrylamide gels
(NuPAGE® Bis-Tris, Invitrogen, U.K.). The Western blot apparatus was supplied by
Invitrogen, U.K. (XCell Surelock™ Mini Cell) and was assembled as follows; The comb was
gently removed from the pre-cast gel cassette exposing the gels' sample loading wells which
were gently rinsed with running buffer (NuPAGE® MES SDS Running Buffer, Invitrogen,
U.K.). The tape covering the slot on the back of the gel cassette was also removed. The
buffer core was lowered into the lower buffer chamber so that the negative electrode fit the
opening in the gold plate on the lower buffer chamber. The gel tension wedge (unlocked)
was inserted behind the buffer core and the gel cassette(s) were placed on either side of the
core with the "well" side of the cassette facing the buffer core. To hold the gels in place the
gel tension wedge was pulled into the locked position. The upper chamber (the void between
the two gel cassettes) was filled with -200 ml of running buffer ensuring complete coverage
of the sample wells. Finally, 500 pi of antioxidant (NuPAGE® Antioxidant, Invitrogen,
U.K.) was added to the upper chamber. Individual samples and markers (2 pi of
MagicMarkers™ Western Protein Standards and 5 pi of Seeblue® Plus2 standard protein
markers, Invitrogen, U.K.) were loaded into the sample wells and run for 35- 40 min at a
constant 200 V.
At the end of the run, the gel cassettes were removed from the chamber and the
two plates separated using a gel knife. Sponge pads (Invitrogen, U.K.), filter paper (BioRad,
U.K.) and nitrocellulose transfer membranes (Hybond ECL, Amersham Biosciences, U.K.)
were pre-soaked for 10 min in NuPAGE® Transfer buffer (Invitrogen). When polyvinylidene
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difluoride (PVDF: Hybond™-P, Amersham Biosciences) transfer membranes were used, the
membrane was pre-wet in 100 % methanol and rinsed in deionised water before soaking in
Nupage® transfer buffer (Invitrogen, U.K.) for 10 min. Gels, transfer membrane, and
blotting pads were arranged in the following order on top of the cathode (-) core of the XCell
11™ Blot Module (Invitrogen; for 1 gel); 2 blotting pads, filter paper, gel, transfer membrane,
filter paper, 2 blotting pads. After placing the anode (+) core on top of the pads, the blot
cassette was placed in the cathode core of the XCell II™ Blot Module (Invitrogen, U.K.), in
line with the guide rails, and the gel tension wedge locked in place. The blot module was
filled with transfer buffer until the gel/membrane assembly was completely covered. The
outer buffer chamber was filled with -650 ml of deionised water and the gels were
transferred at a constant 30 V for 1 h.
At the end of the transfer period the membrane was blocked by phosphate
buffered saline (PBS: 137 mM NaCl, 2.7 mM KC1, 10 mM phosphate buffer solution, pH
7.4) containing 5 % skimmed milk powder (BioRad, U.K.) and incubated overnight (4°C)
with the appropriate antibody (Table 2.3). After three 5 min washes in PBS containing 0.05
% Tween 20 (Sigma, U.K.) the appropriate secondary horseradish peroxidase conjugated
antibody was added in PBS containing 5 % skim milk powder for 1 h at room temperature
(Table 2.3). After a further three 5 min washes in PBS containing 0.05 % Tween 20, the
horseradish peroxidase, second antibody labelled bands were visualised using an ECL Plus
Western Blotting detection kit (Amersham Biosciences).
2.7.4 Co-Immunoprecipitation Analysis of Human nAChRs and Human APi_42
SH-EP1 cell lines stably expressing the human a4p2 or a7 nAChRs were
maintained in culture as previously described (Section 2.2.1) with both cell lines plated at a
density of 5 million/10 cm2 dish (Coming® Life Sciences, U.K.) and left overnight at 37°C.
On the following day, each dish was rinsed three times with 2 ml ofwarm sodium phosphate
buffer (NP Buffer; 100 mM NaCl, 25 mM NaH2P04, pH 7.4), a further 5 ml of NP buffer
added to each dish, the cells scraped and collected in a 50 ml centrifuge tube. Samples were
then spun at 1,000 g for 5 min (22°C) and the supernatant discarded. The pellet was
resuspended in NP buffer (200 pi/confluent plate) containing 1 pM human APi_42 (Rpeptide,
U.S.A.) and the tube secured on a rotary mixer (22 - 25°C) to allow for equilibration. After
1 h the tube was centrifuged for 10 min at 13,000 rpm (4°C), the supernatant discarded and
the pellet resuspended in NP buffer (200 pl/confluent plate) containing protease inhibitors
supplemented with 1 % Triton X-100 (NPT Buffer). The tube was secured again on a
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Table 2.3: Antibodies Used for Western Blot and Co-Immunoprecipitation,
Immunoprecipitation Experiments


















































































All antibodies were diluted in PBS with 5 % non-fat milk unless otherwise stated. The goat
polyclonal antibody sc-1447 (Santa Cruz) was used at a dilution of 1:100 for a7 nAChR Western blots
with an anti-goat IgG secondary antibody (1:10,000, Sigma).
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rotating platform at room temperature (22 - 25UC). After 45 min the tube was centrifuged at
13,000 r.p.m. for 10 min (4°C) and the pellet discarded. A small amount of supernatant was
kept and labelled as starting material (SM). The remaining supernatant fraction (1 mg) was
incubated overnight (4°C) with the appropriate antibody (Table 2.3) in the presence of
protein G agarose beads (Sigma, U.K.). Immunoprecipitates were collected by
centrifugation and washed three times in NPT buffer before resuspension in NuPAGE® LDS
sample buffer (Invitrogen, U.K.) containing p-mercaptoethanol (20 pi per sample, Sigma).
Samples of supernatant were retained after each wash step and labelled (in order) Wl, W2,
W3 and depleted supernatant (DSn). The immunoprecipitate and sample buffer mix was
heated at 95°C for 10 min before undergoing western analysis as described above.
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3 Pharmacological Characterisation of the a4p2 and a7 nAChRs
3.1 INTRODUCTION
Although a number of recent papers have highlighted a potentially direct
interaction between the nAChRs and APi_42 (Kihara et al., 1998; Wang et al., 2000a,b; Court
et al., 2001; Dineley et al., 2001, 2002a,b; Liu et al., 2001; Pettit et al., 2001; Tozaki et al.,
2002; Fu & Jhamandas, 2003; Grassi et al., 2003; Fodero et al., 2004; Wu et al., 2004;
Kihara & Shimohama, 2004a,; de Fiebre & de Fiebre, 2005), controversy remains as to the
exact nature of these interactions or indeed the subtype(s) of nAChR involved. To date, the
majority of these new but still limited studies have focused primarily on the interaction
between the a7 nAChR and APi„42 (Wang et al., 2000a,b; Dineley et al., 2001, 2002a,b; Liu
et al., 2001; Pettit et al., 2001; Grassi et al., 2003; Fodero et al., 2004) although some have
focused on the interaction with the a4p2 nAChR (Kihara et al., 1998; Tozaki et al., 2002; Fu
& Jhamandas, 2003; Wu et al., 2004).
The functional characterisation of the a7 nAChR both in vitro and in vivo has
proven somewhat difficult due to the combined lack of subtype-selective ligands (Kem,
2000) and difficulties with maintaining stable expression of the a7 nAChR in cultured
mammalian cell lines (Cooper & Millar, 1997). Although some studies have demonstrated
the presence of a7 mRNA (Aztiria et al., 2000; Sweileh et al., 2000) or protein (Cooper &
Millar, 1997) in a variety of cell types transfected with the a7 nAChR, only a limited number
of these cell lines have sufficient surface expression of this receptor to characterise
radioligand binding of the a7 nAChR-specific antagonist, aBgTx (Cooper & Millar, 1997;
Craig et al., 2004). To solve the problem of low or no surface expression of the a7 nAChR,
many researchers have resorted to overexpressing the a7 nAChR in cell lines that
endogenously express other types of nAChRs (Puchacz et al., 1994; Blumenthal et al., 1997)
or by generating an a7/5-hydroxytryptamine-3 (5HT3) receptor chimera that retains a7
nAChR pharmacology whilst utilising the effective expression of the 5HT3 receptor (Cooper
& Millar, 1998; Dineley & Patrick, 2000; Craig et al., 2004). The human neuroblastoma cell
line SH-SY5Y has been used to successfully over-express the a7 nAChR (Puchacz et al.,
1994; Cooper & Millar, 1997), however this cell line endogenously expresses a range of
nAChRs including the a7 nAChR itself (Cooper & Millar, 1997). In contrast, the SH-EP1
human epithelial cell line which is related to the SH-SY5Y cell line (Peng et al., 1999), has
no native nAChRs and can be treated to produce many of the characteristics of neurons
(Ross et al., 1983). This cell-line has been used to stably express both the a4p2 (Eaton et al.,
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2003) and a7 nAChRs (Peng et al., 1999) and, through an excellent collaboration, Dr. R. J.
Lukas (Barrow Neurological Institute, Texas, U.S.A.) has kindly supplied these two stable
cell lines.
Historically, characterisation of the a7 nAChR has been perfonned using
abungarotoxin (aBgTx), a potent a7 nAChR antagonist derived from the venom of the snake
Bungarus multicinctus (Couturier et al., 1990; Schoepfer et al., 1990; Seguela et al., 1993).
However, unlike the small molecule methyllycaconitine (MLA), controversy exists around
whether a large peptide such as aBgTx can access all 5 potential binding sites on the a7
nAChR (Conti-Tronconi & Raftery, 1986; Palma et al., 1996; Balass et al., 1997; Rangwala
et al., 1997; Arias, 2000). The recent availability of the a7 nAChR-specific antagonist
methyllycaconitine in a tritiated form ([3H]-MLA; Davies et al., 1999) facilitates a more in-
depth analysis of the a7 nAChR, although the number of studies to date remain limited to a
few separate studies of a7 nAChR pharmacology in rat (Davies et al., 1999), mouse
(Whiteaker et al., 1999), and insect brain tissues (Lind et al., 2001). Importantly, because of
the problems surrounding a7 nAChR expression in neuronal cell lines discussed above, no
systematic cross-species comparison of rodent and human a7 nAChRs has been performed
nor indeed has a systematic analysis of the human a7 nAChR itself been performed using
[3H]-MLA. However, initial [3H]-MLA binding studies in rodent brain tissue have suggested
that although the majority of binding sites in rat (Davies et al., 1999) and mouse (Whiteaker
et al., 1999) brain are labelled by [3H]-MLA, a small proportion of sites were found to be
insensitive to aBgTX.
Prior to assessing whether A(3i_42 interacts with a4p2 and/or a7 nAChRs, it is
important to establish robust information of the pharmacology of both receptor subtypes. As
such, two radioligand binding assays were established to examine the pharmacology of the
a4p2 nAChR ([3H]-epibatidine and [3H]-cytisine) and the a7 nAChR ([3H]-MLA and [3H]-
aBgTx). The affinity of a core group of nicotinic ligands ((-)nicotine, cytisine, 1,1-
dimethyl-4-phenylpiperazinium, <7-tubocuranne & MLA; Paterson & Nordberg, 2000;
Sharpies & Wonnacott, 2004) for a4p2 and a7 nAChRs was determined using [3H]-
epibatidine, [3H]-cytisine, and [3H]-MLA binding assays. In addition, the range of
compounds examined in the [3H]-MLA assay was expanded to include drugs such as the
putative a7 nAChR-specific agonists AR-R17779 (Levin et al., 1999) and RJR-2403
(Bencherif et al., 1996), acetylcholinesterase inhibitors such as galanthamine (Zwart et al.,
2000), and allosteric potentiating ligands such as codeine (Storch et al., 1995). Furthermore,
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using the SH-EP1 cell line in which the human a7 nAChR was overexpressed, the [3H]-MLA
and [3H]-aBgTx assays have been directly compared to further investigate the differences in
the ability ofMLA and aBgTx to bind to the a7 nAChR, observed in previous studies using
rat and mouse brain tissue (Davies et al., 1999; Whiteaker et al., 1999).
Finally, the [3H]-cytisine and [3H]-MLA binding assays were used as part of a
collaborative set of studies with the behaviourists in out Fujisawa Institute of Neuroscience
in Edinburgh to examine a7 nAChR knockout mice and their heterozygous and wildtype
littermates. Aspects of this work have been incorporated into one published (Young et al.,
2004) and one accepted manuscript (Young et al., 2006, in press).
55
3.2 RESULTS
3.3 Characterisation of a4|32 nAChR Pharmacology in Rat Brain and SH-EP1-
ha4p2 Cell Membrane Preparations Using [3H]-Epibatidine
Species differences in receptor pharmacology have been observed for a number of
ion channels (Price et al., 1996; Hibell et al., 2000). The availability of SH-EP1 cells
overexpressing the human a4p2 nAChR allowed the thorough characterisation of the
pharmacology of this receptor subtype, prior to examining its interaction with APi_42.
Membranes were prepared from rat brain tissue (P2 fraction) and the SH-EPl-ha4p2 cell line
and a4p2 nAChR pharmacology examined using the high affinity nicotinic agonist [3H]-
epibatidine. Epibatidine itself is an alkaloid isolated from skin extracts of the poisonous
Ecuadorian frog epipedorates tricolour (Daly, 1995).
3.3.1 Time Course of [3H|-Epibatidine Binding in the SH-EPl-ha4p2 Cell
Membrane Preparation
To determine when [3H]-epibatidine binding to the a4p2 nAChR was at
equilibrium, the radioligand (15 pM) was incubated with membranes prepared from rat brain
tissue or from the SH-EP1 cell line over-expressing human a4p2 nAChRs (SH-EPl-ha4p2)
and specific binding measured as a function of time (Figure 3.1). When [3H]-epibatidine was
incubated with rat brain membranes at 22°C, equilibrium was attained by ~2 h and remained
constant for at least 6 h (Figure 3.1A). In contrast, when [3H]-epibatidine was incubated
with the SH-EPl-ha4p2 cell membranes, equilibrium was only attained at 4 h and held at a
constant level of specific binding for up to 6 h (Figure 3.IB). As a consequence, all
subsequent [3H]-epibatidine binding experiments were terminated by vacuum filtration after
a 4 h incubation period.
3.3.2 Concentration Dependence of [3H]-Epibatidine Binding in SH-EPl-ha4p2 Cell
Membrane Preparations
Radioligand binding levels in a membrane preparation (e.g. tissue or cells) are
dependent upon the protein content of the preparation and the specific activity of the chosen
radioligand (Bennett, 1985; Keen, 1995; Foreman, 2002). Parameters measured are total
binding, (the amount of binding measured in the absence of an unlabelled competitor) and
non-specific binding (the amount of binding measured in the presence of an excess
unlabelled competitor e.g. in the current experiments non-specific binding was detennined
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by 300 pM (-)nicotine) with specific binding determined by subtracting the non-specific
from the total binding.
To detennine the equilibrium dissociation constant (KD) for [3H]-epibatidine
binding sites in rat brain and SH-EPl-hcc^ cell membranes, hot saturation experiments
were performed using increasing concentrations of [3H]-epibatidine (Figure 3.2). These
studies showed that [3H]-epibatidine binding was saturable and consistent with a single high
affinity binding site in rat brain (nH = 0.88 ± 0.06, n = 4) and SH-EPl-ha4p2 cell membranes
(nH = 1.00 ± 0.05, n = 4). From the representative examples of the concentration dependence
of [3H]-epibatidine in rat brain and SFI-EPl-ha4p2 membrane preparations shown in Figure
3.2, Kd values were calculated to be 26.1 ± 2.5 pM (« = 4) and 28.5 ± 5.5 pM (n = 4) in the
rat and human preparations, respectively. Specific [3FI]-epibatidine binding in rat brain
membranes accounted for 92.2 ± 0.6 % of total binding sites at a free radiolabel
concentration close to the KD (20 - 30 pM; Figure 3.3A). Similar levels of specific binding
were observed in the SH-EPl-ha4P2 cell membranes where specific binding accounted for
91.4 ± 3.1 % of total binding sites (Figure 3.3B).
In all subsequent binding experiments, [3H]-epibatidine binding (15 pM) was
perfonned at 25°C for 4 h.
3.3.3 Inhibition of [3H]-Epibatidine Binding to Rat and Human a4p2 nAChRs by
Cholinergic Agonists and Antagonists
A range of standard nAChR ligands were examined for their ability to inhibit [3H]-
epibatidine (15 pM) binding to rat brain or SH-EPl-ha4p2 cell membrane preparations. All
six nicotinic ligands examined inhibited [3Fl]-epibatidine (15 pM) binding in both rat brain
and SFFEPl-ha4p2 cell membranes in a concentration-dependent manner (Figure 3.4). The
rank order of potency for the ligands studied was (±)epibatidine > cytisine > (-)nicotine >
l,l-dimethyl-4-phenylpiperazinium iodide (DMPP) > MLA = cZ-tubocurarine with data from
a typical experiment shown in Figure 3.4 and with average KD/Ki values shown in Table 3.1.
Unlabelled (±)epibatidine inhibited [3FI]-epibatidine binding in rat brain and SH-EPl-ha4p2
cell membranes with KDs values equal to 26.9 ± 7.05 pM (« = 9) and 42.2 ±13.2 pM (n = 4),
respectively. These values are consistent with the KD values obtained in the hot saturation
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Time Course of Specific [3H]-Epibatidine Binding in (A) Rat Brain and (B) SH-EPI-IKX4P2
Membrane Preparations. Membranes (250 pg rat; 80 pg SH-EPl-ha4P2) were incubated (22°C)
with [3H]-epibatidine (15 pM) in a total assay volume of 4 ml for up to 6 h. Each total binding was
tested in duplicate with its non-specific counterpart (defined by 300 pM (-)nicotine) tested in
singulate. Specific binding points were derived by subtracting non-specific binding from total binding
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Concentration Dependence of [3H]-Epibatidine Binding in a4p2 nAChR Membrane
Preparations. (A) Rat brain (250 pg) or (B) SH-EPl-houPa cell membranes (80 pg) were incubated
(22°C) with increasing concentrations of [3H]-epibatidine in a total assay volume of 4 ml for 4 h.
Non-specific binding was determined in the presence of 300 pM (-)nicotine. These data are from
representative hot saturation studies in rat brain and SH-EPl-ha4p2 cell membranes, respectively.
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from nanomolar for cytisine (540 ± 110 pM, n = 4 in rat brain; 1710 ± 500 pM, n = 4 in SH-
EPl-ha4p2 cells) to the micromolar range for MLA (3.27 ± 0.95 pM, n = 5 in rat brain; 4.70
± 1.31 pM, n = 5 in SH-EPl-ha4p2 cells) (Figure 3.4, Table 3.1). In general the Hill
coefficients (nH) for both the agonists and antagonists were close to unity in both membrane
preparations (Figure 3.4, Table 3.1) and are in agreement with the single site affinity
observed in the hot saturation experiments. No significant differences in compound affinity
was detected on comparing the results for both species, giving an excellent correlation for
the ligand affinities at a4p2 nAChRs in rat brain and in the SH-EPl-ha4p2 cell membranes (r2


























Proportions of ['H]-Epibatidine Binding in Rat Brain or SH-EPl-ha.^ Cell Membrane
Preparations. Membranes ((A) 250 pg, rat or (B) 80 pg, SH-EPl-ha4p2 cells) were incubated with
[3H]-epibatidine (15 pM) in a total assay volume of 4 ml for 4 h at 22°C. Non-specific binding was







































Pharmacology of [3H]-Epibatidine Binding Sites in Rat and Human a4p2 nAChR Membranes.
(A) Rat brain (250 jag) or (B) SH-EPl-ha4p2 cell membranes (80 fig) were incubated (22°C) with
[JH]-epibatidine (15 pM) in the presence of the nicotinic agonists (±)epibatidine (•) cytisine (■) and
(-)nicotine (A) and the antagonists d-tubocurarine (T) and MLA (♦) in a total assay volume of 4 ml
for 4 h. Non-specific binding was determined in the presence of 300 pM (-)nicotine. The data
represent a typical experiment with each point performed in duplicate and with mean data obtained
from at least 3 individual experiments (Table 3.1).
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Figure 3.5
log Human IC (M)
Correlation of the Kj values ofNicotinic Ligands for [3H]-Epibatidine Binding Sites in Rat Brain
and SH-EPI-IUX4P2 Cell Membranes. The solid line represents a linear regression through the Kj
values shown in Table 3.1. The r2 value (0.99) is close to unity indicating no species differences in
compound affinity for rat and human a4(32 nAChRs.
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3.4 Pharmacological Characterisation of the a4p2 nAChR in Rat Brain and SH-
EPl-ha4p2 Cell Membranes Using [3H]-Cytisine
Historically, radiolabelled versions of the nicotinic agonists epibatidine and
cytisine have been used to characterise a4p2 nAChR pharmacology (Pabreza et a/., 1991;
Gnadisch et al., 1999). The [3H]-epibatidine assay described in Section 3.1 used a large
assay volume and a low ligand concentration in an attempt to avoid depletion. However, this
assay is not amenable to miniaturisation and cannot be reduced to a 96-well format for high
throughput characterisation of a4p2 nAChR pharmacology.
In addition to assessing whether depletion had occurred in the [3H]-epibatidine
assay, I was given the opportunity to visit the laboratories ofmy Ph.D sponsor, the Fujisawa
Pharmaceutical Company (now Astellas Pharma Inc.) in Japan, where I was involved in the
set up and miniaturisation of high throughput screening assays for the nicotinic receptor
programme. Both the [3H]-cytisine and [3H]-MLA (see Section 3.3) binding assays were
successfully transferred to 96-well plate format and screening was initiated. Although I
personally screened approximately 40,000 compounds, reorganisation of disease areas and
project rationalisation led to the discontinuation of this approach. To date, there is still a
lack of truly receptor-selective a4p2 and a7 nAChR agonists and antagonists which would
help in clearly elucidating the role of these receptors in a variety of central and peripheral
diseases.
In this next section I will present the development of the [3H]-cytisine binding assay
for the assessment of rat and human a4p2 nAChR pharmacology.
3.4.1 Time Course of [3H]-Cytisine Binding in Rat and Human a4p2 nAChR
Membrane Preparations
The incubation temperature of any assay can affect the time it takes for a ligand-
receptor interaction to reach equilibrium. While colder temperatures (e.g. 4°C) may increase
the time to attain equilibrium, conversely warmer temperatures (e.g. 37°C) may decrease it
(Bennett, 1985).
To determine when [3H]-cytisine binding (3 nM) to rat a4p2 nAChRs reached
equilibrium, the binding of this radioligand was examined in rat brain tissue as a function of
time (Figure 3.6 & 3.7). Initial time course studies were performed at 4°C as Pabreza and
colleagues (1991) had shown that [JH]-cytisine binding in rat brain membranes achieved
equilibrium within 60 min. In contrast, my studies showed that when pHj-cytisine (3 nM)
was incubated with rat brain membranes at 4°C, specific binding failed to attain equilibrium
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despite using incubation periods of up to 4 h (Figure 3.6). Therefore, I examined [3H]-
cytisine (3 nM) binding in rat brain membranes at 25°C and 37°C (Figure 3.7). At both
incubation temperatures [3H]-cytisine (3 nM) binding in rat brain a4p2 membranes reached
equilibrium within minutes remaining constant for up to 4 h (Figure 3.7).
To facilitate a direct comparison between [3H]-cytisine binding in rat brain tissue
with membranes prepared from the SFI-EP1 cell line over-expressing the human a4p2
nAChRs (SH-EPl-ha4p2), and with the [3Fl]-epibatidine binding studies, the time course of
[3H]-cytisine binding was examined using the latter membrane preparation. When SH-EP 1-
ha4p2 cell membranes were incubated with [3FI]-cytisine (3 nM) at 25°C, equilibrium was
attained by about 10 min, even faster than that observed for rat brain membranes and
remained constant for up to 2 h (Figure 3.8).
As a consequence, all subsequent [3H]-cytisine binding experiments using both rat
brain and SFI-EP1-ha4p2 cell membranes were terminated by vacuum fdtration after a 60
min period at 25°C.
3.4.2 Concentration Dependence of [3H]-Cytisine Binding in Rat and Human a4p2
Membrane Preparations
At a free radiolabel concentration close to the expected KD (2.5 - 4 nM), specific
[3H]-cytisine binding in rat brain membranes accounted for 85.2 ±3.9 % of total binding
sites. This value was higher in SH-EPl-ha4p2 cell membranes where specific binding
accounted for 95.2 ± 1.3 % of total binding sites (Figure 3.9).
In order to determine KD and max values for [3H]-cytisine binding sites in rat brain
and SH-EPl-ha4p2 cell membrane preparation, hot saturation experiments were conducted
with increasing concentrations of the radioligand. Representative examples of the
concentration dependence of [3PI]-cytisine binding in rat brain and SH-EP1-hoc4p2 membrane
preparations are shown in Figure 3.10. The affinity (KD) of [3H]-cytisine was equal to 3.77 ±
0.86 nM (n = 4) and 4.11 ± 1.21 nM (n = 5) in rat brain and SH-EPl-ha4p2 cell membranes,
respectively (Figure 3.10, Table 3.2). These studies showed that [3H]-cytisine binding was
saturable and consistent with a high affinity binding site in rat brain (nn = 0.81 ± 0.10, n = 4)
and SH-EPl-ha4p2 cell membranes (nH = 1.32 ± 0.35, n = 5; Table 3.2). The density of [3H]-
cytisine binding sites (max) in rat membranes was significantly less (max = 0.43 ± 0.15
pmol/mg protein; n = 4) than that found in the SH-EP l-ha4p2 cell membrane preparations
(max = 131 ±35 pmol/mg protein; n = 5; p < 0.05 (Table 3.2). However, the max value for rat


























Time Dependence of [ H]-Cytisine Binding in Rat Brain Membrane Preparations at 4°C.
Membranes (400 pg) were incubated with [3H]-cytisine (3 nM) in a total assay volume of 250 pi for
various times at 4°C. For each time point, total binding was determined in duplicate with their non¬
specific counterpart (defined by 10 pM (-)nicotine) tested in singlet. Specific binding was calculated






Time Dependence of [3H]-Cytisine Binding in Rat Brain Membrane Preparations at 25°C and
37°C. Membranes (400 fig) were incubated with [3H]-cytisine (3 nM) in a total assay volume of 250
pi for various times at (A) 25°C or (B) 37°C. For each time point, total binding points was determined
in duplicate with their non-specific counterpart (defined by 10 pM (-)nicotine) tested in singlet.
Specific binding was calculated by subtracting non-specific binding from total binding, with this
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Incubation of [3H]-Cytisine with SH-EPl-ha4p2 Cell Membranes. Membranes (SH-EPl-ha4p2,
115 |ag) were incubated with [3H]-cytisine (3 nM) in a total assay volume of 250 pi for various times
at 25°C. Bound radioligand was separated from free by filtration through GF/B glass-fibre filters and
analysed using liquid scintillation spectrometry. Total binding points were tested in duplicate with
their non-specific counterpart (defined by 10 pM (-)nicotine) tested in singulate. Specific binding
points were derived by subtracting non-specific binding from total binding with these data













Proportions of [3H]-Cytisine Binding in Membranes Prepared From Rat Brain or SH-EP1-
hajP: Cell Membrane Preparations. (A) Rat brain (400 pg) or (B) SH-EPl-ha+Pj cell membranes
(115 pg) were incubated (22°C) with [3H]-cytisine (3 nM) in a total assay volume of 250 pi for 60
min. These data are from an average of 4-5 individual hot saturation studies.
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Figure 3.10
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Concentration Dependence of [3H]-Cytisine Binding in a4p2 nAChR Membrane Preparations.
(A) Rat brain (400 pg) or (B) SH-EPl-ha4p2 cell membranes (115 pg) were incubated with increasing
concentrations of [3H]-cytisine in a total assay volume of 250 pi for 60 min at 25°C. Bound
radioligand was separated from free by filtration through GF/B glass-fibre filters and analysed using
liquid scintillation spectrometry. Non-specific binding was determined in the presence of 10 pM (-
)nicotine. These data are from a representative hot saturation study.
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Table 3.2 Kd and BIllax Values for [3H|-Cytisine Binding Sites in Rat
Brain and SH-EPl-ha4(32 Cell Membranes
Species Kd (nM) n nii Bmax
(pmol/mg protein)
Rat 3.77 ±0.86 4 0.81 ±0.10 0.43 ±0.15*
Human 4.11 ± 1.21 5 1.32 ±0.35 131 ±35*
Affinity (KD), Hillslope (nH), and binding site densities (Bmax) determined for [3H]-cytisine
binding using hot saturation assays as described in the methods. Values are expressed as mean
± S.E.M., (n = 4-5). Statistical analyses were performed using one-way ANOVA with
Bonferroni post-hoc testing where p < 0.05 was used to indicate a significant difference. No
difference in ligand affinity between species was observed, although there was a considerable
difference in receptor density.
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1993; Gopalakrishnan et al., 1997). The high density of [JH]-cytisine binding sites in the
SH-EP1 stable cell line (~300-fold higher than in rat brain membranes) makes these cells
particularly useful for pharmacological studies of the binding properties of ligands, as much
less tissue is used when compared to that required in the rodent studies.
For the subsequent competitive inhibition studies, [3H]-cytisine was used at a final
concentration of 3 nM, just below the KD value.
3.4.3 Inhibition of [3H]-Cytisine Binding to Rat and Human a4p2 nAChRs by
Cholinergic Agonists and Antagonists
Five cholinergic agonists and antagonists were examined in the [3H]-cytisine
binding assay. All the nicotinic ligands examined inhibited [3H]-cytisine (3 nM) binding in
both rat brain and SH-EPl-ha4p2 cell membranes in a concentration dependent manner
(Figure 3.11). The rank order of potency for the ligands studied in both membrane
preparations was cytisine = (-) nicotine > DMPP > MLA > J-tubocurarine with data from a
typical experiment shown in Figure 3.11 (Table 3.3). Unlabelled cytisine inhibited [3H]-
cytisine binding in rat brain and SH-EPl-ha4p2 cell membranes with KD values equal to 1.18
± 0.30 nM (n = 4) and 3.35 ± 0.43 nM (n = 3), respectively (Table 3.3). As predicted, the KD
values for cytisine at rat and human a4p2 nAChRs were similar when determined in hot (Kd)
and/or cold saturation experiments (Tables 3.2 & 3.3). The affinity (Kj) of the other
compounds tested ranged from low nanomolar for (-)nicotine (3.81 ± 1.91 nM, n = 3 in rat
brain; 4.40 ± 1.50 nM, n = 4 in SH-EPl-ha4p2 cells) to the micromolar range for d-
tubocurarine (17.2 ± 2.03 pM, n = 3 in rat brain; 5.05 ± 1.14 pM, n = 4 in SH-EPl-ha4p2
cells) (Figure 3.11, Table 3.3).
Although the range of compounds examined is limited, Figure 3.12 shows a good
correlation between the Kj values of the ligands for rat brain and SH-EPl-ha4p2 cell
membranes. However, the agonist DMPP (256 ± 47 nM in rat brain vs. 71.5 ± 14.4 nM in
SH-EPl-ha4p2 cells; p < 0.05) and the antagonist r/-tubocurarine (17.2 ± 2.0 pM in rat brain
vs. 5.04 ± 1.14 pM in SH-EPl-ha4p2 cell membranes; p < 0.05), both exhibited marginally
higher affinities at the human a4p2 nAChRs. This difference is evident when the Kj ratios
are determined for the individual ligands with both DMPP and d-'IC having a ratio of around
3 (Table 3.3). Although the Hill coefficients for the nicotinic ligands were generally close to
unity in both membrane preparations although there was some degree of variability
particularly with cytisine which had a nH = 1.92 ± 0.39 (« = 5; Figure 3.11, Table 3.3).
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Pharmacology of |3H]-Cytisine Binding Sites in Rat and Human nAChR Membranes. (A)
Rat brain (400 pg) or (B) SH-EPl-ha4p2 cell membranes (115 pg) were incubated (22°C) with [3H]-
cytisine (3 nM) in the presence of the nicotinic agonists cytisine (•), (-)nicotine (■), DMPP (A), and
the antagonists MLA (▼) and d-tubocurarine (♦) in a total assay volume of 250 pi for 60 min.
Bound radioligand was separated from free by filtration through GF/B glass-fibre filters and measured
using liquid scintillation spectrometry. Non-specific binding was determined in the presence of 10
pM (-)nicotine. These data represent a typical experiment with each point performed in duplicate
with mean data obtained from at least 3 experiments (Table 3.3).
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Figure 3.12
log Human K, (M)
Correlation of the Kj values of Nicotinic Ligands for [3H]-Cytisine Binding Sites in Rat Brain
and SH-EPl-ha4p2 Cell Membranes. The solid line represents a linear regression through the
nicotinic data represented in Table 3.3. The similarity of both the r2 value (0.95) and slope (1.12) to
unity indicates no species differences in compound affinity for rat and human a4p2 nAChRs.
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As mentioned earlier, due to the picomolar affinity of epibatidine, binding studies
unless conducted properly could be subject to depletion. To circumvent this problem we
increased the volume of the [3H]-epibatidine binding assay to 4 ml. As Figure 3.13 clearly
shows; there is an excellent correlation between the ligand affinities in the [3H]-cytisine and
[3H]-epibatidine assays using the human a4p2 nAChR membrane preparation. Although




Correlation of the Ki values of Nicotinic Ligands for [3H]-Epibatidine and [3H]-Cytisine Binding
Sites in SH-EPl-houPi Cell Membranes. The solid line represents a linear regression for the
compound affinities (Kj) represented in Tables 3.1 & 3.3. Both the r2 value (0.99) and the slope (1.01)
are at unity indicating no differences in ligand affinity between the two assays.
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3.5 Pharmacological Characterisation of the a7 nAChR in Rat Brain and SH-
EPl-ha7 Cell Membranes Using [3H]-Methyllycaconitine
As discussed in the introduction, the a4(32 and a7 nAChRs are the two major
nicotinic receptors in the CNS. The a7 nAChR continues to be investigated as it has
potential roles in inflammation (e.g. Wang et al., 2003), schizophrenia (e.g. Guan et al.,
1999; De Luca et al., 2004; Deutsch et al., 2005), and AD (e.g. Bednar et al., 2002; O'Neill
et al., 2002; Yu et al., 2005). Although there are still no potent and selective a7 nAChR
agonists commonly available in a radiolabelled form, historically the antagonist
aBungarotoxin ([125I]-aBgTx) has been used to characterised a7 nAChR pharmacology
(Clarke et al., 1985; Falk et al., 2003). The identification of MLA as a small and potent
competitive a7 nAChR antagonist (unlike the large peptide antagonist aBgTx) therefore
potentially circumvented problems such as use of the iodinated compound and access to
synaptic receptors and therefore led to the production of [3H]-MLA (Aiyar et al., 1979;
Davies et al., 1999; Whiteaker et al., 1999; Lind et al., 2001). However, [3H]-MLA binding
studies remain limited to studies analysing the rodent (Davies et al., 1999; Whiteaker et al.,
1999) or amphibian a7 nAChR (Lind et al., 2001). Therefore, a systematic and
comprehensive comparison of rat and human a7 nAChR pharmacology was conducted using
the antagonist [3H]-MLA.
3.5.1 Time Course Determination of [3H]-MLA Binding in Rat Brain and SH-EP1-
ha7 Cell Membrane Preparations
To determine when [3H]-MLA binding to the a7 nAChR attained equilibrium, the
antagonist was incubated with membranes prepared from either rat brain tissue or from a
human cell line over-expressing the human a7 nAChR (SH-EPl-ha7) and specific binding
measured over a two hour period. [3H]-MLA binding attained equilibrium within 20 min (at
25°C) in both membrane preparations and held constant for at least 2 h (Figure 3.14). These
observations are consistent with the findings of Davies and colleagues (1999) using rat brain
membranes and as a consequence, all subsequent experiments were conducted for 60 min at
25°C and terminated by vacuum filtration.
3.5.2 Concentration Dependence of [3H]-MLA Binding in a7 nAChR membrane
preparations
Specific [3H]-MLA binding in rat brain tissue accounted for 70.9 ± 3.4% of total




Time Course of Specific [3H]-MLA binding in (A) Rat Brain and (B) SH-EPl-ha7 Membrane
Preparations. Membranes (400 pg rat; 60 pg SH-EPl-ha7) were incubated (22°C) with [3H]-MLA
(2.5 nM) in a total assay volume of 250 pi for up to 2 h. Each total binding was tested in duplicate
with its non-specific counterpart (defined by 10 pM c/-tubocurarine) tested in singulate. Specific
binding points were derived by subtracting non-specific binding from total binding with these data
representing a typical experiment.
80
1999). This value was slightly higher in SH-EPl-ha7 cell membranes where specific
binding accounted for 80.3 ± 4.5% of total binding sites (Figure 3.15).
To determine KD and Bmix values for [3H]-MLA binding sites in membranes from
rat brain and SH-EPl-ha7 cells, hot saturation experiments were performed with increasing
concentrations of [3H]-MLA. Representative examples of the concentration dependence of
[3H]-MLA binding to rat and human membrane preparations are shown in Figure 3.16, with
affinity (KD) values of 1.71 ± 0.32 nM (n = 5) and 5.10 ± 0.95 nM (n = 5) in rat brain and
SH- EPl-ha7 cell membranes, respectively shown in Table 3.4. [3H]-MLA binding was
saturable and consistent with a single high affinity binding site in both rat brain (nH = 1.37 ±
0.20, n = 5) and SEl-EPl-ha7 cell membranes (nH = 1.17 ± 0.05, n - 5; Figure 3.16).
Furthermore, saturable binding in the hot saturation studies allowed the measurement of the
density of a7 nAChRs in these membrane preparations, giving Binax values of 0.18 ± 0.01
pmol/mg protein (rat; n- 5) and 7.08 ± 0.70 pmol/mg protein (SH-EPl-ha7; n = 5; Figure
3.16, Table 3.4). The Kp/Ki of MFA was also determined using inhibition studies in which
[3H]-MFA (2.5 nM) was incubated with increasing concentrations of unlabelled MFA. In
excellent agreement with the KD values determined in the hot saturation studies, the K^/Kj
values for MLA in the inhibition experiments were 2.74 ± 0.34 (n = 9) and 5.04 ± 0.68 (n =
11) in rat brain and SH-EPl-ha7 cell membranes, respectively (Figure 3.17). Indeed, the
high density of [3H]-MFA binding sites in the stable cell line (-35 times greater than in rat
brain tissue) makes these cells particularly useful for pharmacological studies of the binding
properties of ligands, as much less tissue is required for studying the human a7 nAChR.
In all subsequent binding experiments, [3H]-MFA binding (2.5 nM) was
performed at 25°C for 60 min unless otherwise stated.
3.5.3 Inhibition of [3H]-MLA Binding to Rat and Human oc7 nAChRs by
Cholinergic Agonists and Antagonists
3.5.3.1 Inhibition of [3H]-MLA Binding to Rat Brain and SH-EPl-ha7 Cell
Membranes by Cholinergic Receptor Antagonists
The receptor-selective antagonists MLA (Figure 3.17) and aBgTx both inhibited
[3H]-MLA binding in rat brain and SH-EPl-ha7 cell membranes in a concentration-
dependent manner (Figure 3.18). The rank order of potency for the four nicotinic
antagonists examined was aBgTx = MLA > d-tubocurarine > mecamylamine in both
membrane preparations, with representative inhibition curves shown in Figure 3.18 and












Proportions of [3H]-MLA Binding in Rat Brain or SH-EPl-h(X7 Cell Membrane Preparations.
Membranes ((A) 400 pg rat; (B) 60 pg, SH-EP-ha7) were incubated with [3H]-MLA (2.5 nM) in a
total assay volume of 250 pi for 60 min at 22°C. Non-specific binding was determined in the presence




Concentration Dependence of [3H]-MLA Binding in a7 nAChR Membrane Preparations. (A)
Rat brain (400 pig) or (B) SH-EPl-ha7 cell membranes (60 pg) were incubated with increasing
concentrations of [3H]-MLA in a total assay volume of 250pl for 60 min at 22°C. Non-specific
binding was determined in the presence of 10 pM d-tubocurarine. These data are from representative
hot saturation studies in rat brain and SH-EPl-ha7 cell membranes, respectively.
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Table 3.4 Kd and Bmax Values Determined for [3H]-MLA Binding Sites in
Rat Brain and SH-EPl-ha? Cell Membranes
Species KD (nM) n nH Bmax (pmol/mg protein)
Rat 1.71 ±0.32 5 1.37 ±0.20 0.18 ±0.01
Human 5.01 ±0.95 5 1.17 ±0.05 7.08 ±0.70*
Affinity (KD), Hill slope (nH), and Bmax determined in [3H]-MLA binding studies using hot saturation
assays as described in the methods. Values are expressed as mean ± S.E.M., (n = 5). Statistical
analyses were performed using one-way ANOVA with Bonferroni post-hoc testing. No difference in
ligand affinity between species was observed, although there was a significant difference in receptor




Inhibition of [3H]-MLA Binding by Unlabelled MLA in Rat Brain and SH-EPl-ha7 Cell
Membrane Preparations. (A) Rat brain (400 pg) or (B) SH-EPl-ha7 cell membranes (60 pg) were
incubated with [3H]-MLA (2.5 nM) and increasing concentrations of unlabelled MLA in a total assay
volume of 250 pi for 60 min at 25°C. Non-specific binding was determined in the presence of 10 pM
uf-tubocurarine. The data represent the mean ± S.E.M. of (A) n = 9, rat or (B) n = 11, SH-EPl-ha7
cold saturation experiments.
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aBgTx (Ki = 1.40 ± 0.42 nM; n = 4;rat brain) and K, = 2.40 ± 0.40; n = 8; SH-EPl-ha7) to
the millimolar range for mecamylamine (10.3 mM; n = 2; rat) and 1.2 ± 0.3 mM (n = 3, SH-
EPl-ha7). However, it must be noted that even concentrations of up to 3 p.M aBgTx did not
produce full inhibition in either rat brain or SH-EPl-ha7 cell membrane preparations. In rat
brain tissue 1 pM aBgTx produced a maximal inhibition of 80 %, whilst a higher (3 pM)
concentration produced only 40 % inhibition in SH-EPl-ha7 membranes (Figure 3.18). This
intriguing observation has been investigated further and these studies are reported in Section
3.6.
In addition to looking at nicotinic antagonists, the ability of the muscarinic
antagonists atropine and scopolamine to inhibit [3H]-MLA binding to rat and human a7
nAChRs was also examined. Interestingly, both compounds inhibited [3H]-MLA binding
with atropine 2-3 fold more potent than scopolamine in both rat and SH-EPl-ha7 membrane
preparations (Table 3.5). Indeed, both compounds were an order of magnitude more potent
than mecamylamine. In general, Hill coefficients (nH) for all the cholinergic antagonists
were close to unity in both membrane preparations (Table 3.5).
Although the number of nicotinic antagonists was limited (MLA, aBgTx, cl-
tubocurarine, and mecamylamine), there is excellent correlation between nicotinic antagonist
Kj values for rat brain and SH-EPl-ha7 cell membranes, with an r2 = 1.00 and a slope of 1.20
(Figure 3.19). Statistical analyses generally showed no significant change in nicotinic
antagonist affinity for the two a7 nAChR membrane preparations. However, the muscarinic
antagonists atropine and scopolamine, were more potent at the human a7 nAChR (p < 0.05).
3.5.3.2 Inhibition of [3H]-MLA Binding to Rat Brain and SH-EPl-ha7 Cell
Membranes by Cholinergic Receptor Agonists
A range of cholinergic agonists were examined for their ability to inhibit [3H]-
MLA binding in rat brain and SH-EPl-ha7 cell membranes. All 11 agonists examined
inhibited [3H]-MLA binding in a concentration-dependent manner with a rank order of
potency at rat a7 nAChRs being; (-)AR-R 17779 = (+)epibatidine > DMPP > cytisine > (-
)nicotine > methylcarbamylcholine chloride (MCCC) > (+)AR-R17779 > RJR-2403 >
acetylcholine > choline > methacholine chloride (Table 3.6). For simplicity, Figure 3.20
shows inhibition curves for four of these compounds. In rat brain tissue, the affinity of the
nicotinic ligands varied from the high nanomolar range for (-)AR-R 17779 (Kj = 252 ± 51




Inhibition of [3H]-MLA Binding by Cholinergic Antagonists. (A) Rat brain (400 pg) or (B) SH-
EPl-ha7 cell membranes (60 pg) were incubated (22°C) with [3H]-MLA (2.5 nM) in the presence of
nicotinic antagonists methyllycaconitine (•), abungarotoxin (■), J-tubocurarine (A), and atropine
(T) in a total assay volume of 250 pi for 60 min. Non-specific binding was determined in the
presence of 10 pM cZ-tubocurarine. The data represent a typical experiment with each point performed
in duplicate with mean data obtained from at least 3 experiments (Table 3.5).
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log Human K. (M)
Correlation of the Affinity (Kj) of Nicotinic Antagonists at [3H]-MLA Binding Sites in Rat Brain
and SH-EPl-ha7 Cell Membranes. The ability of the antagonists abungarotoxin (aBgTx; apparent
Kj), methyllycaconitine (MLA), of-tubocurarine, and mecamylamine to inhibit [3H]-MLA binding in
rat brain and SH-EPl-ha7 cell membranes. The solid line represents a linear regression through the
mean Kj values for the nicotinic antagonists represented in Table 3.5. Both the r2 value (1.00) and the
slope (1.20) are at unity indicating no differences in ligand affinity between the two species.
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In SH-EP1 cell membranes expressing the human a7 nAChR, the rank order of potency for
nicotinic agonists in SH-EPl-ha7 cell membranes was slightly different (i)epibatidine > (-
)AR-R17779 > DMPP > (-)nicotine > cytisine > MCCC > acetylcholine > RJR-2403 >
(+)AR-R17779 > choline > methacholine chloride (Figure 3.20, Table 3.6). In contrast to
the ligand affinities determined for rat brain membranes, the affinity of the nicotinic
compounds in SH-EPl-ha7 cell membranes varied from the low nanomolar range for
(±)epibatidine (K, = 3.35 ± 0.63 nM; n = 8) to the micromolar range for methacholine
chloride (Kt = 80.5 ± 11.9 pM; n = 4, Table 3.6).
The nicotinic agonists generally exhibited a much higher affinity (~2 orders of
magnitude) for human a7 nAChRs when compared to those found in rat brain tissue (Table
3.6). Indeed, (+)epibatidine inhibited [3H]-MLA binding to SH-EPl-ha7 nAChRs with a Kj
value of 3.4 ± 0.6 nM (n = 8) whereas, the Kj value in rat brain tissue was more than 100-
fold higher (Kj = 372 ± 46 nM, n = A\p < 0.005). Interestingly, although (-)AR-R17779 had
a similar potency (Kj = 20.4 ± 8.9 nM; n = 6) to (±)epibatidine in SH-EPl-ha7 cell
membranes, it exhibited only a 10-fold increase in potency in rat brain membranes (K, = 252
± 51; n = 6). The observation that (-)nicotine had more than 100-fold higher affinity for the
human a7 nAChRs in SH-EP1 cell line (K; = 0.3 ± 0.07 pM, n = 6) compared to the rat
brain membrane preparation (Kj = 39.8 ± 5.3 pM, n = 7), has major implications in health
and disease. As the muscarinic antagonists scopolamine and atropine inhibited [3H]-MLA
binding, I also examined two muscarinic agonists McN-A-343 and pilocarpine. Both
compounds inhibited [3H]-MLA binding in rat brain and SH-EPl-ha7 cell membranes with
McN-A-343 more potent than a number of nicotinic agonists (Table 3.7).
Agonist Hill coefficients obtained in rat brain tissue were generally greater than
unity, perhaps indicative of some form of positive co-operativity (Table 3.6 & 3.7). In
contrast, Hill coefficients obtained for agonists at the human a7 nAChR were equal to or
below unity (Table 3.6 & 3.7). These differences in agonist affinity at the a7 nAChR in
different species are illustrated clearly in Figure 3.21, which correlates agonist affinities for
rat and human a7 nAChRs. There is an excellent correlation between agonist affinities




-10 -9 -8 -7
[Drug] (M)
Inhibition of [3H]-MLA Binding by Cholinergic Agonists. (A) Rat brain (400 pg) or (B) SH-EP1-
ha7 cell membranes (60 pg) were incubated (22°C) with [3H]-MLA (2.5 nM) and various
concentrations of the nicotinic agonists (-)AR-R17779 (•), (-)nicotine (■), cytisine (A), and (+)AR-
R17779 (▼) in a total assay volume of 250 pi for 60 min. Non-specific binding was determined in
the presence of 10 pM d-tubocurarine. These data represent a typical experiment with each point
performed in duplicate with mean data obtained from at least 3 experiments (Table 3.6).
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log Human Kj (M)
Correlation of the Affinity (K;) of Nicotinic Agonists at [3H]-MLA Binding Sites in Rat Brain
and SH-EPl-ha7 Cell Membranes. The solid line represents a linear regression through the data
represented in Table 3.6 with an r2 = 0.92 and a slope of 1.09. Data points represent (±)epibatidine
(Epi), (-)AR-R17779 ((-)AR), l,l-dimethyl-4-phenylpiperazinium iodide (DMPP), (-)nicotine (Nic),
cytisine (Cyt), MCCC (MCCC), acetylcholine (ACh), RJR-2403 (RJR), choline (Cho), (+)AR-
R17779 ((+)AR), and methacholine chloride (Meth).
94
3.5.3.3 Inhibition of [3H]-MLA Binding to Rat Brain and SH-EPl-ha7 Cell
Membranes by Acetylcholinesterase Inhibitors, Allosteric Potentiating
Ligands, and General Channel Blockers
It has been known for some time that acetylcholinesterase (AChE) inhibitors such
as galanthamine may also interact directly with nAChRs (Pascuzzo et al., 1984; Alkondon et
al., 1997; Samochocki et al., 2000; Kihara et al, 2004). The ability of related
acetylcholinesterase inhibitors and putative allosteric potentiating ligands to inhibit [3H]-
MLA (2.5 nM) binding in rat brain and SH-EPl-ha7 cell membranes was examined. I also
examined non-selective channel blockers that included 4-aminopyridine (4-AP),
tetraethylammonium (TEA), and (-)bicuculline.
All eight compounds examined inhibited [3H]-MLA binding in a concentration-
dependent manner with four representative compounds shown in Figure 3.22. The rank
order of potency for these ligands at a7 nAChRs in rat brain membranes was; E2020 >
bicuculline methiodide = tacrine > physostigmine > codeine > galanthamine > 4-AP > TEA
(Table 3.8). The rank order of affinity at human a7 nAChRs differed slightly from that seen
in the rat brain membrane preparation being; bicuculline methiodide > E2020 > tacrine >
galanthamine = physostigmine = codeine > 4-AP > TEA (Table 3.8). The affinity of the
ligands in the two membrane preparations differed slightly, although not as considerably as
seen for the agonists. Kj values for the compounds in rat brain varied from the micromolar
range for E2020 (Kj = 44.13 ± 1.72 pM; n = 4) to the high millimolar range for TEA (Kj =
897 ± 106 mM; n = 4), while ligand affinity in the SH-EPl-ha7 cell membrane preparation
were from low micromolar for E2020 (Kj = 11.1 ± 1.4, n = 4) to low millimolar for TEA (Kj
= 22.8 ± 2.8 mM, n = 4).
Hill coefficients for ligands examined in rat brain and SH-EPl-ha7 cell
membranes were generally equal to or marginally greater than unity (Table 3.8). Due to the
varying ligand pharmaco-profiles a correlation plot has not been drawn, however, statistical
analyses using a one-way ANOVA with Bonferroni post-hoc testing indicates the
compounds in general examined exhibited lower affinity for binding sites in rat brain
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Inhibition of [3H]-MLA Binding by Acetylcholinesterase Inhibitors, Allosteric Potentiating
Ligands, or General Channel Blockers in Rat Brain and SH-EPl-ha7 Cell Membranes. (A) Rat
brain (400 pg) or (B) SH-EPl-h(X7 cell membranes (60 pg) were incubated (22°C) with [3H]-MLA
(2.5 nM) and compounds including bicuculline (•), tacrine (■), codeine (T), or galanthamine (A) in
a total assay volume of 250 pi for 60 min. Non-specific binding was determined in the presence of 10
pM (/-tubocurarine. The data represent a typical experiment with each point performed in duplicate
with mean data obtained from at least 3 experiments (Table 3.8).
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3.6 Comparison of |3H]-aBgTx and [3H]-MLA Binding Sites in SH-EPl-ha7 Cell
Membranes
Unlike methyllycaconitine, controversy exists as to whether a large peptide such as
aBgTx can access all 5 potential binding sites on the a7 nAChR (Conti-Tronconi & Raftery,
1986; Palma et al., 1996; Balass et al., 1997; Rangwala et al., 1997; Arias, 2000). In
agreement with the only reasonably comprehensive study on | 'I I]-MLA binding (Davies et
al., 1999), unlabelled aBgTx only produced 80 % inhibition of [3H]-MLA binding sites in
rat brain membranes (Section 3.5, Figure 3.18; Figure 3.23). In addition to aBgTx not
completely inhibiting MLA binding to rat brain, the Hill coefficient was slightly greater than
unity (nH = 1.29 ± 0.05, n = 4), which requires further investigation. To address these issues,
more detailed studies of the aBgTx/[3H]-MLA interaction was examined using the SH-EP 1-
ha7 cell line. As this cell line contains no native nACh receptors and has only been
transfected with the human a7 nAChR it should serve as a pure a7 nAChR population with
potentially no additional sites (Peng et al., 1999; Sweileh et al., 2000). Despite this pure a7
nAChR population, unlabelled aBgTx only produced 40 % inhibition of [3FI]-MLA binding
sites in SH-EPl-ha7 cell membranes, even less than that observed in the rat brain membranes
(Section 3.5, Figure 3.18; Figure 3.23). The Hill coefficient for aBgTx inhibition at the
human a7 nAChR was however, still slightly greater than unity (nH = 1.29 ± 0.07, n =8).
To determine whether the lack of inhibition of [3H]-MLA binding sites by aBgTx
was due to accessibility because of the large size of aBgTx, the assay length was varied to
allow the study of the time course of binding, giving aBgTx an extended period of time to
penetrate the cells/membranes and gain access to the a7 nAChR. Rat brain and SH-EP1 -ha7
cell membranes were incubated in the presence of aBgTx for up to 140 min prior to the
termination of the assay (Figure 3.24). Even using a preincubation period of up to 140 min
for aBgTx in rat brain and SH-EP l-ha7 cell membranes resulted in no increase in the level
of inhibition of [3H]-MLA binding. Data for the latter membranes is shown in Figure 3.24.
This was despite a slight increase in the affinity of aBgTx with increasing incubation time
(Table 3.9). For comparison these studies were also carried out with MLA and as Table 3.9
shows, the affinity ofMLA for SH-EP l-ha7 did not vary with the incubation period.
With no changes in the level of inhibition by aBgTx with time, these differences
were investigated further by establishing a [3H]-aBgTx binding assay using the human a7
nAChR cell membranes. The use of [3H]-aBungarotoxin rather than [l25I]-aBungarotoxin
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Figure 3.23
Inhibition of [3H]-MLA Binding Sites in Rat Brain and SH-EPl-ha7 Cell Membranes by aBgTx.
Rat brain (•, 110 jag) or SH-EPl-ha7 cell membranes (■, 60 jig) were incubated (22°C) with [3H]-
MLA (2.5 nM) and various concentrations of unlabelled aBgTx in a total assay volume of 250 jil for
60 min. Non-specific binding was determined in the presence of 10 |iM J-tubocurarine. Specific
binding points were derived by subtracting non-specific binding from total binding with these data
representing a typical experiment. Triangles represent non-specific binding levels in the rat brain (A)
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The Effect of Lengthening the Incubation Period on aBgTx Inhibition of [3H]-MLA Binding
Sites in SH-EPl-ha7 Cell Membranes. SH-EPl-ha7 cell membranes (60 pg) were incubated with
various concentrations of aBgTx for 20 (•), 60 (■), 80 (A), and 140 (▼) min at 22°C with [3H]-
MLA (2.5 nM) in a total assay volume of 250 pi. Non-specific binding was determined in the
presence of 10 pM <f-tubocurarine with these data representing the mean ± S.E.M. of 4 -5 separate
experiments.
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facilitated a more direct comparison of [3H]-MLA and [3H]-aBgTx binding sites in SH-EP1-
ha7 cell membranes, without the inclusion of a large iodine molecule.
3.6.1 Time Course Determination of [3H]-aBungarotoxin Binding in the
SH-EPl-ha7 Cell Membrane Preparation
To determine when [3H]-aBungarotoxin ([3H]-aBgTx) binding to the human a7
nACliR attained equilibrium, SH-EPl-ha7 cell membranes were incubated with [3H]-aBgTx
(2 nM) and the interaction examined as a function of time (Figure 3.25). Despite incubation
(22°C) of [3El]-aBgTx (2 nM) with SH-EPl-ha7 cell membranes for up to 8 h, specific
binding failed to reach equilibrium (Figure 3.25).
This is probably the result of aBgTx being an irreversible antagonist (Alkondon &
Albuquerque, 1991). To ensure consistency and sufficient specific binding, an incubation
period of 6 h was used in all subsequent studies. At this time point, specific binding of [3H]-
aBgTx to SFI-EPl-ha7 cell membranes was approximately 65% of total binding (Figure
3.25).
3.6.2 Concentration Dependence of [3H]-aBgTx Binding in the SH-EPl-ha7 Cell
Membrane Preparation
After a 6 h incubation period, specific [3H]-aBgTx binding in SFI-EPl-ha7
membranes accounted for 64.3 ± 1.9 % of total binding sites at a free radiolabel
concentration close to the KD (2.5 - 4 nM), with non-specific binding accounting for 35.7 ±
1.9 % (Figure 3.26A).
To determine KD (apparent) and Bmax values for [3FI]-aBgTx binding in SF1-EP1-
ha7 cell membranes, hot saturation experiments were performed using increasing
concentrations of radioligand. A representative [3H]-aBgTx saturation curve for SFI-EP1-
ha7 membrane preparations is shown in Figure 3.26B. These studies demonstrated [3FI]-
aBgTx binding was saturable and consistent with a single high affinity binding site in SH-
EPl-ha7 cell membranes (nH = 1.14 ± 0.11, n = 4). The apparent affinity of [3H]-aBgTx in
SH-EPl-ha7 cell membranes was equal to 2.66 ± 0.73 nM (n = 4; Figure 3.26, Table 3.10).
Saturable binding allowed measurement of the density of a7 nAChRs in this membrane
preparation giving a Bmax equal to 2.40 ± 0.70 pmol/mg protein; n = 4; Table 3.10). The
density of a7 nAChR binding sites determined using [3H]-aBgTx is approximately 35 % of
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Figure 3.25
Time (h)
Time Course of Specific [3H]-aBgTx Binding in SH-EPl-ha7 Cell Membranes. SH-EPl-ha7 cell
membranes (60 pg) were incubated (22°C) with [3H]-aBgTx (2 nM) in a total assay volume of 250 pi
for up to 8 h. Each total binding was tested in duplicate with its non-specific counterpart (defined by
10 pM (-)nicotine) tested in singulate. Specific binding points were derived by subtracting non¬

















































6 8 10 12
[aBungarotoxin] (nM)
Concentration Dependence of [3H]-aBgTx Binding in SH-EPl-ha7 Cell Membrane
Preparations. (A) Proportions of [3H]-aBungarotoxin Binding. (B) Hot Saturation Analysis of
[3H]-aBgTx Binding. Membranes (60 pg) were incubated with 2 nM [3H]-aBgTx in a total
assay volume of 250 pi for 6 h at 25°C. Non-specific binding was determined in the presence of
10 pM (-)Nicotine. These data represent (A) an average of 4 separate hot saturation experiments
or (B) a typical hot saturation experiment.
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Table 3.10 Comparison of Kd and Bmax Generated Using [3H]-aBgTx and






aBgTx 2.66 ±0.73 4 1.14 ± 0.11 2.40 ±0.70
*
MLA 5.10 ± 0.95 5 1.17 ±0.05 7.08 ±0.70
Apparent affinity (KD), Hill slope (nH), and receptor density (Bmax) values were determined in the
[3H]-aBgTx binding assay as described in the methods. Corresponding values for [3H]-MLA are
taken from Section 3.5. Values are expressed as mean ± S.E.M., (n = 4-5) with statistical
analyses (one-way ANOVA with Bonferroni post-hoc testing) where p < 0.05 was used to
indicate a significant difference: (*) A significant difference in receptor density was determined.
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that determined using [3H]-MLA (Bmax = 7.08 ± 0.70 pmol/mg protein; n = 5; Section 3.5.2;
Table 3.10). This is consistent with the earlier finding showing aBgTx can only inhibit 40
% of [3H]-MLA binding in SH-EPl-ha7 cells (Figure 3.23 & 3.24)
In all subsequent [3H]-aBgTx binding studies (2 nM) were performed at 22°C for
6 h with a limited range of compounds to examine whether this had any effect of human a7
nAChR pharmacology.
3.6.3 Inhibition of [3H]-aBgTx Binding Sites by Cholinergic Ligands in SH-EP1-
ha7 Cell Membranes
To characterise [3H]-aBgTx binding sites in SH-EPl-ha7 cell membranes, the
ability of the agonists (-)nicotine and cytisine and the antagonists aBgTx and MLA to inhibit
[3H]-aBgTx binding in SH-EPl-ha7 cell membranes was examined. (-)Nicotine and cytisine
both inhibited [3H]-aBgTx binding in SH-EPl-ha7 cell membranes in a concentration-
dependent manner (Figure 3.27A) giving a Kj value for (-)nicotine of 63.6 ± 14.5 nM (n = 3)
and a K; value of 905 ±115 nM (n = 3) for cytisine. These values are consistent with the K;
values determined using [3H]-MLA as the radioligand (Figure 3.26A, Table 3.11). The Hill
coeffients (nH) for the two agonists were slightly less than unity at 0.82 ± 0.09 (« = 3) for (-
)nicotine and 0.70 ± 0.10 (n = 3) for cytisine, again consistent with the Hillslopes observed
for all the agonists in the [3H]-MLA binding assay (Table 3.6, pg 91).
Although only partial inhibition of [3H]-MLA binding was achieved by aBgTx
(Figure 3.23 & 3.24), both aBgTx and MLA inhibited [3H]-aBgTx binding to SH-EPl-ha7
cell membranes to the same extent in a concentration-dependent manner (Figure 3.27B).
There was no change in the affinity of aBgTx or MLA for [3H]-aBgTx when compared to
[3H]-MLA binding sites in SH-EPl-ha7 cell membranes (Table 3.11). Hill coefficients for
the antagonists in the [3H]-MLA and [3H]-aBgTx binding studies using SH-EPl-ha7 cell
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Inhibition of [3H]-aBgTx Binding by Cholinergic Ligands in SH-EPl-ha7 Cell Membranes. SH-
EP-hciy cell membranes (60 pg) were incubated with [3H]-aBgTx (2 nM) and (A) agonists cytisine
(■) and (-)nicotine (▼) or (B) antagonists methyllycaconitine (•) and aBungarotoxin (A) in a total
assay volume of 250 pi for 6 h at 25°C. Non-specific binding was determined in the presence of 10
pM (-)nicotine with these data representing a typical experiment.
107































Affinity(Kj)a dHillslopes(nH)weredetennin dih[3H]-aBgTx[3H]-MLAb ingssaysd sc ibedithm hods. Membranes(60pg)wereincubat d(22°C)with[3H]- BgTxnMito als ayvolumef50pif rh.Non-spec fici ngwas determinedinhpresenceof10M(-) icoti e.T esdatar pr s ntav r gef2-6i di dualh bitionexperiments.Nsta stical differencenaBgTxdMLAffinity(Ki)wasobservedbetw n;valu sd erminedihoassay .How ver,ig ficant differencesnagoni tffinitywereobserv d[3H]-aBgTx[3H]-MLAbi dingt siS -EPl-hcpllmembranes.
3.7 Pharmacological Characterisation of a4p2 and a7 nAChR Binding Sites in
Mouse Brain Membranes Using [3H]-Cytisine and [3H]-MLA
A number of transgenic mouse models are now available to study the effect of
knocking in, or out, nAChRs in vivo (Orr-Urtreger et al., 1997; Xu et al., 1999a,b; Bansal et
al., 2000; Ross et al., 2000; Broide et al., 2001; Champtiaux et al., 2002; Gil et al., 2002;
Wang et al., 2002; Whiteaker et al., 2002; Cui et al., 2003; Lester et al., 2003; Orb et al.,
2004; Sales et al., 2004). Indeed, as discussed extensively in the introduction, nicotine and
nAChRs are thought to play a key role in regulating attention and memory with pivotal roles
in AD (e.g. Bednar et al., 2002; O'Neill et al., 2002; Yu et al., 2005) and schizophrenia (e.g.
Guan et al., 1999; De Luca et al., 2004; Deutsch et al., 2005). In parallel to my in vitro
characterisation of nAChRs and their interaction with Api.42, our group has also examined
the role of these receptors (in particular the a7 nAChR) in vivo, using a range of behaviour
models.
The 5-choice serial reaction time task (5-CSRTT) is used to assess sustained
attention in rodents and is analogous to the Connors continuous performance test used in
humans (Stolerman et al., 2000). Using this task, our group showed for the first time in
mice, that nicotine could enhance sustained attention, and moreoever, that when the a7
nAChR was knocked-out these mice exhibited a deficit in this task (Young et al., 2004).
This initial observation has now been extended with a second 5-CSRTT study comparing
wildtype, a7-nAChR heterozygote, and a7-nAChR knockout mice. Importantly, there is a
graduated decrease in the ability of the mice, with the a7- nAChR heterozygous mice
exhibiting reduced attention compared to their wildtype littermates and knockout mice
showing a significantly more pronounced deficit in sustained attention. These new
observations have been submitted to Psychopharmacology and the manuscript is under
review. As transgenic manipulations may produce compensatory changes in nAChR density
or changes in receptor pharmacology, in parallel, I examined the nAChR phannacology of
these mice to strengthen the above findings, and as a result I am a co-author on both
manuscripts.
The a7 nAChR-transgenic mice used in these studies were purchased from Jackson
Laboratories (B6.12957 - Chrna7tmlbay; Jackson Laboratories, Bar Harbour, U.S.A.) and
backcrossed onto a C57B16/J background 11 times to produce litters of wildtype,
heterozygous, and knockout mice. Before assessing ot4p2 and a7 nAChR pharmacology and
receptor number in the a7-transgenic mice and due to the limited characterisation (when
compared to [3H]-cytisine) of p'H]-MLA binding sites in mouse (Whiteaker et al., 1999),
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[/'HJ-MLA binding sites were initially characterised in brain membranes from non-littermate
C57B16/J wildtype mice.
3.7.1.1 Time Course Determination of |3H|-MLA Binding in a Mouse Brain
Membrane Preparation
To determine when [3H]-MLA binding to the mouse ot7 nAChR attained
equilibrium, the radioligand was incubated with membranes prepared from C57B16/J mice
and specific binding measured as a function of time (Figure 3.28). At 25°C [T1J-MLA
binding (2 nM) attained equilibrium at 15 nrin and held constant for at least 2 h, consistent
with observations in rat brain and SH-EPl-ha7 cell membranes (Figure 3.28).
As a consequence, all subsequent [3H]-MLA hot saturation and inhibition studies
using mouse brain membranes were terminated by vacuum filtration after a 60 min
incubation period at 25°C; for direct comparison with rat and SH-EP-ha7 studies.
3.7.1.2 Pharmacological Analysis of [3H]-MLA Binding in Mouse Brain Membrane
Preparations
Specific [3H]-MLA binding in mouse brain membranes accounted for 49.8 ± 4.6 %
of total binding sites at a free radiolabel concentration close to the expected KD (-1.5 nM;
Figure 3.29A).
To determine KD and Bmax values for [3H]-MLA binding sites in mouse brain
membranes, cold saturation experiments were performed using 2.5 nM [3H]-MLA and
increasing concentrations of unlabelled MLA. The affinity of [3H]-MLA (KD/Kj) was equal
to 1.34 ± 0.26 nM (n = 5) in mouse brain membranes with a receptor density (Bmax) of 0.016
± 0.003 pmol/mg protein (n = 5), consistent with previously published studies in mouse brain
membranes using ['HJ-MLA or [12~I]-aBgTx (Figure 3.29B; Marks & Collins, 1982;
Whiteaker et al., 1999). This receptor and KD density is also similar to binding variables
determined using rat brain membranes in Section 3.5.2 (pg 105). These studies showed [3H]-
MLA binding was consistent with a single high affinity binding site in mouse brain
membranes with a Hillslope of 0.87 ± 0.04 (n = 5).
3.7.1.3 Inhibition of [3H]-MLA Binding Sites by Cholinergic Ligands in a Mouse
Brain Membranes
Three nAChR agonists and two antagonists, all of which were used in earlier




Time Course of Specific [3H]-MLA binding in Mouse Brain Membranes. Membranes (850 pg)
were incubated (22°C) with [3H]-MLA (2.5 nM) in a total assay volume of 250 pi for up to 2 h. Total
binding was tested in duplicate with its non-specific counterpart (defined by 10 pM tf-tubocurarine)
tested in singulate. Specific binding points were derived by subtracting non-specific binding from











































Pharmacological Characterisation of |3H]-MLA Binding Sites in Mouse Brain. (A) Proportions
of specific and non-specific [3H]-MLA binding and (B) inhibition of [3H]-MLA binding by unlabelled
MLA. Membranes (850 pg) were incubated (22°C) with [3H]-MLA (2.5 nM) in a total assay volume
of 250 pi for 60 min. Non-specific binding was determined in the presence of 10 pM r/-tubocurarine
with these data representing an average of 5 individual inhibition experiments.
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brain membranes. All five compounds produced a concentration-dependent inhibition of
[3H]-MLA binding in mouse brain membranes (Figure 3.30). The rank order of potency for
the ligands studied was; MLA > (-)AR-R 17779 > tZ-tubocurarine > (-)nicotine > (+)AR-
R17779 with data from a typical experiment shown in Figure 3.30 and with mean Kj values
presented in Table 3.12. As discussed above, unlabelled MLA inhibited [3H]-MLA binding
in mouse brain membranes with a KD/K; value equal to 1.34 ± 0.26 nM (« = 5). The affinity
(Kj) of the other compounds tested ranged from nanomolar for (-)AR-R 17779 (247 ± 23 nM,
n = 5) to the high micromolar range for its less active enantiomer (+)AR-R 17779 (136 ± 19
pM; n = 6). In general the Hill coefficients for the nicotinic ligands were close to unity
although there was a degree of variability. This may be a consequence of the large amount
of tissue required due to the low receptor density affecting filtration. Importantly, the
affinity of the compounds for mouse [3H]-MLA binding sites was similar to that observed
for rat brain membranes (Tables 3.4 & 3.5 in Section 3.5.3, pgs 83 & 87; Table 3.12).
Therefore, it would appear that mouse and rat [3H]-MLA binding sites are different from
human a7 nAChR pharmacology, and although antagonist potencies are similar, agonists are
clearly more potent (~ 100-fold) at the human a7 nAChR.
Having characterised [3H]-MLA binding in wildtype mouse membranes, this and
the [3H]-cytisine binding assays were used to characterise CI4P2 and a7 nAChR pharmacology
in a7 nAChR wildtype, heterozygous, and knockout mice. With male mice limited as they
were used in behavioural studies, and with female mice used in a previous behavioural study
(Paylor et al., 1998), tissue from both sexes of mice were used to see if any pharmacological
differences were observed in the radioligand binding assays.
3.7.2 Concentration Dependence of [3H]-MLA Binding in a7 nAChR-Transgenic
Mouse Brain Membrane Preparation
To assess the affinity (KD) and receptor density (Bmax) of [3H]-MLA and f'H]-
cytisine binding at a7 and CC4P2 nAChRs, respectively, membranes were prepared from
littermate male and female a7-WT, a7-HT, and a7-KO mice. Initially, [TIJ-MLA binding
was assessed in transgenic mouse brain membranes by treating each brain individually. As
Figure 3.31 clearly shows, at a radiolabel concentration of 3 nM, specific [3H]-MLA binding
accounted for 74.4 ± 2.2 % of total binding sites in male a7-WT mouse brain membranes
(panel A) and 62.9 ± 5.9 % in male a7-HT membranes (panel B). The amount of specific
[ H]-MLA binding in male a7-WT brain membranes is consistent with that observed in
























Inhibition of [ HJ-MLA Binding by Cholinergic Ligands in Mouse Brain Membranes. Mouse
brain membranes (850 gg) were incubated (22°C) with [3H]-MLA (2.5 nM) and the antagonists
antagonists methyllycaconitine (•) or <7-tubocurarine (A) or with the agonists (-)nicotine (▼), (-)AR-
R17779 (■), or (+)AR-R17779 (♦) in a total assay volume of 250 gl for 60 min. Non-specific
binding was determined in the presence of 10 gM (/-tubocurarine with these curves representing a
typical experiment.
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Table 3.12: The Affinity of Cholinergic Ligands for |3H|-MLA Binding Sites
in Mouse Brain Membranes
Compound Kj (nM) nH «
Antagonists
MLA 1.34 ±0.26 0.87 ±0.04 5
</-Tubocurarine 1,811 ±74 1.48 ±0.44 3
Agonists
(-)AR-R17779 247 ± 23 1.41 ±0.19 5
(-)Nicotine 5,262 ± 829 1.06 ±0.09 3
(±)AR-R17779 135,504 ± 19,118 1.37 ±0.12 6
Affinity (Kj) and Hillslopes (nH) were determined in the [3H]-MLA binding assay as described in the











Proportions of [3H]-MLA Binding Sites in Male a7 nAChR Transgenic Mouse Brain
Preparations. Membranes (-850 pg) from individual male (A) a7-WT (B) a7-HT or (C) a7-KO
mouse brains were incubated (22°C) with [3H]-MLA (2.5 nM) in a total assay volume of 250 pi for 60
min. Non-specific binding was determined in the presence of 10 pM d-tubocurarine and these data












Proportions of [3H]-MLA Binding Sites in Female a7 nAChR Transgenic Mouse Brain
Preparations. Membranes (-850 pg) from individual female (A) a7-WT (B) a7-HT or (C) a7-KO
mouse brains were incubated (22°C) with [Tf]-MLA (2.5 nM) in a total assay volume of 250 pi for 60
min. Non-specific binding was determined in the presence of 10 pM rZ-tubocurarine and these data
represent an average of4-7 female mice brains, each examined individually.
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addition and in excellent agreement with [3H]-MLA binding in male mouse brain
membranes, specific binding accounted for 77.1 ± 3.4 % of total binding sites in female a7-
WT mouse brain membranes (Figure 3.32A) and 62.1 ± 9.4 % in female a7-HT brain
membranes (Figure 3.32B). Moreover, and most importantly, male and female a7-KO mice
exhibited no appreciable specific [JH]-MLA binding, consistent with deletion of the a7
nAChR gene (Figure 3.31C & 3.32C). To confirm these binding data showing loss of a7
nAChRs, genotyping was also performed in parallel to the binding studies. Wildtype a7
nAChR mice produced a single 440 b.p. band on the PCR gel (Figure 3.33). In contrast, a7-
HT mice produced two bands (440 b.p. and 750 b.p.) while a7-KO mice produced a single
750 b.p. band (Figure 3.33), indicating the absence of the a7 nAChR gene. Because brain
tissue from a7-KO mice exhibited no specific binding and because of the low receptor
density, all subsequent experiments comparing a7-nAChR pharmacology were conducted
using male and female a7-WT and a7-HT mice using pooled brain membranes.
To determine KD and Bmax values for [3H]-MLA binding sites in a7-WT and a7-HT
mouse brain membranes, hot saturation experiments were performed using increasing
concentrations of [3H]-MLA. Representative saturation curves for [3H]-MLA binding in a7-
WT and a7-HT transgenic mouse brain membranes are presented in Figure 3.34. These
studies showed that [3H]-MLA binding was saturable in both membrane preparations. The
density of a7 nAChRs (Bmax) in male wildtype littermate mouse brain membranes was 66.6 ±
8.0 fmol/mg protein (n = 5). Importantly, this receptor density was reduced by almost
exactly 50% in male a7-HT brain tissue with a Bmax = 34.2 ± 2.3 [n = 3, p = 0.006).
Although there was a significant reduction in receptor density between the preparations, the
Kd of [3H]-MLA was not significantly different between wildtype (KD = 7.41 ± 0.75, n = 5)
and a7-HT mice (KD = 10.7 ± 2.2, n = 3; Figure 3.34A, Table 3.13).
A similar observation was made when KD and Bmax values were measured using
female a7-nAChR transgenic mouse brain membranes. The density of receptors in female
wildtype mouse brain membranes was 73.1 ± 3.6 fmol/mg protein (n = 5), consistent with
their male counterparts. Again this number was also significantly reduced by just over half
in female a7-HT brains with a Bmax = 27.0 ± 4.0 (n = 5; p < 0.001). Likewise, although there
was a significant reduction in receptor density between the female a7-WT and a7-HT
membrane preparations, the ligand affinity was not significantly different with a KD value of
7.32 ± 0.58 (n = 5) and 10.5 ± 2.6 (n = 5) in wildtype and heterozygous preparations,
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Figure 3.33
WT WT KO KO HT +ve -ve
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a7 nAChR Trangenic Mouse Genotyping. Confirmation of the genotypes of a7 nAChR wildtype
(WT), heterozygous (HT), and knockout (KO) mice. Wildtype mice exhibit only one allele (at 440
b.p.), knockout mice exhibit a single allele at 750 b.p., whilst heterozygous mice exhibit both alleles.
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respectively (Figure 3.34B, Table 3.13). These values were almost identical to the KD values
obtained for male mouse brain membranes. In general, the Hill coefficients (nH) were close
to unity in both male and female a7-WT and a7-HT mouse brain membrane preparations
(Table 3.13).
3.7.3 Concentration Dependence of [3H]-Cytisine Binding in a7 nAChR-Transgenic
Mouse Brain Membrane Preparation
Although there was no change in the affinity of [3H]-MLA for a7 nAChRs despite
a reduction in receptor density, a genetic alteration in a7-nAChR gene expression might
result in a compensatory change in the density of other cholinergic receptors. If such a
change occurred, this could have made interpretation of our behavioural data more
problematic (Young et al., 2004; Young et al., 2006, in press). Therefore, it was necessary
to determine the density and pharmacology of the 014P2 nAChR, the other major nicotinic
receptor in rodent brain (Paterson & Nordberg, 2000). To characterise the a4p2 nAChR
pharmacology a [3H]-cytisine binding was established and KD and Bmax values were
determined using pooled membranes prepared from male and female a7-WT littermates, a7-
HT, and a7-KO mouse brains. As Figure 3.35 clearly shows, at a radiolabel concentration of
3 nM, specific binding accounted for 89.8 ± 3.9 % (« = 4) of total binding sites in male a7-
WT littermate mouse brain membranes (Figure 3.35A) and 67.6 ± 7.8 % (» = 4) in male a7-
HT mouse brain membranes (Figure 3.35B). Consistent with [3H]-cytisine binding in male
mouse brain membranes, specific binding accounted for 79.1 +3.1 % (n = 4) of total binding
sites in female a7-WT mouse brain membranes (Figure 3.36A) and 80.9 ± 3.7 % (n = 3) in
female a7-HT mouse brain membranes (Figure 3.36B). The level of specific [3H]-cytisine
binding was not significantly reduced in either male (70.6 ± 6.8 %; n = 4) or female (67 %, n
= 2) a7-KO mouse brain membranes when compared to the level of specific binding in their
respective WT and HT littermate mouse brain membranes (Figure 3.35C & 3.36C).
To determine KD and Bmax values for [3H]-cytisine binding in a7-WT, a7-HT, and
a7-KO mouse brain membranes, hot saturation experiments were performed using increasing
concentrations of [3H]-cytisine. Representative saturation curves for [3H]- cytisine binding
in a7-WT, a7-HT and a7-KO male transgenic mouse brain membranes are shown in Figure
3.37. These studies showed that [3H]-cytisine binding was saturable in all three male mouse
membrane preparations, with comparable KD for [3H]-cytisine binding; KD = 2.75 ± 0.31 nM




[ [3H]-MLA ] (nM)
Concentration Dependence of [3H]-MLA Binding in a7-nAChR Transgenic Mice. Membranes
(850 pg) from littermate (A) male WT (•) or HT (O) (B) female WT (•) or HT (O) mice were
incubated (22°C) with increasing concentrations of [3H]-MLA in a total assay volume of 250 pi for 60
rnin. Non-specific binding was detennined in the presence of 10 pM d-tubocurarine with these data
representing an average hot saturation study.
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Table3.13:KdandBma vV lu sfor[3H|-MLABi ingSiti017-WildtypeLittermatand7-HeterozygousMous BrainMembra es TransgenicK0nHBmax (nM)(fmol/mgprotein) Male a7-Wildtvpe7.41±0.751.000 13566.68 0* a7-Heterozygous10.7±2.21.1±0 0734.22.3* Female a7-Wildtype7.32±0.581.12±0.0953.1±3.6* a7Heterozygous10.5±2.61.19±0 1452 .0±4.0* Affinity(KD),Hillslopes(nH ,a dreceptorde sity(Bmax)w redet rm n dh[3H]-MLAb ngas aysd scribedit e hods.V lua expressedam an±S.E.M.(n=3-5)withstatisticalan lysesperform du ingon -wayANOVAw thBo f ronipost hoct ing.ignificant differenceinl ga dffinityfor[3H]-MLAbindingsit sa7-WTd-Hmou ebraembraneswasobserved,lthoughth rwdi r c







Proportions of [ H]-Cytisine Binding in Male a7 nAChR Transgenic Mouse Brain Preparations.
Membranes (~850 |ig) from male (A) a7-WT (B) a7-HT or (C) a7-KO mouse brains were incubated
(22°C) with [3H]-cytisine (3 nM) in a total assay volume of 250 pi for 60 min. Non-specific binding
was determined in the presence of 10 pM (-)nicotine and these data represent an average of 4









































Proportions of [ H]-Cytisine Binding in Female a7 nAChR Transgenic Mouse Brain
Preparations. Membranes (~850 pg) from female (A) a7-WT (B) a7-HT or (C) a7-KO mouse brains
were incubated (22°C) with [T I]-cytisine (3 nM) in a total assay volume of 250 pi for 60 min. Non¬
specific binding was determined in the presence of 10 pM (-)nicotine with these data representing an
average of 2-4 individual female mice brain experiments.
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3.37, Table 3.14). Receptor densities were also similar across membrane preparations at 269
± 21 fmol/mg protein for a7-WT mice, 270 ± 16 for a7-heterozygotes, and 241 ± 15 for a7-
knockont mice (Figure 3.37, Table 3.14). Indeed, both affinity and receptor density data are
consistent with previously published studies of [3H]-cytisine binding sites in roden brain
membranes (Pabreza et al., 1991; Anderson & Arneric, 1994; Didier et al., 1995; Davila-
Garcia et al., 1999). Although the Hill coefficient for male a7-WT was close to unity (nil =
1.05 ± 0.07, n = 4), the Hill coefficients for a7-HT (1.77 ± 0.20, n =4) and a7-KO mice (1.54
± 0.31, n = 4) were slightly above unity, although there was a considerable degree of
variability.
Consistent with the observations made for the male a7-nAChR transgenic mice,
the binding affinity (KD) of [3H]-cytisine was similar in all three female mouse brain
preparations; KD = 5.31 ± 0.79 nM (a7-WT, n = 4), 7.05 ± 2.27 nM (a7-HT, n =3), and 4.75
nM (a7-KO, n = 2) (Figure 3.38, Table 3.14). Again, these KD values are almost identical to
their male counterparts discussed above (Table 3.14). The density (Bmax) of a4p2 nAChRs in
female mouse brains was also reasonably consistent between the three membrane
preparations at 254 ± 40 fmol/mg protein for a7-WT mice (n = 4), 302 ± 42 fmol/mg protein
for a7-heterozygotes (n = 3), and 145 fmol/mg protein for a7-knockout mice {n = 2; Figure
3.38, Table 3.14). These values are also consistent with the receptor density determined for
male mice while the lower value determined for the female a7-knockout mouse is probably
due to the low sample number. In general, Hill coefficients were all above unity; 2.14 ± 0.41
for a7-WT mice (n = 4), 1.51 ± 0.30 for a7-heterozygotes (n = 3), and 1.31 for a7-knockout








































































[ [3H]-Cytisine ] (nM)
Concentration Dependence of | H)-Cytisine Binding in Male a7-nAChR Transgenic Mice.
Membranes (850 pg) from littermate male (A) arWT (B) a7-HT (C) a7-KO mice were incubated
(22°C) with increasing concentrations of [3H]-cytisine in a total assay volume of 250 pi for 60 min.
Non-specific binding was determined in the presence of 10 pM (-)nicotine with these data





[ [3H]-Cytisine ] (nM)
Concentration Dependence of [3H]-Cytisine Binding in Female a7-nAChR Transgenic Mice.
Membranes (850 pg) from littermate female (A) a7-WT (B) a7-HT (C) a7-KO mice were incubated
(22°C) with increasing concentrations of [3H]-cytisine in a total assay volume of 250 pi for 60 min.
Non-specific binding was determined in the presence of 10 pM (-)nicotine with these data
representing an average hot saturation study.
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3.8 DISCUSSION
As discussed in the main introduction, although there are two main hypotheses of
AD, the cholinergic and the amyloid, both have been treated separately in many respects.
During the period of my Ph.D, a number of papers have shown a direct interaction between
nAChRs and APi.42, however it remains unclear what the basis of this interaction is and
indeed which subtypes of nAChRs are actually involved (Wang et al., 2000a,b; Dineley et
al., 2001, 2002a; Liu et al., 2001; Pettit et al., 2001; Tozaki et al., 2002; Fu & Jhamandas,
2003; Grassi et al., 2003; Wu et al., 2004; de Fiebre & de Fiebre, 2005). Due to the
generosity of Dr. R. J. Lukas who provided the SH-EP1 cell lines stably expressing the
human a4p2 and a7 nAChRs, I have been able to systematically compare human, rat, and
mouse nicotinic receptor pharmacology. Two radioligand binding assays were established
for both the a4p2 ([3H]-epibatidine and [3H]-cytisine) and a7 nAChRs ([3FI]-MLA and [3H]-
aBgTx), and cholinergic receptor pharmacology extensively examined. These assays
highlighted species differences in a7 nAChR pharmacology that were not observed for the
a4p2 nAChR as well as showing differences in the properties of the a7 nAChR ligands [3H]-
MLA and [3H]-aBgTx. Moreover, these assays were used to show that various forms of
A-Pi_42 did not inhibit binding to either nAChR subtype. Finally, these assays were then used
in a collaborative set of studies with the behaviourists in our Institute to examine nAChR
pharmacology in a7 nAChR-transgenic mice, which has resulted in one published and one
accepted manuscript (Young et al., 2004; 2006 accepted). In this discussion for simplicity, I
will systematically discuss each of these findings.
3.8.1 Pharmacological Characterisation of [3H]-Epibatidine Binding Sites in Rat
Brain and SH-EPl-ha4p2 Cell Membranes
The discovery in the late 1970's that epibatidine was a potent agonist at nAChRs,
subsequently led to its radiolabelling with tritium ([3H]-epibatidine) and iodine ([125I]-
epibatidine) (Daly et al., 1978; Badio & Daly, 1994). In the current study, [3FI]-epibatidine
(15 pM) underwent a slow association with the a4p2 nAChR at 22°C in both rat brain and
SH-EPl-ha4p2 cell membranes, reaching equilibrium by approximately 2 h. This
observation is comparable with earlier studies using human, rat, and mouse membranes
(Figure 3.1; Marks et al., 1998; Whiteaker et al., 1998). This time course for epibatidine
binding is quicker than some other studies using human a4p2 nAChRs expressed in M10
cells (equilibrium reached within 2 rather than 4 h; e.g. Gnadish et al., 1999) however, as
radioligand concentrations and incubation temperatures were identical, this is most likely
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due to differences in membranes preparations. All subsequent studies were performed using
a 4 h incubation period to allow for a direct comparison between studies using rat brain and
human a4p2 nAChRs.
Hot saturation studies indicated that [3H]-epibatidine bound with low picomolar
affinity to receptors in rat brain (KD = 26.1 pM) and to the human a4p2 nAChR stably
expressed in SH-EP1 cells (KD = 28.5 pM; Figure 3.3, pg 61). With the affinity of the ligand
in rat brain membranes and the SH-EPl-ha4p2 nAChRs being almost identical, this indicates
that under the assay conditions used [3H]-epibatidine bound to a4p2 nAChRs in both
membrane preparations, and that there was no species differences in a4p2 receptor
pharmacology. Furthermore, Hill slopes were close to unity in both membrane preparations
signifying single site binding of the ligand (Figure 3.3, pg 61). It is important to note that
although epibatidine also binds to other nicotinic subunits with high affinity (e.g. a3p2a5
nAChR; Wang el al., 1996), low affinity epibatidine binding sites had, until recently, only
been partially characterised. However, Peng and colleagues (2005) have shown that [3H]-
epibatidine can be used to characterise the pharmacology of the human a7 nAChR over-
expressed in the SH-EP1 cell line. This cell line is useful as it contains no other nAChR
subunits and consequently, these authors demonstrated that [3H]-epibatidine bound with high
picomolar affinity (KD = 640 pM) to the 0,7 nAChR and as such, it forms one of the low
affinity binding sites for epibatidine. Obviously, this low affinity site would not be detected
in the current study due to the non-expression of a7 nAChRs in the SH-EPl-ha4(32 cell line
and because of the radioligand concentration used.
The subnanomolar affinity of [3H]-epibatidine for a4p2 nAChRs in rat brain and
SH-EPl-ha4p2 cell membranes means radioligand binding assays utilising this ligand can be
fraught with technical difficulties. Indeed, the specific activity of a radioligand, and hence
radioligand concentration, can limit accurate estimations of potencies of labelled and
unlabelled ligands, particularly when working with tritiated compounds. These difficulties
have been described in many studies using both theoretical and practical systems (Goldstein
& Barrett, 1987; de Vries et al., 1988; Crawford et al., 1999). In order to obtain an accurate
estimate of ligand potencies in any radioligand binding study, it is advisable to use a
radioligand concentration that is less than the KD of the ligand under examination. A variety
of KD/Kj values have been obtained for [3H]-epibatidine in previous studies (Houghtling et
al., 1995; Chavez-Noriega et al., 1997; Marks et al., 1998; Sihver et al., 1998; Whiteaker et
al., 1998; Gnadisch et al., 1999) and, as such, it has already been noted that some studies
may have underestimated the KD/Kj values for high affinity ligands because of epibatidine's
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subnanomolar affinity (Gnadisch et al., 1999). To avoid such problems, Gnadisch and
colleagues (1999) increased the incubation time and volume of their [3H]-epibatidine assay,
and decreased their radioligand concentration to avoid an underestimation of ligand
affinities. Indeed, these conditions were also used in the current studies and, furthermore,
whole rat brain tissue was used to compensate for any variations seen in binding
characteristics in different brain regions (Gnadisch et al., 1999). Despite these caveats, our
Kd value for [3H]-epibatidine of 26.1 pM in rat brain membranes (Figure 3.3) was similar to
that obtained by Gnadisch and colleagues (1999; KD = 8 pM), with both rat and human KD
values also being consistent with those obtained in other studies using rodent and human
a4p2 nAChRs (Houghtling et al., 1995; Marks et al., 1998; Sihver et al., 1998). The rank
order of potency for ligands competing against ['HJ-epibatidine ((±)epibatidine > cytisine >
(-)nicotine > DMPP > MLA = r/-TC) is also consistent with the previous values presented for
both rat and human a4p2 nAChRs (Gerzanich et al., 1995; Houghtling et al., 1995; Chavez-
Noriega et al., 1997; Marks et al., 1998; Sihver et al., 1998; Whiteaker et al., 1998;
Gnadisch et al., 1999).
Interestingly, the non-selective nAChR agonist 1,1-Dimethyl-4-
phenylpiperazinium iodide (DMPP) exhibited a small, but significantly higher affinity for
o.4p2 nAChRs in rat brain membranes (K, = 21.3 nM) when compared with human a4p2
nAChRs (Kj = 42.9 nM; p < 0.05), although Hill slopes were close to unity in both
preparations. Unlike the other three agonists examined, when cytisine was used to inhibit
[3H]-epibatidine binding in rat brain membranes it yielded a Hill coefficient of less than one,
indicating that epibatidine may indeed bind (as discussed above) to more than one binding
site, perhaps with similar affinities whereas cytisine can discriminate between then more
clearly. Indeed, a biphasic pattern consistent with the presence of two sites has been
previously reported for cytisine inhibition of [3H]-epibatidine binding (Marks et al., 1998)
whilst in SH-EPl-ha4p2 cell membranes, where only the nAChR present is the a4p2, the
cytisine Hill slope is at unity. In agreement with previous studies (Xiao & Kellar, 2004;
Sobrio et al., 2005), no differences in affinity were observed for ligands at rat and human
a4p2 nAChRs.
3.8.2 Pharmacological Characterisation of [3H]-Cytisine Binding Sites in Rat Brain
and SH-EPl-ha4p2 Cell Membranes
Many researchers correct their data sets to minimise or remove the well-
documented depletion problems associated with epibatidine binding assays (Houghtling et
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al., 1995; Chavez-Noriega et al., 1997; Marks et al., 1998; Whiteaker et al., 1998; Gnadisch
et al., 1999). In the [3H]-epibatidine binding assay discussed above, the assay volume and
incubation time were increased and the concentration of radioligand minimised to mitigate
against depletion. However, with the subnanomolar affinity of [3H]-epibatidine for a4(32
nAChRs requiring a large volume assay (4 ml) and low ligand concentration (15 pM) to
avoid depletion, this assay was unsuitable for use in a 96-well format for rapid
characterisation of a4p2 nAChR pharmacology. Traditionally, radiolabeled versions of both
(±)epibatidine and cytisine have been used to characterise a4p2 nAChR pharmacology
(Pabreza et al., 1991; Gopalakrishnan et al., 1996; Gnadisch et al., 1999; Eaton el al., 2003).
With cytisine reported to bind with low nanomolar, rather than picomolar, affinity to the
a4p2 nAChR, it could be usable in a small volume radioligand binding assay avoiding the
potential problems of depletion associated with [3H]-epibatidine when utilised incorrectly
(Pabreza et al., 1991; Houghtling et al., 1995; Gopalakrishnan et al., 1996; Chavez-Noriega
et al., 1997; Gnadisch et al., 1999).
Using rat brain and SH-EPl-ha4p2 cell membranes, initial studies examined the
time course of [3H]-cytisine binding (3 nM) in a 250 pi assay volume at 4°C. In contrast to
previously published studies in which [3H]-cytisine binding reached equilibrium within 1 h
in rat brain (Pabreza et al., 1991) or human a4p2 nAChRs expressed in HEK293 cells
(Gopalakrishnan et al., 1996), in the current study, [3H]-cytisine binding did not attain
equilibrium at 4°C even when incubated for up to 4 h (Figure 3.6). As a consequence studies
were performed at both 25°C and 37°C with the optimal incubation temperature for [3H]-
cytisine and rat brain membranes determined to be 25°C with equilibrium reached within 1 h.
The reasons for this difference in incubation temperature could relate to tissue/cell or other
slight technical differences between these assays, although no systematic examination of the
differences was conducted.
Hot saturation studies using increasing concentration of [3H]-cytisine showed that
the ligand bound with low nanomolar affinity to receptors in rat brain (KD = 3.77 nM) and
SH-EPl-ha4p2 nAChRs cell membranes (KD = 4.11 nM) which are consistent with data
using rat, mouse, and over-expressed human a4p2 nAChRs (Pabreza et al., 1991; Whiting et
al., 1991; Flores et al., 1992; Decker et al., 1995; Didier et al., 1995; Gopalakrishnan et al.,
1996). Consistent with the data obtained in the [3H]-epibatidine assay, Hill slopes were
close to unity. As such, although cytisine binding to high and low affinity nicotinic sites has
been well documented, there is little evidence for such circumstances in the current study.
Unsurprisingly, the density of receptors labelled by [Tl]-cytisine in rat brain (Bmax = 0.43
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pmol/ mg protein) was considerably lower than that in the SH-EP1 cell line overexpressing
the human a4p2 nAChR (Bmax =131 pmol/mg protein, p < 0.05). However, both Bmax values
were consistent with that already reported by Pabreza and colleagues (1991) for rat (Bmax =
126 pmol/mg protein) and Eaton and colleagues (2003) using the same cells as chacterised in
this study (Bmax = 140 pmol/ mg protein). The affinity of the other cholinergic compounds
for p'HJ-cytisine binding sites in rat brain and SH-EPl-ha4p2 cell membranes was also
comparable to previously published studies using rat brain (Pabreza et al., 1991) and human
a4p2 nAChRs expressed in HEK293 (Gopalakrishnan et al., 1996) or SH-EP1 cells (Eaton et
al., 2003) and to that obtained with the [3H]-epibatidine assay (rank order of potency =
cytisine > (-)nicotine > DMPP > MLA > c/-tubocurarine). With the exception of d-TC and
DMPP, the data sets were remarkably consistent in both species (Table 3.3, pg 76). DMPP
exhibited a slightly higher affinity for human a4p2 nAChRs (Ki = 71.5 nM) when compared
to rat brain membranes (K, = 256 nM). Furthermore, a species difference in affinity was also
observed for c/-tubocurarinc (Ki = 5.0 pM at human a4p2 nAChRs compared to 17.2 pM at
rat a4p2 nAChRs). As discussed above, this difference in affinity is likely to be due to
multiple receptor stoichiometrics in rat brain membranes, and perhaps the presence of one or
more lower affinity binding sites.
Analysis of [3H]-cytisine binding in rat brain and SH-EPl-ha4p2 cell membranes
has revealed that cytisine is indeed a potent agonist at a4p2 nAChRs. Furthermore, the
similar ligand affinities in the [3H]-cytisine and [3H]-epibatidine assays confirm not only the
absence of ligand depletion in the latter assay but also that no species differences exist for rat
and human a4p2 nAChRs. Finally, the successful miniaturisation of the [3H]-cytisine
binding led to its being successfully used in a small volume assay format for high-throughput
screening.
3.8.3 Pharmacological Characterisation of [3H]-MLA Binding Sites in Rat Brain
and SH-EPl-ha7 Cell Membranes
As discussed in Section 3.5 (pg 79), the a7 nAChR is currently being intensively
investigated, with potential roles in inflammation (Wang et al., 2003), schizophrenia (Guan
et al., 1999; De Luca et al., 2004; Deutsch et al., 2005), and Alzheimer's disease (Bednar et
al., 2002; O'Neill et al., 2002; Yu et al., 2005). A radioligand binding assay using [3H]-
MLA, a potent and putatively selective antagonist of the a7 nAChR, has been previously
used to characterise the pharmacology of this receptor in rodent brain and insect tissues
(Macallan et al., 1988; Ward et al., 1990; Davies et al., 1999; Whiteaker et al., 1999; Lind et
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al., 2001). The current study has extended these observations in rodent brain membranes by
using [3H]-MLA to comprehensively characterise a7 nAChR pharmacology in rat brain,
mouse brain, and in a SH-EP1 cell line over-expressing the human a7 nAChR.
In agreement with Davies and colleagues (1999) and consistent with the known
properties and selectivity ofMLA, [3H]-MLA bound to rat brain membranes with an affinity
and pharmacological profile characteristic of a7-subunit containing nAChRs (Macallan et
al., 1988; Ward et al., 1990; Alkondon et al., 1992; Drasdo et al., 1992; Wonnacott et al.,
1993; Palma et al., 1996; Tian et al., 1997). Furthermore, [3H]-MLA bound to the human a7
nAChR over-expressed in the SH-EP1 cell line with a profile similar to that observed in the
previously mentioned rat brain studies. Indeed, [3H]-MLA binding reached equilibrium
rapidly (at 22°C) in both membrane preparations (Figure 3.14, pg 80). Saturation binding
studies showed that [3H]-MLA bound with high affinity to a homogenous receptor
population in both rat brain (KD =1.71 nM) and SH-EPl-ha7 cell membranes (5.01 nM),
consistent with previous studies in rat brain (KD =1.8 nM; Davies et al., 1999) and SH-EP1-
ha7 cell membranes (KD = 1 nM; Peng et al., 1999). The density of binding sites in both rat
brain (Bmax = 0.18 pmol/mg protein) and SH-EPl-ha7 cell membranes (Bmax = 7.08 pmol/mg
protein) also correlate well with previously published studies of [3H]-MLA, [125I]-MLA, or
[125I]-aBgTx binding to a7 nAChRs in rat brain (Quik et al., 1996; Davies et al., 1999;
Mugnaini et al., 2002; Navarro et al., 2002) and SH-EPl-ha7 cell membranes (Peng et al.,
1999, 2005; Schroeder et al., 2003).
Following this initial characterisation, inhibition studies were performed to assess
the pharmacological profile of [3H]-MLA binding sites in both membrane preparations. K;
values for the inhibition of [3H]-MLA binding by various cholinergic antagonists (Table 3.5,
pg 88) compare well with those in previously published studies (Davies et al., 1999; Peng et
al., 2005). No species differences were apparent between rat and human a7 nAChRs,
however, aBgTx did not completely inhibit [3H]-MLA binding sites in rat brain membranes
or those binding sites in SH-EPl-ha7 cell membranes. This observation has been observed
in rat (Davies et al., 1999) and mouse (Whiteaker et al., 1999) brain membranes, however,
this is the first reported observation of aBgTx's inability to completely inhibit [3H]-MLA
binding to the human a7 nAChR. As a consequence, the inability of aBgTx's to completely
inhibit [3H]-MLA binding to the rat and human a7 nAChR is discussed below (Section
3.10.3.3).
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3.8.3.1 Cholinergic Agonists Exhibit Different Affinity for Rat and Human 017
nAChRs.
Cholinergic agonists generally exhibited a much higher affinity (~2 orders of
magnitude) for human a7 nAChRs than for rat a7 nAChRs. Although the slight difference in
sequence homology (~ 6 %) between the two species could play a role in this observation,
the alteration in affinity may, at least in part, be attributed to potential variations in a7
nAChR stoichiometry in rat and human membrane preparations (Couturier et al., 1990;
Seguela et al., 1993; Peng et al., 1994b). A growing body of evidence now suggests that the
a7 nAChR can exist in a combination of homomeric and heteromeric complexes that are
dependent upon species and tissue and cellular source (Quik et al., 1996; Yum et al., 1996;
Guo et al., 1998; Yu & Role, 1998; Girod et al., 1999; Palma et al., 1999; Rakhilin et al.,
1999; Drisdel & Green, 2000; Ferreira et al., 2001; Severance et al., 2004). Although some
splice variants of human and chick a7 nAChRs have now been identified, almost all of these
contain premature stop codons and are unable to be functionally expressed in Xenopus laevis
oocytes (Garcia-Guzman et al., 1995; Gault et al., 1998; Yu & Role, 1998; Villiger et al.,
2002; Saragoza et al., 2003). However, a7 and p2 subunits have been reported to coassemble
and form functional receptors following expression in Xenopus laevis oocytes (Zarei et al.,
1999; Khiroug et al., 2002). As these subunits are co-expressed throughout the CNS, these
findings suggest native heteromeric receptors containing at least one a7 subunit may yet be
identified (Azam et al., 2003). The a7 nAChR has been traditionally characterised as a fast
desensitising receptor which binds aBgTx irreversibly, however, biophysical and
phannacological differences have been reported between native and expressed receptors
(Alkondon & Albuquerque, 1993; Shao & Yakel, 2000; Sudweeks & Yakel, 2000). More
specifically, the properties of putative a7 nAChRs in rat hippocampal interneurons do not
have identical pharmacological properties to recombinantly expressed rat homomeric a7-
nAChRs (Shao & Yakel, 2000; Sudweeks & Yakel, 2000). While rat a7 nAChRs in
hippocampal interneurons desensitise rapidly and bind aBgTx irreversibly, native a7
nAChRs desensitise more slowly and have smaller single channel conductances (Alkondon
& Albuquerque, 1993; Shao & Yakel, 2000; Sudweeks & Yakel, 2000). A slow
desensitisation of the a7 nAChR has also been observed in denervated mouse muscle
(Tsuneki et al., 2003). Moreover, although Cuevas and Berg (1998) detected a rapidly
desensitising a7-nAChR in rat superior cervical ganglionic neurons, a second distinct a7
nAChR subtype was also detected in the same preparation that, like those in mammalian
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autonomic neurons, desensitises slowly and binds aBgTx rapidly and reversibly (Cuevas &
Berg, 1998; Cuevas et al., 2000). Whether these differences reflect combination with the p2
subunit or triplet receptors remains to be determined. It has been shown that the properties
of heterologously expressed chick homomeric a7 nAChRs also do not match those of native
chick a7 nAChRs (Anand et al., 1993; Yu & Role, 1998; Girod et al., 1999). Again, like the
human/rat a7 nAChR, the chick a7 nAChR can also form heteromeric a7 AChRs in
heterologous expression systems with p3 (Palma et al., 1999) and a^/fT nAChR subunits
(Girod et al., 1999).
Recently two isoforms of the a7-nAChR (a7-l and a7-2) were identified in rat
brain and intracardiac ganglia and these two isoforms do indeed exhibit different biophysical
and pharmacological properties (Severance et al., 2004). Isoform a7-l desensitises rapidly
and is irreversibly blocked by aBgTx while a7-2 desensitises slowly and binds aBgTx
rapidly and reversibly (Severance et al., 2004). Therefore, it is not inconceivable that the
potential presence of homomeric and heteromeric a7 nAChRs and their associated isoforms
results in the observed affinity difference in agonist binding affinity between rat and human
a7 nAChRs. In contrast to the lack of species difference observed between rat and human
a4p2 nAChRs (Section 3.4), the several-fold higher affinity of a7 nAChR agonists for human
a7 compared to rat a7 nAChRs, has considerable large implications for the use of a7 nAChR
agonists in man. Indeed, when developing a7 nAChR agonists for clinical use, it is
important to note that a micromolar affinity determined in rodent brain tissue may have a
nanomolar affinity for the human receptor. Aspects of this work have already been
presented in published form (Crawford et al., 2004).
3.8.3.2 Modulation of the a7 nAChR by Acetylcholinesterase Inhibitors, Allosteric
Potentiators, and General Channel Blockers
Until recently, acetylcholinesterase (AChE) inhibitors were the only established
treatment for Alzheimer's Disease, however, memantine, an NMDA antagonist, has just
been approved (Schmitt et al., 2004; Sonkusare et al., 2005). Tacrine (1,2,3,4-tetrahydro-9-
aminoacridine) was the first AChE inhibitor approved for the treatment of AD, which was
followed by a second generation of AChE inhibitors such as donepezil and galanthamine,
both of which are available for the symptomatic treatment of patients with mild to moderate
AD (Whitehouse, 1993; Kelly et al., 1997; Scott & Goa, 2000). However, it has been known
for some time that AChE inhibitors such as galanthamine may also interact directly with
nAChRs (Alkondon et al., 1988; Taylor et al., 1994; van den Beukel et al., 1998; Zwart et
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al., 2000). Moreover it is almost 30 years since Katz and Miledi (1977) showed
physostigmine could act as an agonist of nAChRs. Subsequently, several laboratories have
since demonstrated that galanthamine and physostigmine do not act directly but do in fact
cause an allosteric potentiation of the intrinsic ACh response, in addition to their effects on
AChE (Zwart & Vijverberg, 1997; Sabey et al., 1999; Maelicke et al., 2000).
Allosteric modulation of receptors is a common mechanism of altering
neurotransmission, with probably the most famous example being the benzodiazepine-
positive modulation (potentiation) of GABAa receptor activity which facilitates the opening
of the integral receptor chloride channel (MacDonald & Twyman, 1992). On nicotinic
receptors, allosteric modulators act at binding sites on the nAChR distinct from those of
competitive agonists and antagonists and as such are classed as non-competitive agonists
(Figure 1.4, pg 15). Although allosteric potentiators such as galanthamine, physostigmine,
and codeine have been shown to bind with low efficacy at nAChRs, the exact subtype of
nAChR through which they may exert the majority of their action remains unknown (Storch
et al., 1995; Samochocki et al., 2000). Indeed, although Samochocki and colleagues (2000)
have reported that galanthamine bound to the a4p2 nAChR, other AChE inhibitors such as
tacrine and donazepil failed to do so. With the purported involvement of the a7 nAChR in
AD aetiology, the AChE inhibitors galanthamine, physostigmine, donepezil (E2020;
Aricept®), and tacrine and the allosteric modulator codeine (Storch et al., 1995) were
examined for their ability to inhibit [3H]-MLA binding sites in both rat brain and SH-EP1-
ha7 cell membranes. In contrast to Samochocki and colleagues (2000) observations for
AChE inhibitors at the a4p2 nAChR, all the compounds examined exhibited moderate-to-low
affinities for a7 nAChRs in both membrane preparations. Every compound examined
produced a complete concentration dependent inhibition of pH]-MLA binding in both
membrane preparations. In the current studies there were a number of significant differences
in affinity between rat and human a7 nAChRs (Table 3.8, pg 97). For E2020, tacrine,
physostigmine, galanthamine, and codeine, there was a 2-4 fold increase in affinity for the
human a7 nAChR. Moreover, this is the first study to show that these compounds can
directly inhibit [3EI]-MLA binding indicating that there must be some overlap between the
allosteric and the agonist/antagonist binding sites on the a7 nAChR.
The a7 nAChR is also thought to modulate several other neurotransmitter systems
including the GABAergic (Alkondon et al., 2000; Buhler & Dunwiddie, 2002; Kawai et al.,
2002) and glutamatergic (Guo et al., 1998; Guo et al., 2005) systems and, therefore, the non¬
selective ion channel blockers (-)bicuculline, 4-aminopyridine (4-AP), and
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tetraethylammonium (TEA) were examined for their ability to inhibit fH]-MLA binding
sites in rat brain and SH-EPl-ha7 cell membranes. Alpha7 nAChRs are widely expressed on
GABAergic interneurons and appear to be involved in GABAergic synaptic activity
(Alkondon et al., 2000; Adams et al., 2001; Buhler & Dunwiddie, 2002; Kawai et al., 2002;
Hajos et al., 2005). (-)Bicuculline, a potent antagonist of GABAa receptors, inhibited [3H]-
MLA binding sites in rat brain and SH-EPl-ha7 cell membranes with micromolar affinity
with this compound again being 10-fold more potent at the human a7 nAChR (Table 3.8, pg
97). In agreement with our observation, Demuro and colleagues (2001) showed (-
)bicuculline competitively inhibited ACh responses at rat a7 nAChRs expressed in Xenopus
laevis occytes while non-competitively inhibiting ACh responses at a4p2 nAChRs. The co-
expression of a7 nAChRs and GABA receptors on GABAergic interneurons and the
observed involvement of the a7 nAChR in GABAergic synaptic transmission indicate
examination of compound cross-reactivity is vital when characterising selective agonists for
these two receptors. The non-selective channel blockers 4-AP and TEA exhibited millimolar
affinity for [3H]-MLA binding sites in rat brain and SH-EPl-ha7 cell membranes.
Interestingly, these compounds, like the range of agonists and allosteric modulators showed
significant differences in affinity between a7 nAChRs expressed in rat brain and SH-EP1-
ha7 cell membranes. These observations highlight the importance of examining drug
affinities in more than one species when examining new compounds for potential therapeutic
benefit. Indeed, it should be noted that many in vitro electrophysiological studies of learning
and memory routinely include (-)bicuculline and TEA at this type of concentration and
therefore, interpretation of results from these type of studies should take into account that
these compounds may be blocking multiple channels.
3.8.3.3 The Inability of aBgTx to Fully Inhibit [3H]-MLA Binding Sites in Rat Brain
and SH-EPl-ha7 Cell Membranes
In agreement with studies performed by Wonnacott and colleagues (Davies et al.,
1999; Whiteaker et al., 1999) in rodent brain membranes, our data confirmed that aBgTx
was only able to inhibit up to ~ 80 % of [3H]-MLA binding sites in rat brain membranes. If
different isoforms of a7 or heteromeric a7 nAChR stoichiometries were responsible for the
incomplete inhibition of [3H]-MLA binding sites, it is possible to postulate that, by using a
homogenous population of a7 nAChRs, such as those expressed in the SH-EPl-ha7 cell line
which are devoid of other nicotinic receptors (Peng et al., 1994b; Severance et al., 2004),
you would expect to see complete inhibition of [3H]-MLA binding. Surprisingly, the reverse
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was observed with ccBgTx only capable of inhibiting about 40 % of [3H]-MLA binding sites
in the SH-EPl-ha7 cell membranes (Figure 3.23, pg 99). This suggests that although
multiple isoforms of the a7 nAChR or heteromeric receptor stoichiometries may exist, these
differences are not the reason why aBgTx fails to fully inhibit [3H]-MLA binding sites in
either rat brain or SFI-EPl-ha7 cell membranes. Much debate and subsequent controversy
has centred around whether a peptide as large as aBgTx (Mwt = ~ 8 kDa) can access all 5
putative binding sites on the a7 nAChR (Conti-Tronconi & Raftery, 1986; Palma et al.,
1996; Balass et al., 1997; Rangwala et al., 1997; Arias, 2000). In contrast, the
norditerpenoid alkaloid, methyllycaconitine (MLA; Aiyar et al., 1979), is a much smaller
compound (Mwt = 874) that should be capable of simultaneously binding to all 5 putative
binding sites on the a7 nAChR. To investigate whether aBgTx's inability to completely
inhibit [3H]-MLA binding sites is potentially due to its size and whether it is capable of
accessing all 5 putative binding sites on the a7 nAChR two approaches were used. Firstly,
the effect of increasing [3H]-MLA binding assay incubation time with aBgTx and secondly,
a [3H]-aBgTx binding assay was established and compared directly with the [3H]-MLA
assay. If [3H]-MLA binds to more sites than [3H]-aBgTx (putatively 5), it should be
completely inhibited by unlabelled MLA but only partially by the larger aBgTx as shown in
Figure 3.26B (pg 104). Again for this hypothesis to be true, [3H]-aBgTx should only label a
fraction (compared to [3H]-MLA) of the available binding sites on the a7 nAChR, with these
sites being completely inhibited by both unlabelled MLA and aBgTx. Most importantly, the
a7 nAChR binding site density (Bmax) should therefore be lower when measured using [3H]-
aBgTx than when measured using [JH]-MLA. The use of [3H]-aBgTx rather than [12"I]-
aBgTx allowed the closest possible comparison of binding properties with the smallest
labelled compound available.
No change in aBgTx affinity (Kj) or level of inhibition of [3H]-MLA binding sites
was observed despite extending the incubation period of the assay up to 140 min, indicating
that increased time to allow for penetration of aBgTx did not alter the result. Whilst
establishing a [3H]-aBgTx binding assay, I showed that the time course of [3H]-aBgTx (2
nM) binding to SH-EPl-ha7 cell membranes did not reach equilibrium, despite incubation of
the ligand with membranes for up to 8 h. This observation in a binding assay indicates that
aBgTx is an irreversible antagonist in a binding assay and, as such, binding was terminated
at 6 h when specific binding was consistently > 65 % (Figure 3.25, pg 103). These findings
are consistent with the literature showing that aBgTx is an irreversible antagonist (Lukas et
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al., 1981; Walker et al., 1981). In competitive inhibition studies aBgTx completely
inhibited [3H]-aBgTx binding sites in SH-EPl-ha7 cell membranes but only inhibited a
maximum of 40 % of j/HJ-MLA binding sites in the same membrane preparation. In
contrast, MLA fully inhibited both [3H]-aBgTx and [3H]-MLA binding sites in SH-EPl-ha7
cell membranes as did the other nicotinic agonists (cytisine and (-)nicotine) examined. This
result is consistent with the above hypothesis that aBgTx and MLA compete for the same
binding site.
To determine if [3H]-aBgTx and [3H]-MLA label different densities of binding
sites, hot saturation studies were performed using SH-EPl-ha7 cell membranes and the
radioligands [3H]-aBgTx and [3H]-MLA. Saturation binding data showed [3H]-aBgTx
bound to SH-EPl-ha7 cell membranes with high affinity (KD = 2.66 nM) with this value
correlating well with those from previously published studies on Torpedo californica and rat
brain (Lukas et al., 1981; Walker et al., 1981). Although the apparent affinity of aBgTx for
a7 nAChRs measured either by hot saturation (KD = 2.66 nM) or by inhibition studies of
[3H]-MLA binding sites in SH-EPl-ha7 cell membranes (Kj = 2.40 nM) was identical, the
density of binding sites labelled by [JH]-aBgTx was significantly lower (2.4 pmol/mg
protein) than those labelled by [3H]-MLA (7.1 pmol/mg protein; p < 0.05).
The significantly lower (65 %) receptor density measured using [3H]-aBgTx
indicates that the size of aBgTx appears to prevent it from binding to all the available
binding sites on the a7 nAChR. The level of reduction in Bmax value (65 %) is consistent
with aBgTx only inhibiting 40 % of [3H]-MLA binding (Figure 3.18, pg 87). Therefore,
these studies indicate that aBgTx is probably only capable of binding to 2 sites on the a7
nAChR pentamer. However, as the agonists cytisine and (-)nicotine fully inhibit [3H]-
aBgTx binding, aBgTx must also cover the agonist binding site as it exhibits identical
affinity for both ['Hj-MLA and [3H]-aBgTx binding sites. Further studies could address
whether allosteric modulators or compounds effecting other sites on the a7 nAChR would
inhibit [3H]-aBgTx binding.
With the pharmacological characterisation of both [3H]-MLA and [3H]-cytisine
binding sites complete, these assays were used to examine the interaction with APi_42 prior to
characterising the a7 ([3H]-MLA) and a4p2 ([3H]-cytisine) nAChRs in a7 nAChR mutant
mice.
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3.8.4 Characterisation of a7 and nAChR Pharmacology in a7 nAChR
Transgenic Mice
Nicotine, the predominant psychoactive compound in tobacco smoke and a non¬
selective nAChR agonist, is able to enhance attention and improve symptomology in
diseases such as Alzheimer's, Parkinson's, attention deficit hyperactivity disorder, and
schizophrenia (Levin & Simon, 1998; White & Levin, 1999; O'Neill et al., 2002; Shytle et
al., 2002; Yang et al., 2002). However, the paucity of truly receptor selective nicotinic
ligands has led to the use of a number of nicotinic receptor transgenic mouse models to try
and elucidate the exact role of the individual subtypes of nAChR in various diseases (Hsiao,
1998; Gordon et al., 2001; Drago et al., 2003; Savonenko et al., 2005). The a7 nAChR
knockout (null) mouse was developed by Orr-Urtreger and colleagues in 1997; with this
mouse lacking aBgTx binding sites and the hippocampal fast nicotinic currents associated
with the a7 nAChR. Furthermore, these mice are generally considered to exhibit normal
physiology and behaviour with only two notable exceptions. Firstly, a7 nAChR knockout
mice do not breed well in comparison to their wildtype littermates (Orr-Urtreger et al., 1997;
Paylor et al., 1998), with a recent study demonstrating that although female knockouts can
achieve pregnancy, litter sizes are significantly smaller than their wildtype littermates,
whereas male knockouts have minimal fertility problems (Morley & Rodriguez-Sierra,
2004). In breeding the a7 knockout mice for behavioural studies discussed below, we
encountered the same problem (unpublished observations) and consequently, heterozygous
females were predominantly used for breeding. Secondly, in behavioural studies a7 nAChR
knockout mice exhibit mostly normal behavioural although they appear to exhibit anxiety in
certain behavioural test when compared to their wildtype controls (Paylor et al., 1998).
Finally, a7 nAChR knockout mice have recently been shown to suffer from some learning
difficulties (Keller et al., 2005) which support our data using the 5-CSR task (Young et al.,
2004), in which a7 nAChR knockout mice exhibit deficits in sustained attention when
compared to their age-matched littermantes.
For these studies a7 nAChR knockout mice were bred in our Institute by
backcrossing a breeding pair 11 times onto a C57B1/6 background. The genotype of the
transgenic mice (wildtype (WT), heterozygous (FIT), or knockout (KO)) was confirmed prior
to behavioural studies of [3H]-MLA binding sites. The pharmacological characterisation in
brain membranes from non-littermate wildtype (C57B1/6) mice before examined both a7 and
a4p2 nAChRs binding sites in the a7-transgenic mice.
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Consistent with the data presented earlier in this chapter using using rat brain
membranes (Figure 3.14, pg 79) and in agreement with the only other published study, [3H]-
MLA (2.5 nM) underwent a fast association with the a7 nAChR in mouse brain membranes,
reaching equilibrium within 15 min (Whiteaker et al., 1999). Futhermore, the KD (1.32 nM)
and Bmax values (16 fmol/mg protein) for [3FI]-MLA in mouse brain are also consistent with
previously published data using either [125I]-aBgTx or ["'HJ-MLA (Marks & Collins, 1982;
Whiteaker et al., 1999). Analysis of the affinity of other cholinergic ligands for [3F1]-MLA
binding sites in mouse brain tissue yielded a rank order of potency ofMLA > (-)AR-R17779
> r/-tubocurarine > (-)nicotine > (+)AR-R17779. The Kj values obtained were comparable to
those obtained from rat brain membranes (Tables 3.6 (pg 92), 3.7 (pg 93), 3.13 (pg 122)) and
the Hill coefficients were in general slightly greater than unity perhaps indicative of positive
co-operativity, however there was some variability, the cause of which is unknown.
As discussed above, only a limited number of studies have assessed the behaviour
of mutant a7 nAChR mice in a variety of tasks, however, no others have systematically
addressed whether there are differences in nAChR pharmacology (Orr-Urtreger et al., 1997;
Paylor et al., 1998; Franceschini et al., 2002; Morley & Rodriguez-Sierra, 2004; Keller et
al., 2005). By definition, a heterozygous a7 nAChR mouse has only one allele coding for
the a7 nAChR gene whilst a wildtype mouse possesses a pair of a7 nAChR alleles. Needless
to say, a7 nAChR KO mice possess neither allele. An initial study assessing the density of
[3H]-MLA binding sites in individual a7 transgenic mouse brain membranes confirmed the
absence of a7 nAChRs in KO mice (Young et al., 2004). This initial observation has now
been extended with a second 5-CSR study comparing wildtype, a7-nAChR heterozygote, and
a7-nAChR knockout mice (currently accepted for publication in European J
Psychopharmacology). As transgenic manipulations may produce compensatory changes in
nAChR density or changes in receptor pharmacology, in parallel, the nicotinic receptor
pharmacology of these mice was investigated to enhance the above findings, and I am a co¬
author on both manuscripts.
Although no change in [3H]-MLA affinity was observed between male WT (KD =
7.4 nM) and HT mice (KD = 10.7 nM), or between female WT (KD = 7.3 nM) and HT mice
(Kd = 10.5 nM), the receptor density was significantly altered. Indeed, this is the first study
to confirm that the [3H]-MLA binding site density in HT mice (Bmax = 34 and 27 fmol/mg
protein in male and female HT mice, respectively) is almost exactly half of that measured in
WT mouse membranes (Bmax = 66 and 73 fmol/mg protein in male and female mice,
respectively). These values are consistent with those determined in rat brain and SH-EP1-
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ha7 cell membranes (Section 3.5.2) and with previously published studies using the a7
nAChR knockout mice (Orr-Urtreger et al., 1997). Furthermore, Hill coefficients were close
to unity indicating that [3H]-MLA binds to a single population of receptors in both WT and
HT mouse brain membranes, consistent with observations in rat and SH-EPl-ha7 cell
membranes (Section 3.5.2).
Any genetic manipulation in a7 nAChR gene expression may result in a
compensatory change in other cholinergic receptors. As such it was necessary to examine
the density and pharmacology of the a4p2 nAChR, the other major nicotinic receptor in
rodent brain (Paterson & Nordberg, 2000). When compared to their littermate controls, there
was no alteration in the affinity (KD) of [3H]-cytisine on comparing WT and KO mouse brain
membrane preparations. Furthermore, no alteration in [3H]-cytisine binding density was
observed between mice (Table 3.14, pg 128). These findings are in agreement with Orr-
Utreger and colleagues (1997) who showed a7 KO mice lack MLA binding sites but still
have a4p2 nAChRs when measured using [3H]-cytisine. Interestingly, and in agreement with
the current [3H]-MLA binding data (Table 3.13, pg 122), no gender specific differences in
[3H]-cytisine binding sites were observed (Table 3.14, pg 128). Hill slopes were close to
unity, indicating single-site affinity for [JH]-cytisine. As such it must be concluded that a4p2
nAChRs do not appear to undergo up- or down-regulation to compensate for the loss of [3H]-
MLA binding sites in a7 nAChR KO mouse brain.
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3.9 CONCLUSIONS
In order to pharmacologically characterise human and rodent a4p2 and a7
nAChRs, I successfully established and characterised 4 separate radioligand binding assays
using pHj-epibatidine (ot4p2), [JH]-cytisine (a4p2), [3Fl]-MLA (a7), and [3H]-aBgTx (a7).
Using these assays I showed that [3H]-cytisine may be successfully substituted for [3H]-
epibatidine in order to characterise a4p2 nAChRS in a small volume radioligand binding
assay and that no species differences exist. Furthermore, I have utilised the [3H]-MLA and
[3FI]-aBgTx assays to show that aBgTx and MLA bind to different proportions of the 5
available competitive antagonist sites on the homomeric a7 nAChR. Finally a7 nAChR KO
mice bred in-house were shown to lack a7 nAChRs using both the [3H]-MLA binding assay
and genotyping. In addition, I have shown that removal of the a7 nAChR does not result in
any compensatory up or down regulation of a4p2 nAChRs. To this end, one behavioural
paper has already been published showing removal of the a7 nAChR results in a deficit in
sustained attention in the 5-CSR task (Young et al., 2004) whilst a second paper has also
been accepted for publication {Eur J Psychopharmacology). This latter paper compares the
ability of a7 nAChR KO mice with their heterozygous and wildtype littermates in the 5-CSR
task, showing both KO and heterozygous mice exhibit deficits in sustained attention
compared to their wildtype littermates.
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4 Pharmacological Interaction between APi_42 and nAChRs
4.1 INTRODUCTION
Although a growing body of evidence now supports a direct interaction between
AP1.42 and nAChRs, controversy exists over the exact nature of this interaction, the subtype of
nAChR involved and indeed, which the form of Apt.42 is neurotoxic.
In 2000, Wang and colleagues published a paper indicating that picomolar
concentrations of APm2 could inhibit the binding of a7 nAChR antagonists [l25I]-aBgTx and
[3H]-MLA to the a7 nAChR (Wang et al., 2000a). These initial findings were closely
followed by a second paper indicating that ApM2 exhibited >5000-fold higher affinity for the
a7 nAChR compared to the a4p2 nAChR (Wang et al., 2000b). However, these finding have
not been replicated by other groups despite the use of Api_42 concentrations ranging from
femtomolar to nanomolar (de Fiebre & de Fiebre, 2005).
Further complicating the study of any potential interaction between APi_42 and
nAChRs, is a debate as to which form of Api_42 is supposedly neurotoxic. AP is present in all
animals in multiple conformations including monomers, oligomers, protofibrils, and mature
fibrils and as such, it is difficult to define which form causes neurodegeneration (Walsh et al.,
1997; Teplow, 1998; Conway et al., 2000; Bitan et al., 2003).
Consequently, in order to examine any potential phannacological interaction
between APi_42 and nAChR, the solubility APi_42 in a number of different vehicles was first
assessed using a thioflavin T aggregation assay. Thioflavin T is a fluorescent dye that
specifically binds to P-sheet fibrous structures (Vassar & Culling, 1959; LeVine, 1993;
Yoshiike et al., 2003). . Following the assessment of AP]_42 solubility and by establishing
radioligand binding assays (Chapter 3) the ability of APi_42 to inhibit [3H]-cytisine and [3H]-
MLA binding to a4p2 and a7 nAChRs, respectively, was studied.
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4.2 Human APi_42 Has No Direct Effect on Binding to the Human a4p2 and a7
AChRs
Recent studies provide pharmacological evidence for and against a direct
interaction of Ap,_42 with the a4p2 nAChR (Kihara et al., 1998; Wang et al., 2000b; Tozaki
et al., 2002; Fu & Jhamandas, 2003; Wu et al., 2004) and the a7 nAChR (Wang et al.,
2000a,b; Dineley et al., 2001, 2002a; Liu et al., 2001; Pettit et al., 2001; Nagele et al., 2002;
Grassi el al., 2003; Wu et al., 2004; de Fiebre & de Fiebre, 2005). Flowever, only three of
these papers have presented binding data (Wang et al., 2000a,b; de Fiebre & de Fiebre,
2005). In addition, whilst variations exist within these papers in terms of the form, source
and species of APi_42 used, these former studies acted as a forerunner to a large body of
research investigating a direct link between nAChRs and APi_42 (for reviews see Kem, 2000;
Court et al., 2001; O'Neill et al., 2001; Kihara & Shimohama, 2004a). To address whether
there was any such direct interaction between various forms of Ap,.42, the putatively
neurotoxic peptide, and nAChRs, a4p2 nAChRs (using [TIJ-cytisine) and a7 nAChRs (using
[3H]-MLA) that were characterised in Sections 3.4 and 3.5, respectively, were used. Prior to
assessing the action of APi.42 at these nAChR subtypes, thioflavin T studies were performed
to determine the fibrillation state of APi_42 in the various assay buffers and protocols to be
used.
4.2.1 Determination of the Aggregation State of Human Apr^2
Although Ap is predominantly found in a fibrillar form in the brains of AD
patients, recent studies also show that soluble oligomers of Ap and not monomers or fibrils
inhibit long term potentiation and cause neurodegeneration (Selkoe, 1994; Kihara et al.,
1997; Walsh et al., 1997, 2002a; Teplow, 1998; Conway et al., 2000; O'Neill et al., 2002;
Bitan et al., 2003). Methodologically, Ap may be resuspended in a range of vehicles to
achieve different states of solubility including an aggregated form (Wang et al., 2000a,b; Liu
et al., 2001; Pettit et al., 2001). The level of solubility/aggregation of Api_42 in a number of
different vehicles can be assessed using a Thioflavin T fluorescence based assay (Yoshiike et
al., 2003). Thioflavin T (ThT) is a yellow dye that specifically binds to P-sheet structures
such as amyloid fibrils (LeVine, 1993; Yoshiike et al., 2003).
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4.2.1.1 Time Course of Human APi_42 Aggregation
Calbiochem provide human APi_42 in a lyophilised form and to induce aggregation
they suggest their human Api_42 is resuspensed in 1/3 magnesium and potassium-free PBS
(PBS), and 2/3 sterile water, prior to incubating the solution at 37°C for 48 h. Using this
dilutant, the time course of human A(3i_42 aggregation was assessed by incubating the human
A(3].42 (100 pM final assay concentration) with ThT (10 pM) in a 96-well plate.
Fluorometric measurements were carried out every 30 min for 48 h at 37°C using a
Flexstation fluorescence plate reader. Pluman APi_42 showed signs of aggregation almost
immediately after the incubation was initiated (Figure 4.1). The level of fluorescence and
presumably aggregation declined slightly before reaching a plateau that held constant for
approximately 32 h.
4.2.1.2 Fluorometric Analysis of ApM2 Aggregation in Different Assay Buffers
The controversy surrounding the pharmacologically relevant form
(soluble/insoluble) of Ap makes it important to determine what effect the assay buffer has on
the form of AP).42 utilised before assessing its interaction with a4p2 and a7 nAChRs. Ap
was resuspended in 4 different vehicles supposedly producing soluble or aggregated forms of
Api_42. These samples were then diluted in 3 different assay buffers ([3H]-MLA (a7
nAChRs), [3H]-cytisine (a4p2 nAChRs) or electrophysiology buffer (a7 and a4p2 nAChRs,
see Chapter 4), and the state of solubility/aggregation assessed using the ThT assay.
The first protocol used was that recommended by Calbiochem® (Product No:
PP69) to induce aggregation. As discussed previously, human APi_42 (250 pg) was
resuspended in a mixture of magnesium and potassium-free PBS and sterile water and then
incubated at 37°C for 48 h. Following this incubation period, the human APi_42 was serially
diluted in either of the two radioligand binding assay buffers or in the electrophysiology
buffer at concentrations ranging from 100 pM to 1 pM (Figure 4.1). Levels of aggregation
in these experiments were significantly lower than those observed in the time course study,
probably reflecting the lower concentration of Apu42 (< 1 pM) examined (Figure 4.1 & 4.2).
The highest levels of thioflavin T fluorescence were detected in APi_42 samples at
a concentration > 100 nM Ap,.42, regardless of the assay buffer used (Figure 4.2). Indeed,
when compared to control samples, significant aggregation was detected in Ap,.42 samples at
concentrations of >100 nM when Ap.42 was serially diluted in [3H]-MLA or [3H]-cytisine
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Figure 4.1
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Time Course of Human P-Amyloidi^2 Aggregation. p-Amyloid]_42 was dissolved in magnesium
and potassium-free PBS to a final concentration of 100 pM as recommended by Calbiochem® U.K.
The state of aggregation of the peptide was then assessed by dilution in sterile water to a final assay
concentration of 1 pM and addition of thioflavin T (10 pM final assay concentration), in a total assay
volume of 200 pi. Fluorometric measurements were carried out in triplicate every 30 min for 48 h at
37°C using a Flexstation® Microplate Reader (Molecular Devices, U.K.) with excitation and emission
wavelengths set to 444 nm and 485 nm, respectively. Between readings the plate was kept covered at
37°C in a C02 (5 %) incubator with the data shown representive of a typical experiment.
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radioligand binding assay buffers (p < 0.05; Figure 4.2 A&B). Likewise, significant
aggregation was not detected at ApM2 concentrations < 100 nM in samples serially diluted in
electrophysiology buffer (Figure 4.2C). Furthermore, P-sheet aggregation was not detected
in any of the diluted APi.42 samples at concentration of < 10 nM, regardless of assay buffer
(Figure 4.2).
4.2.1.3 Assessment of the Solubility/Aggregation State of Human Ap(^2 Dissolved in
5% Acetic Acid Solution
In the following experiments, a soluble Ap solution is defined as one in which
insignificant or no P-sheet aggregation is detected whilst "control" fluorescence refers to
fluorescence measured in a 1 pM sample of pre-aggregated human APi_42 and serially diluted
in the radioligand binding or electrophysiology buffers as described in Section 3.9.1.2.
Calbiochem® recommend resuspending the human APi_42 in a 5 % acetic acid solution to
generate a soluble form of APi_42. P-Amyloidi_42 (100 pM) was resuspended in a 5 % acetic
acid solution prior to serial dilution in radioligand binding assay and electrophysiological
buffers, and assessed for P-sheet aggregation. Surprisingly, aggregation was detected at an
APi_42 concentration of 1 pM in all the assay buffers examined (Figure 4.3). Levels of
fluorescence were highest at 1 pM AP i_42 in the [3H]-MLA assay buffer (~17 x 103 r.f.u.,
Figure 4.3A) however, P-sheet aggregation was also detected at this concentration in both
the [3FI]-cytisine assay (~6 x 103 r.f.u., Figure 3.30B) and electrophysiological buffers (~11 x
103 r.f.u., Figure 4.3C). At all other concentrations examined (0.1 - 100 nM), AP[.42 in 5 %
acetic acid showed little sign of fibril formation in any of the three assay buffers tested
(Figure 4.3). Indeed, the amount of fluorescence measured did not reach 10 % of the control
fluorescence (Figure 4.3).
4.2.1.4 Assessment of the Solubility/Aggregation State of Human APi_42 Dissolved in
DMSO/Tris Solution
Wang and colleagues published the two pivotal papers showing that human APi_42
binds with picomolar affinity to the a7 nAChR (Wang et ai, 2000a,b). In these papers
human APi_42 was resuspended in a 50/50 mixture of DMSO and Tris HC1 at pH 8.0 to form
a soluble APi_42 solution (personal communication). Therefore, this method was used and
human Apu42 was resuspended in the Wang DMSO/Tris solution and its degree of
solubility/aggregation measured using the ThT assay.
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Figure 4.2
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[Aggregated A(3M2] (nM)
Effect of Dilution in Different Assay Buffers on Pre-Aggregated APi_42. Human Ap,_42 (1 mg/ml)
was aggregated in a magnesium-free, potassium-free sterile water solution for 48 h at 37°C.
Following this incubation, APi .42 was serially diluted in (A) [3H]-MLA (a7 nAChR), (B) [3H]-cytisine
(a4p2 nAChR) or (C) electrophysiology assay buffers and aggregation assessed using the P-sheet
specific dye Thioflavin T (10 pM). The degree of P-sheet aggregation was assessed by the relative
amount of fluorescence intensity. Readings were made at 37°C using the Flexstation® fluorescence
plate reader (excitation & emission wavelengths of 444 nrn & 485 nm, respectively). When compared
to control samples (ThT dye and buffer only), significant levels of P-sheet aggregation were detected
in all the human APi_42 samples at amyloid concentrations of >100 nM, with the highest levels
observed in samples diluted in electrophysiology buffer. Each data point was performed in triplicate.
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Figure 4.3
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Effect of Dilution in Different Assay Buffers on the Solubility/Aggregation of Ap^ Solublised
in 5 % Acetic Acid. Human Ap^ (100 pM) was solubilised in a 5 % acetic acid solution.
Following this incubation, APi_42 was serially diluted in (A) [3H]-MLA (a7 nAChR), (B) [3H]-cytisine
(a4p2 nAChR) or (C) electrophysiology assay buffers and assessed for aggregation using the P-sheet
specific dye Thioflavin T (10 pM). The degree of P-sheet aggregation was assessed by the relative
amount of fluorescence intensity. Readings were made at 37°C using the Flexstation® fluorescence
plate reader (excitation and emission wavelengths of 444 nm and 485 nm, respectively). When
compared to control samples (Th'T dye and buffer only), significant levels of P-shcct aggregation were
detected in all 1 pM human APi_42 samples. Each data point was performed in triplicate.
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When assessed in terms of fluorescence intensity, a high level of P-sheet
aggregation were present in the 1 pM human APi_42 samples in all three assay buffers
examined (Figure 4.4). High levels of fluorescence intensity (indicating p-sheet
aggregation) were also observed in the 100 nM Api.42 samples diluted in [JH]-cytisine assay
buffer (Figure 4.4B). Although the levels of aggregation in the 1 pM APi_42 samples
dissolved in [3H]-MLA and electrophysiology assay buffers exceeded that measured in their
pre-aggregated controls (Figure 4.4 A & C), the 1 pM human Ap,_42 sample dissolved in
[3H]-cytisine assay buffer was not significantly different from its pre-aggregated control
(Figure 4.4B). At all the other human APi_42 concentrations, the degree of aggregation was
less than 6 % of their respective aggregated control (Figure 4.4).
4.2.1.5 Assessment of the Solubility/Aggregation State of Rpeptide Apt.42
Until recently, Api_42 was only available as a lyophilized trifluoroacetate salt that
required resuspension in a vehicle such as acetic acid or DMSO to generate a soluble Ap
solution. However, p-amyloid^ prepared in l,l,l,3,3,3-hexafluoro-2-propanol (HFIP) is
now available from Rpeptide as an acetate salt. This has the advantage that the peptide may
be resuspended in sterile water with negligible levels of acetic acid present in the final
sample. As such, human APi_42 was purchased from Rpeptide and resuspended to 1 mg/ml
according to their instructions prior to serial dilution in either radioligand or
electrophysiology assay buffers.
Very high levels of fluorescence intensity were observed for all 1 pM Apt.42
solutions regardless of the assay buffer used for dilution (Figure 4.5). Furthermore, at an
APi_42 concentration of 100 nM, the fluorescence intensity was ~33 % of that observed in the
control pre-aggregated samples (Figure 4.5). At concentrations of < 10 nM, P-sheet
aggregation was less than 5 % of the value observed in the control samples (Figure 4.5).
In summary, and with the exception of APi_42 (100 nM) solublised in DMSO/Tris
HC1 and diluted in [3H]-cytisine assay buffer but including pre-aggregated controls, all APi_
42 samples at concentrations of < 100 nM exhibited negligible or no P-sheet aggregation in
comparison to their equivalent pre-aggregated control. In contrast, all supposedly soluble















0.1 1 10 100 1000 Veh Ctrl
[ApM2 in DMSO/Tris] (nM)
Effect of Dilution in Different Assay Buffers on the Solubility/Aggregation of A(3i_42 Solublised
in 50/50 DMSO/Tris HCI. Human Ap,_42 (100 pM) was solubilised in a 50/50 mixture of
DMSO/Tris (pH 8.5). Following this incubation, AP|.42 was serially diluted in (A) [3H]-MLA (a7
nAChR), (B) [3H]-cytisine (a4p2 nAChR) or (C) electrophysiology assay buffers and assessed for
aggregation using the P-sheet specific dye Thioflavin T (10 pM). The degree of p-sheet aggregation
was assessed by the relative amount of fluorescence intensity. Readings were made at 37°C using the
Flexstation® fluorescence plate reader (excitation and emission wavelengths of 444 nm and 485 nm,
respectively). When compared to control samples (ThT dye and buffer only), significant levels of P-
sheet aggregation were detected in all 1 pM human APi_42 samples, and at 100 nM when diluted in
[JH]-cytisine assay buffer. Each data point was performed in triplicate.
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Figure 4.5
0.1 ] 10 100 1000 Ctrl
[Rpeptide A [1M21 (nM)
Effect of Dilution in Different Assay Buffer on the Solubility/Aggregation of Rpeptide Api_42.
Human AP1.42 (100 pM, Rpeptide) was solubilised in sterile water. Following this incubation, AP1.42
was serially diluted in (A) [3H]-MLA (a7 nAChR), (B) [3H]-cytisine (a4p2 nAChR) or (C)
electrophysiology assay buffers and assessed for aggregation using the p-sheet specific dye Thioflavin
T (10 pM). The degree of P-sheet aggregation was assessed by the relative amount of fluorescence
intensity. Readings were made at 37°C using the Flexstation® fluorescence plate reader (excitation
and emission wavelengths of 444 ryn and 485 nm, respectively). When compared to control samples
(ThT dye and buffer only), significant levels of P-sheet aggregation were detected in all 1 pM human
AP].42 samples. Each data point was performed in triplicate.
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4.3 Human and Rat Ap,_42 Do Not Inhibit |3H|-Cytisine or [3H|-MLA Binding
Sites in SH-EPl-ha4p2 and SH-EPl-ha7 Cell Membranes
Human APi_42 was purchased from Calbiochem and dissolved in a number of
different vehicles to form putatively soluble (5 % acetic acid, 50/50 DMSO/Tris HC1, pl l
8.0) or insoluble (magnesium and potassium-free PBS) solutions. The insoluble
(aggregated) suspension was prepared 48 h in advance to induce aggregation as previously
discussed. Following an initial resuspension, concentrated human APi_42 solutions were then
serially diluted in either [3H]-cytisine (a4p2 nAChRs) or [3H]-MLA (a7 nAChRs) assay
buffers. Due to Rpeptide APi.42 not being available when these initial experiments were
performed, its ability to inhibit [3H]-cytisine or [3H]-MLA binding to SH-EPl-ha4p2 or SH-
EPl-ha7 cell membranes, respectively, has not been assessed.
Regardless of the vehicle used for resuspension or the assay buffer used, human APi_
42 (100 pM - 10 pM) did not inhibit either [3H]-cytisine or [3H]-MLA binding sites in
membranes prepared from SH-EPl-ha4p2 or SH-EPl-ha7 cell membranes, respectively
(Figures 4.6). The ability of rat APi_42 to inhibit [3H]-MLA binding sites was also examined
in rat and mouse brain membranes (Figure 4.7). In agreement with the observations for the
human a7 nAChR in the SH-EP1 cell membrane preparations, and again regardless of
vehicle, rat APi_42 failed to inhibit [3H]-MLA binding sites in either rat or mouse brain
membranes. In contrast to Wang and colleagues (2000a), increasing the number of pre-assay
washes of either the rodent brain or SH-EP1 cell membranes from three to five did not reveal
any human or rat APi_42 inhibition of [3H]-cytisine or [3H]-MLA binding sites in rodent brain,
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Human APi^ Does Not Inhibit [3H]-Cytisine or [3H]-MLA Binding to Human a4p2 or a7
nAChRs. Human Api.42 was incubated (22°C) with (A) [3H]-cytisine (3 nM) and SH-EPl-ha4p2
membranes (115 jig) or (B) [3H]-MLA and SH-EPl-ha7 membranes (150 pg) in a total assay volume
of 250 pi for 60 min. No human APi_42-induced inhibition of [3H]-cytisine or [3H]-MLA binding sites
was observed. Symbols represent human A(3,.42 dissolved in 5% acetic acid (•), 50/50 DMSO/Tris
HC1 (■), or Aggregated in Mg2+ and K+-free PBS (♦); ▲ represent their respective NSB. Non¬
specific binding was determined in the presence of 10 pM rf-tubocurarine or 1 mM (-)nicotine with
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Rat Ap1-42 Does Not Inhibit [3H]-MLA Binding to Rat or Mouse a7 nAChRs. Rat A.Pi.42 was
incubated (22°C) with [3H]-MLA (2.5 nM) and (A) rat brain (400 jag) or (B) mouse brain membranes
(850 jig) in a total assay volume of 250 jil for 60 min. No rat APi_42-induced inhibition of [3H]-MLA
binding sites was observed. Symbols represent human ApM2 dissolved in 5% acetic acid (•), 50/50
DMSO/Tris IIC1 (■), or Aggregated in Mg2+ and K+-free PBS (♦); ▲ represent their respective NSB.
Non-specific binding was determined in the presence of 10 jiM (f-tubocurarine with these data
representing a typical experiment.
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4.4 DISCUSSION
As mentioned earlier, a number of recent studies have looked at the effects of APi_
42 on functional responses at a7 and a4p2 nAChRs (Dineley et al., 2001, 2002a; Liu et al.,
2001; Pettit et al., 2001; Tozaki et al., 2002; Eaton et al., 2003; Fu & Jhamandas, 2003; Wu
el al., 2004), with only a limited number assessing binding (Wang et al., 2000a,b; de Fiebre &
de Fiebre, 2005). Despite extensive pharmacological characterisation of both the [3H]-
cytisine and [3H]-MLA binding assays, these studies provided no direct pharmacological
evidence that human Api.42 could inhibit radioligand binding to human a4p2 or a7 nAChRs,
or indeed to rat or mouse membranes. The preparation of APi_42 to promote the solubility (in
5 % acetic acid or 50/50 DMSO/Tris HC1, pH 8.0) or insolubility (aggregated in Mg2+-free,
KF-free PBS and MQ FLO for 48 h) of the peptide had no effect on these results, with no form
of amyloid directly inhibiting binding at concentrations of up to 10 pM. These findings are in
direct contrast to those of Wang and colleagues (2000a,b) who showed human APi_42
(prepared in 50/50 DMSO/Tris) selectively inhibited [3FI]-MLA and [125]-aBgTx binding to
human a7 nAChRs expressed in SK-N-MC cell membranes. However, our finding is in
agreement with de Fiebre and de Fiebre (2005) who reported that rat APi_42 did not inhibit
[l25I]-aBgTx binding to mouse a7 nAChRs.
Interestingly, neither de Fiebre and de Fiebre (2005) nor Wang et al., (2000a,b)
discussed the state of Ap^ aggregation in their respective studies. By examining the
potential putative confonnation of Ap,.42 in all the vehicles used in the current study and
those presented in Chapter 4, the Thioflavin T studies revealed that regardless of vehicle or
assay buffer used, amyloid conformation was dependent on its concentration. All 1 pM
samples of Api_42 yielded positive signs of aggregation in the Thioflavin T assay (Section
3.7.1, pg 108). Surprisingly, using the 50/50 DMSO/Tris HC1 vehicle, favoured by Wang and
colleagues (2000a,b), APi_42 diluted in the [3H]-cytisine assay buffer exhibited signs of
aggregation at a concentration of 100 pM. Furthermore, even in protocols designed to cause
Ap, .42 aggregation, the peptide only exhibited signs of aggregation concentrations in excess of
1 pM. At all other concentrations (0.1 nM - 1 pM) examined in the three assay buffers ([3H]-
cytisine, [3H]-MLA, and electrophysiology), human APi_42 failed to show signs of
aggregation. These findings highlight the difficulty of working with solutions of P-amyloid
and the necessity to try and determine whether you have soluble or aggregated APi_42 before
including the peptide in any study.
Wang and colleagues (2000a) reported that multiple washings of SK-N-MC cells
were required to remove soluble factors such as the endoplasmic reticulum amyloid binding
protein, and thereby uncover high affinity [3H]-MLA binding sites for Api_42. Even after
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incorporating this 5-step washing protocol, we could provide no evidence that Ap,_42 inhibited
[3H]-MLA binding. De Fiebre and de Fiebre (2005) suggest that this extensive washing of
membranes may have uncovered non-a7 nAChR binding sites for [3H]-MLA and APi_42.
Furthermore, it is unlikely that the choice of radiolabel plays a role in the negative response
observed by de Fiebre and de Fiebre (2005) ([125I]-aBgTx) and ourselves ([3FI]-MLA) as
Wang and colleagues (2000a,b) utilised both [123I]-aBgTx and [3H]-MLA with identical
positive results. Therefore, the major differences between the various assays appear to be
technique, vehicle and tissue of choice. However, little detail is given on the exact assay
conditions (incubation times, filtrations systems, plates, etc) under which these experiments
were performed (Wang et al., 2000a,b; de Fiebre & de Fiebre, 2005).
Both Wang and colleagues (2000a,b, personal communication) and I dissolved
human Ap[.42 in a 50/50 mixture of DMSO and Tris HC1 at pH 8.0 but with different results.
Again, de Fiebre and de Fiebre (2005) used rat APi_42 dissolved in either distilled water (and
then incubated to promote aggregation) or in HEPES buffer to promote solubility and failed
to show APi.42-induced inhibition of [125I]-aBgTx binding sites. The other major difference
in experimental protocol between Wang and colleagues (2000a,b) and the current studies lie
in the choice of cell line for a7 nAChR expression (Figure 3.32, pg 116). Wang and
colleagues (2000a,b) utilised the SK-N-MC cell line to over-express the human a7 nAChR
while we used the SH-EP1 cell line. In contrast, both de Fiebre and de Fiebre (2005) and
ourselves used mouse brain homogenates while we also used rat brain homogenates (Figure
3.34, pg 119). Alpha7 nAChRs are notoriously difficult to stably express in cell systems
(Cooper & Millar, 1997; Peng et al., 1999; Schroeder et al., 2003; Craig et al., 2004;
Williams et al., 2005) and although it is possible that there is a difference in receptor
conformation of the a7 nAChR in the SK-N-MC cell line in comparision to the SH-EPl-ha7
cells, Biedler and colleagues (1979) did show that these cells were derived from the same
original source. However, this would not explain the lack of APi„42 inhibition of [125I]-aBgTx
binding sites in rat brain homogenates in the current studies and in the mouse brain
homogenates used by de Fiebre and de Fiebre (2005).
In addition to [3H]-MLA binding, we showed for the first time that human APi_42 did
not inhibit [3H]-cytisine binding sites in the SH-EPl-ha4p2 cell line. Although, Wang et al.,
(2000b) investigated the effects of amyloid on [3H]-cytisine binding sites in rat brain
membranes, they did not observe any inhibition.
159
4.5 CONCLUSIONS
In order to examine any potential pharmacological interaction between APi_42 and
the nAChRs a4p2 and a7, I have established the solubility of Ap,_42 in a variety of different
vehicles. Furthermore, I have presented evidence that soluble and insoluble forms of human
APi_42 do not inhibit [3H]-MLA binding to the human a7 nAChR nor do they inhibit [3H]-
cytisine binding to the human a4p2 nAChR. This latter data has been published in two book
chapters (Crawford et al., 2004; Finlayson et al., 2005).
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5.0 Functional analysis of a4p2 and a7 nAChRs
5.1 INTRODUCTION
A number of recent studies have examined the functional interaction between Api_
42 and nAChRs (Kihara et al., 1998; Dineley et al., 2001; Kihara et al., 2001; Liu et al.,
2001; Pettit et al., 2001; Tozaki et al., 2002; Dineley et al., 2002a; Fu & Jhamandas, 2003;
Grassi et al., 2003; Fodero et al., 2004; Wu et al., 2004). The majority of these studies have
focused on the functional interaction between APi_42 and the a7 nAChR (Dineley et al.,
2001; Liu et al., 2001; Pettit et al., 2001; Dineley et al., 2002a; Grassi et al., 2003; Fodero el
al., 2004). However, the interaction of AP]_42 with nAChRs is not exclusive to the a7
nAChR with several studies examining the role of the a4p2 nAChR (Kihara et al., 1998;
Tozaki et al., 2002; Fu & Jhamandas, 2003; Fodero et al., 2004; Wu et al., 2004; Lamb et
al., 2005). All of the above studies have utilised electrophysiology and have been performed
using both native (e.g. the rat hippocampal slice) and expressed nAChRs (e.g. in nAChR-null
cell lines or in Xenopus oocytes). As well as the complexity of comparing different
preparations of APi_42, these studies are further complicated by the number of vehicles in
which Api_42 has been prepared. For examples, Liu and colleagues (2001) used rat APi_42
resuspended in 5 % acetic acid whilst Dineley and colleagues (2001) used a HEPES buffer.
In AD, the exact neurotoxic form of APi_42 remains the subject of much debate.
Indeed, in the studies mentioned above, APi_42 has been dissolved in a range of vehicles to
produce both soluble and insoluble APi_42. However, although Ap^ itself appears to inhibit
responses at both a4p2 and a7 nAChRs, it is perhaps surprisingly that very few of these
studies closely examine the effect of the Ap^ vehicles used (Kihara et al., 1998; Dineley et
al., 2001; Kihara et al., 2001; Liu et al., 2001; Pettit et al., 2001; Tozaki et al., 2002; Dineley
et al., 2002a; Fu & Jhamandas, 2003; Grassi et al., 2003; Fodero et al., 2004; Wu et al.,
2004). The vehicles used to dissolve Ap were as diverse as 5 % acetic acid (Liu et al.,
2001), 50/50 DMSO/Tris (Wang et al., 2000a, Wang et al., 2000b, personal
communication), HEPES buffer (Dineley et al., 2001), and sterile water (Wu et al., 2004).
The maintenance of stable functional expression of nAChRs, in particular the a7
subtype, also presents a considerable challenge (Cooper & Millar, 1997). In contrast to the
a4p2 nAChR, which can be easily over-expressed in cell lines (Gopalakrishnan et al., 1996),
only limited reports of successful a7 nAChR expression exist (Puchacz et al., 1994; Quik et
al., 1996; Peng et al., 1999; Zhao et al., 2003), with a number of papers highlighting
problems in maintaining stable expression in mammalian cell lines (Cooper & Millar, 1997;
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Peng et al., 1999; Sweileh et al., 2000). A considerable amount of research has focused on
increasing surface expression by altering cell culture conditions (Molinari et al., 1998;
Schroeder et al., 2003), generating a7-5HT3 chimera's (Eisele et ah, 1993; Craig et ah,
2004), or by using site-directed mutagenesis studies (Dineley & Patrick, 2000). Indeed, a
non-densensitising mutant has also been used in vitro and in vivo (Orr-Urtreger et al., 2000;
Broide et al., 2001; Gil et al., 2002; Dineley et al., 2002a). As discussed in Chapter 3, SH-
EP1 cell lines over-expressing the a4p2 and a7 nAChRs were used for the examination of the
functional interaction with human APi_42. SH-EP1 cells contain no native nAChRs, however
there are reports of successful expression of the human a4p2 (SH-EPl-ha4p2) and human a7
(SH-EPl-ha7) nAChRs (Peng et al., 1999; Eaton et al., 2003; Schroeder et al., 2003; Wu et
al., 2004). To comprehensively examine whether human APi.42 has any direct or indirect
effect on the a4p2 and a7 nAChR subtypes, Api_42 was dissolved in several different vehicles
to produce both soluble and insoluble forms of APi_42. A number of approaches were taken
and include the ability of human APi_42 to effect changes in intracellular calcium or
membrane potential, assessed using fluorescence-based assays. Both these assays have been
used to assess the functionality of nAChRs with the membrane potential recently shown to
be potentially more sensitive than the calcium assay (Fitch et al., 2003). These assays use
calcium-sensitive or membrane potential-sensitive fluorescent dyes to assess changes in
intracellular calcium and ionic flux, respectively. Whole cell current recording was used to
characterise the pharmacology and re-confirm functional expression of a4p2 and a7 nAChRs
in the SH-EP1 stable cell line.
Finally, a recent study has shown APi_42 to co-localise with the a7 nAChR in tissue
from human AD patients (Wang et al., 2000a). Furthermore, it has been demonstrated that
amyloid plaque accumulation is accelerated in transgenic mice co-expressing the mutant
human presenilin I and amyloid precursor proteins and that the a7 nAChR is simultaneously
upregulated in these animals (Dineley et al., 2002b). Following on from these initial studies,
a more direct role for the a7 nAChR in APi_42 accummulation has been demonstrated
(Nagele et al., 2002; Wang et al., 2002). Nagele and colleagues (2002) demonstrated a
substantial intracellular accumulation of APi_42 in neurons expressing relatively high levels
of a7 nAChRs. Furthermore, they demonstrated that the rate and extent of Ap|.42 in these
cerebellar neurons was directly proportional to the level of a7 nAChR protein expression.
Wang and colleagues (2002) extended these finding using the neuroblastoma cells
expressing high levels of a7 nAChR, showing rapid internalisation and intracellular
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accumulation of APi_42 in these cells in vitro. As a consequence, I incubated SH-EP1 cells
over-expressing either the human a4p2 or a7 nAChRs with human APi_42 and preformed co-
immunoprecipitation experiments to examine co-localisation of these human nAChR
subtypes with human APi_42.
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5.2 RESULTS
5.2 Characterisation of Calcium and Membrane Potential Responses in Human
a4p2 and a7 nAChRs
Functional assays for ion channels include classical electrophysiology (Velicelebi
et al., 1999; Fucile et al., 2002; Palma et al., 2002; Fayuk & Yakel, 2005), radioisotopic ion
flux (Lukas & Cullen, 1988; Bertrand el al., 1997), and fluorescence assays using ion- or
voltage-sensitive dyes (Manning & Sontheimer, 1999; Chavez-Noriega et al., 2000; Fitch et
al., 2003). In order to detect any functional interaction between the human nAChR subtypes
CX4P2 and a7, simple population cell-based assays were performed prior to undertaking data
rich but labour-intensive, and complex whole cell patch clamp electrophysiology studies (see
Section 5.3). The following two sections describe the characterisation of calcium flux and
membrane potential assays in SH-EPl-ho^Pi and SH-EPl-ha7 cell lines.
5.2.1 Characterisation of Intracellular Calcium ([Ca2+h) Responses in SH-EP1-
ha4p2 Cells.
5.2.1.1 Effect of Cell Density on (-)Nicotine Evoked [Ca2+|j Responses in SH-EP1-
ha4p2 Cells
The calcium flux assay is a cell based fluorescence assay in which changes in
intracellular calcium are detected by loading cells with a calcium-sensitive fluorescent dye.
The signal is then detected using a standard 510-570 nm emission filter on a fluorescent plate
reader such as the FLEXstation® (Molecular Devices (MD), U.K.).
To determine whether exposure to (-)nicotine could elicit [Ca2+]i response in SH-
EPl-ha4p2 cells, different cell densities were plated (50,000, 75,000, and 100,000 cells per
well) and incubated overnight. (-)Nicotine produced a concentration-dependent increase
with a half-maximal concentration (EC50) of 11.3 nM (50,000 cells), 12.2 nM (75,000 cells)
and 12.0 nM (100,000 cells) giving an overall EC50 of 11.8 ± 0.4 nM with a Hillslope (nH) of
1.44 ± 0.4 (n = 3; Figure 5.1). Although the EC50 of (-)nicotine was similar at all 3 cell
densities, the maximum fluorescence was density-dependent. At a maximal concentration (1
pM) (-)nicotine produced 35.1 ± 0.6 (x 103) relative fluorescence units (r.f.u.) when plated at
a density of 50,000 cells per well, 53.8 ±1.1 (x 103) r.f.u. at 75,000 cells per well, and 75.0 ±
0.4 (x 103) r.f.u. at 100,000 cells per well (Figure 5.1). When cells were plated at 100,000
cells/well a consistent level of confluency was attained, whilst a further increase in cell
density resulted in irregular adherence of SH-EPl-ha4p2 cells, and a greater variation in
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signal. As such, all subsequent experiments were performed at a SH-EPl-ha,4P2 cell density
of 100,000 cells/well.
5.2.1.2 Effect of Additional External Calcium on the |Ca2+]j Response Size in SH-
EPl-hct4p2 Cells
It is well documented that nAChR function is modulated by the external Ca2+
concentration (Mulle et al., 1992; Vernino et al., 1992; Chavez-Noriega et al., 2000).
Indeed, a potentiation of agonist-induced responses is observed at low calcium
concentrations, with less enhancement observed at relatively high calcium concentrations
(Mulle et al., 1992; Chavez-Noriega et al., 2000). To determine if the (-)nicotine-induced
[Ca2+]j response in SH-EPl-ha4p2 cells was sensitive to changes in external Ca2+, increasing
concentration of calcium were included in the buffer prior to exposure to (-)nicotine (10 nM)
addition. The standard calcium assay kit buffer (MD, U.K.) already contains 1.4 mM Ca2+,
therefore the addition of 2.5 to 20 mM Ca2+ gave a final external Ca2+ assay concentration
that ranged from 1.4 to 21.4 mM. Even the addition of just 2.5 mM Ca2+ resulted in a
considerable increase in the (-)nicotine evoked [Ca2+]j response in SH-EPl-ha4p2 cells
(Figure 5.2). As such, in all subsequent experiments 2.5 mM Ca2+ was added to the assay
buffer giving a final Ca2+ concentration of 3.9 mM.
5.2.1.3 Pharmacological Characterisation of [Ca2+]i Responses in SH-EPl-houPi Cells
Prior to examining the effect of human Api_42 on [Ca2+]j responses in SH-EP1-
ha4p2 cells, the pharmacological profile of this receptor subtype was determined. To
determine the half-effective concentration (EC50) of agonists in the SH-EPl-ha4p2 cell line,
data was collected over a range of agonist concentrations (0.001 - 3 pM) fitted to the
maximal response and analysed with the empirical Hill equation. The rank order of potency
for the three nicotinic agonists studied was (±)epibatidine > (-) nicotine = cytisine, with
normalised data shown in Figure 5.3. The EC50 value determined for (+)epibatidine was
1.04 ±0.11 nM (nH = 1.63 ± 0.25; n = 3), while the EC50 for cytisine was 18.3 ± 7.73 nM; nH
= 0.83 ± 0.4; n =3) and (-)nicotine 22.8 ± 6.9 nM; nH = 1.43 ± 0.42; n = 3; Figure 5.3).
Having established and characterised a4p2 nAChR response to these nicotinic agonists,
antagonist pharmacology was assessed using (-)nicotine at a concentration of 10 nM, close to
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Effect of Cell Density on (-)Nicotine-Evoked [Ca2+]j Responses in SH-EPl-ha.,P2 Cells. Cells
were plated at (A) 50,000 (B) 75,000 or (C) 100,000 cells per well in a poly-D-lysine coated 96-well
plate and incubated overnight (37°C). Calcium assay buffer and fluorescence dye (MD, UK) were
added as detailed in methods. (-)Nicotine concentrations were applied using the robotic
microinjection system within the Flexstation fluorescence plate reader (MD, U.K.) and changes in
fluorescence analysed. Excitation and emission wavelengths were set to 485 nrn and 525 nm,
respectively, with these data (maximum response - minimum response) representive of a typical
experiment performed in triplicate. Affinity (EC50) was similar at all cell densities, however, maximal
fluorescence and confluency of cells was achieved at a cell density of 100,000 cells per well.
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Figure 5.2
Effect of Adding Additional External Ca2+ on the (-)Nicotine Evoked [Ca2+]j Response in SH-
EPl-ha4p2 Cells. Standard calcium assay kit buffer (MD, U.K.) contains 1.4 mM Ca2+, therefore the
final assay concentration ranged from 1.4 mM to 21.4 mM. Cells were loaded with a calcium-
sensitive dye as described in Materials and Methods. (-)Nicotine concentrations were applied using
the robotic microinjection system within the Flexstation® (MD, U.K.) and changes in [Ca2+]j analysed.
Excitation and emission wavelengths were set to 485 nm and 525 nm, respectively. These data
represent a typical experiment with each data point representing the mean value (maximum response -






Nicotinic Agonists Produce a Concentration-Dependent Increase in [Ca2+]| in SH-EPI-IHX4P2
Cells. The nAChR agonists (+)epibatidine (•), cytisine (■), and (-)nicotine (A) evoked a large
increase in [Ca2+]; in a concentration-dependent manner. Calcium assay buffer and fluorescence dye
(MD, UK) were added as detailed in methods. Agonist concentrations were applied using the robotic
microinjection system within the Flexstation fluorescence plate reader (MD, U.K.) and changes in
[Ca2+]i analysed. Excitation and emission wavelengths were set to 485 nm and 525 nm, respectively,
with these data (maximum response - minimum response) representive of a typical experiment
performed in triplicate. The rank order of potency for the three nicotinic ligands examined was
(±)epibatidine > (-)nicotine = cytisine.
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-induced [Ca2+]j response by the nicotinic antagonists MLA and J-tubocurarine in SFI-EP1-
ha4p2 cells. IC50 were 876 ± 66 nM (nH = 1.61 ± 0.33; n = 3) and 5,315 ± 367 pM (nH = 1.44
± 0.62; n = 4) for MLA and d-TC, respectively. Antagonists had no effect on [Ca2"]j
response on their own (data not shown).
5.2.1.4 The Effect of Human APi_42 on [Ca2+]j Responses in SH-EPl-ha4p2 Cells
The issue over which form of AP is neurotoxic in AD is not resolved (Selkoe,
1993; Tucker et al., 2002; Walsh et al., 2002a) and as previously discussed, APi.42 is
routinely dissolved in a range of vehicles to produce soluble and insoluble forms of the
peptide (Wang et al., 2000a; Wang et al., 2000b; Dineley et al., 2001; Liu et al., 2001; Pettit
et al., 2001; Tozaki et al., 2002; Dineley et al., 2002a; Wu et al., 2004). Therefore, the
ability of both soluble and insoluble human APi_42 to inhibit (-)nicotine-induced [Ca2+];
responses in SH-EPl-ha4p2 cells was examined. (-)Nicotine was again used at a
concentration of 10 nM, consistent with the antagonist studies above.
Human AP]_42 was dissolved in 100 mM HEPES (pH 8.0) and the effect that this
soluble form of APi_42 had on (-)nicotine, (±)epibatidine, and cytisine-evoked changes in
[Ca2+]i in SH-EPl-ha4p2 cells was examined (Figure 5.5). On average, Ap,.42 had no effect
on agonist-evoked changes in [Ca2+]: in the SH-EPl-ha4p2 cell line. When APi_42 (< 10 pM)
was dissolved in 5% acetic acid (Figure 5.6A), a 50/50 mixture of DMSO/Tris HC1 (Figure
5.6B), or reconstituted as the Rpeptide water soluble acetate salt (Figure 4.6C), no form of
soluble human AP]_42 inhibited the (-)nicotine-evoked changes in [Ca2+]; in the SH-EP-ha4p2
cell line. Although 10 pM AP]_42, in the 5% acetic acid and 50/50 DMSO/Tris HC1 vehicles
appeared to produce significant inhibition (5 % acetic acid) or potentiation (DMSO/Tris) of
(-)nicotine-evoked changes in [Ca2+]i response, respectively, this was clearly due to a vehicle
effect as seen in their respective control bars (Figure 5.6).
Having demonstrated that four different forms of soluble APi_42 had no effect on
agonist-evoked [Ca2+]j responses in SH-EPl-ha4p2 cells, the ability of aggregated (insoluble)
Api_42 alone or on (-)nicotine evoked [Ca2+]i response was assessed. Again, the addition of
concentrations of aggregated amyloid that ranged from 100 pM to 10 pM, insoluble APi_42





Nicotinic Antagonists Produce a Concentration-Dependent Decrease in the (-)Nicotine-Evoked
[Ca2+], Response in SH-EPl-ha4p2 Cells. (A) MLA and (B) <7-tubocurarine were incubated (10 min,
22°C) with calcium assay dye and SH-EPl-ha4p2 cells. (-)Nicotine concentrations were applied using
the robotic microinjection system within the Flexstation® and changes in [Ca2+]i analysed. Excitation
and emission wavelengths were set to 485 nm and 525 nm, respectively. Data represent a typical
experiment with each data point representing the mean value of three individual wells. The nAChR
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[HEPES Ap,_42] (nM)
Human A|}i_42 Dissolved in HEPES Did Not Alter (-)Nicotine-Evoked [Ca2+]j Responses in SH-
EPl-ha4p2 Cells. Human A(3M2 was dissolved in HEPES buffer (pH 8.0) was preincubated for 10
rnin with SH-EPl-ha4(32 cells and calcium-sensitive dye. (A) 10 nM (-)nicotine, (B) 0.5 nM
(±)epibatidine, (C) 5 nM cytisine was applied using the robotic microinjection system within the
Flexstation® and changes in [Ca2+]j analysed. Excitation and emission wavelengths were set to 485
nm and 525 nm, respectively. These data represent a typical experiment with each data point
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Soluble Human Ap^ Does Not Alter (-)Nicotine-Evoked [Ca2+]j Respones in SH-EPl-ha4p2
Cells. Human APi_42 was dissolved in (A) 5 % acetic acid, (B) 50/50 DMSO/Tris HCI mixture, and
(C) MQ H20 and preincubated for 10 min with SH-EPl-ha4p2 cells and the calcium-sensitive dye. (-
)Nicotine (10 nM) was applied using the robotic microinjection system within the Flexstation® and
changes in [Ca2+]i analysed. Excitation and emission wavelengths were set to 485 nm and 525 nm,
respectively. These data represent a typical experiment with each data point representing the mean
value of three individual wells.
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Figure 5.7
0.1 1 10 100 1,000 10,000 Ctrl
[Aggregated Ap l_42] (nM)
Preaggregated Human ApM2 Docs Not Alter the (-)Nicotine-Evoked [Ca2+]j Responses in SH-
EPl-ha4p2 Cells. Human APi.42 (preaggregated for 48 h) was preincubated for 10 min with SH-EP1-
ha4p2 cells and the calcium-sensitive dye. (-)Nicotine (10 nM) was applied using the robotic
microinjection system within the Flexstation® and changes in [Ca2+]j analysed. Excitation and
emission wavelengths were set to 485 nm and 525 nm, respectively. These data represent a typical
experiment with each data point representing the mean value of three individual wells. Control (Ctrl)
data represent calcium assay buffer and dye only.
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5.2.2 Establishment of a Membrane Potential Fluorescence Assay for the
Characterisation of a4p2 nAChR Pharmacology and its Interaction with
Human APi_42
Membrane potential assays allow an indirect but relatively rapid and sensitive
assessment of ionic flow through ion channels. Ion flow through the channel causes a
change in membrane potential which in turn can be detected by a fluorescent dye (Baxter et
a/., 2002). As with the [Ca2+]j assay, the membrane potential assay facilitates a functional
examination of the effects of agonists and antagonists at ion channels such as the a4p2
nAChR (Baxter et al., 2002). In a recent publication, Fitch and colleagues (2003) showed
that the membrane potential assay was more sensitive than the calcium assay in detecting
changes in ion flux through rat and human a4p2 nAChRs. Therefore, the membrane potential
assay may be more likely to detect changes in ion flux through nAChRs and perhaps identify
a more subtle interaction between nAChRs and ApM2.
5.2.2.1 Effect of Cell Density on (-)Nicotine-Evoked Alterations in Membrane
Potential in SH-EPl-ha4p2 Cells
To determine the optimal cell density to conduct pharmacological studies, SH-
EPl-ha4p2 cells were plated at increasing numbers (25,000 to 125,000 cells/well) and
incubated (37°C) overnight prior to use in the assay the following day. SH-EPl-ha4p2 cells
were incubated with the membrane potential dye (Molecular Devices (MD), U.K.) for 30
min at 22°C, prior to challenge with 10 nM (-)nicotine. (-)Nicotine (10 nM) induced a
density dependent increase in fluorescence in SH-EPl-ha4p2 cells, although there was little
difference in response size above 50,000 cells/well (Figure 5.8). As described for the [Ca2+]j
assay, when the cells were plated at 100,000 cells/well, there was almost full confluency,
therefore and this cell density was used in all subsequent experiments.
5.2.2.2 Effect of Additional Ca2+ on (-)Nicotine-Evoked Changes in Membrane
Potential in SH-EPl-ha4p2 Cells
For compatability with the [Ca2+]i assay, the sensitivity of the (-)nicotine-evoked
change in membrane potential to an alteration in external Ca2+ was examined in SH-EP1-
ha4p2 cells. The concentration dependence of the (-)nicotine-evoked change in membrane
potential was measured in the presence and absence of an additional 2.5 mM Ca2~ in the
external solution. In contrast to the [Ca2+]i assay, the presence of the additional Ca2+
decreased the maximal response of SH-EPl-ha4p2 cells across the whole (-)nicotine dose-
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Figure 5.8
SH-EPI-ha4p2 Cells/Well (x 103)
Effect on Cell Density on the (-)Nicotine-Evoked Change in Membrane Potential in SH-EP1-
ha4p2 Cells. Cells were plated at increasing densities ranging from 25,000 to 125,000 cells/well in a
poly-D-lysine coated 96-well plate and incubated overnight (37°C). Following removal of media, a
membrane potential sensitive fluorescence dye (MD, U.K..) was added and the cells equilibrated
(22°C) for 30 min. (-)Nicotine (10 nM) was applied using the robotic microinjection system within
the Flexstation and changes in membrane potential measured as a change in fluorescence. Excitation
and emission wavelengths were set to 535 nm and 560 nm, respectively, with these data representing a
typical experiment performed in triplicate. Relative fluorescence units were calculated by subtracting
minimum from the maximum response. There was little difference in responses at cell densities above
50,000 cell/well, therefore, as almost full confluency was achieved at 100,000 cells/well, a cell density
of 100,000 cells/well was used for all subsequent studies.
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response curve (Figure 5.9, grey bars indicate where Ca2+ added). Therefore, all subsequent
membrane potential experiments were performed in the standard MD assay kit buffer with
no additional calcium.
5.2.2.3 Pharmacological Characterisation of Nicotinic Agonists and Antagonists on
Membrane Potential Responses in SH-EPl-ha4p2 Cells
Prior to examining the effect of human Api_42 on (-)nicotine induced changes in
membrane potential in SH-EPl-ha4p2 cells, the pharmacological profile of this nAChR was
characterised. To determine the half-effective concentration (EC5o) of all the agonists in the
SH-EPl-ha4p2 cell line, data was collected over a range of drug concentrations (1 pM - 10
pM), normalised to the maximal drug concentration and fitted with the empirical Hill
equation. The rank order of potency for the nicotinic agonist ligands examined was
(±)epibatidine > cytisine > nicotine=DMPP with representative data shown in Figure 5.10.
The EC50 for (-)nicotine was 19.5 ± 6.5 nM with a Hill coefficient of 1.94 ± 0.04 (« = 4;
Figure 5.1OA). The half-maximal concentrations for the other compounds examined ranged
from 0.56 ± 0.11 nM (nH = 1.23 ± 0.01, n = 3) for (±)epibatidine to 96.9 ± 12.6 nM (nH =
0.95 ± 0.13, n = 3) for DMPP (Figure 5.1 OA). Although cytisine gave an EC50 value of 3.09
± 0.83 pM (n = 3), initial studies indicated the Hillslope was less than 1 for cytisine in the
SH-EPl-ha4p2 cells. Therefore, the number of cytisine concentrations examined was
increased to twenty to try and ascertain whether the cytisine-evoked membrane potential
response in human a4p2 nAChRs had more than one component. Using the F-test, cytisine
data was better fit with a two-site model rather than a one-site model (Figure 5.10B; p <
0.05). EC50 vlaues for the high and low affinity sites were 1.03 pM and 3.18 nM,
respectively. This is in agreement with previously published data indicating cytisine is a
partial agonist at a4p2 nAChRs (Papke & Heinemann, 1994).
In addition, to examine the antagonists I attempted to determine pKB values for the
nicotinic antagonists MLA and d-TC at the human a4p2 nAChR expressed in SH-EP1 cells.
A full (-)nicotine concentration-response curve was perfonned in the presence and absence
of 3 different antagonist concentrations (30, 100, and 300 nM; Figures 5.11). MLA caused a
parallel shift to the right of the (-)nicotine concentration-response curve with no change in
maximal response size. The (-)nicotine EC50 moved from 11.4 nM (no MLA) to 34.0 nM in
the presence of 300 nM MLA. A subsequent Schild analysis generated a slope of -1.40, with
the pKB (pA2) estimated to be 6.38 (Figure 5.11, inset).
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Figure 5.9
Effect of an Additional 2.5 mM External Ca2+ on the (-)Nicotine-Evoked Change in Membrane
Potential in SH-EPl-hiXiPj Cells. Standard membrane potential buffer contains 1.26 mM Ca2+,
therefore, the final assay concentration of Ca2+ was 3.76 mM. Following removal of the media,
membrane potential sensitive fluorescence dye (MD, U.K.) was added to the cells and left for for 30
min at 22°C. (-)Nicotine concentrations were applied using the robotic microinjection system within
the Flexstation® and changes in membrane potential measured as a change in fluorescence. Excitation
and emission wavelengths were set to 535 nm and 560 nm, respectively, with these data representing a
typical experiment performed in triplicate. Relative fluorescence units were calculated by subtracting
minimum from the maximum response. The addition of an extra 2.5 mM external Ca2+ inhibited the (-





















Nicotinic Agonists Produce a Concentration-Dependent Alteration in Membrane Potential in
SH-EPl-ha4p2 Cells. The nAChR agonists (A) (±)epibatidine (■), DMPP (•), and (-)nicotine (♦)
and (B) cytisine evoked large concentration-dependent increases in fluorescence. Drugs were applied
using the robotic microinjection system within the Flexstation® and alterations in membrane potential
measured as a change in fluorescence. Excitation and emission wavelengths were set to 535 nm and
560 nm, respectively, with these data representing a typical experiment performed in triplicate.
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MLA Inhibited the (-)Nicotine-Evoked Changes in Membrane Potential in SH-EPl-ha4p2 Cells
in a Competitive Manner. (-)Nicotine concentration-response curves were generated in the absence
(•) and presence of 30 nM (•), 100 nM (■) and 300 nM (A) MLA. MLA was preincubated for 10
min prior to the addition of (-)nicotine which were applied using the robotic microinjection system
within the Flexstation®. Changes in membrane potential were measured as changes in fluorescence
with excitation and emission wavelengths set to 535 nm and 560 nm, respectively. These data
representing a typical experiment performed in triplicate with relative fluorescence units calculated by
subtracting the minimum from the maximum response. MLA caused a parallel shift to the right of the
(-)nicotine concentration-response curve with no change in maximal response size. Inset: Schild
analysis of MLA inhibition of (-)nicotine evoked changes in membrane potential in SH-EPI-ha+jL
cells with the pAi calculated as 415 nM.
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In contrast, solubility issues surrounding high concentrations of d-TC (~ICso > 500
pM in membrane potential assay), meant the highest d-TC concentration that could be
examined was 100 pM. At this concentration, d-TC (100 pM) caused a small parallel shift
to the right in the (-)nicotine dose-response curve with a subsequent shift in the EC50 of (-
)nicotine from 27.1 nM to 56.3 nM with no reduction in maximal response (Figure 5.12).
Unfortunately, the inability to examine higher concentrations of d-TC meant a pKB value
could not be calculated using a Schild plot but can be roughly estimated as a" 4.04.
5.2.2.4 Human APi_42 Had No Effect on the (-)Nicotine Evoked Change in Membrane
Potential in SH-EPl-ha4p2 Cells
The ability of soluble and insoluble human APi_42 to modulate membrane potential
responses in SH-EP1 cells expressing the human a4p2 nAChRs was assessed. (-)Nicotine
was used at a concentration of 10 nM, close to its EC50 value and therefore, sufficient to
observe both inhibition or potentiation by Apu42.
To generate soluble APi_42, the peptide was dissolved in 5 % acetic acid, 50/50
DMSO/Tris HC1 (pH 8.0), and MQ H20 (Rpeptide acetate salt). In agreement with the
calcium studies, at concentrations up to 10 pM, none of the soluble amyloid preparations had
any effect alone (not shown) or on the (-)nicotine evoked change in membrane potential
(Figure 5.13). Although it would appear that 10 pM Apj_42 caused a reduction in membrane
potential (Figure 5.13), the equivalent vehicle control produced a similar reduction in
response (Figure 5.14). This is consistent with the findings from the calcium assay.
Furthermore, studies evaluating the effect of aggregated (insoluble) human APi_42 did
nothing alone, nor did it inhibit the (-)nicotine evoked change in membrane potential in SH-
EPl-ha4p2 cells (Figure 5.15).
5.2.3 Establishment of Calcium Flux and Membrane Potential Assays in the SH-
EPl-ha7 Cell Line
Maintenance of high level, stable expression of human a7 nAChRs is known to be
challenging and appears highly dependent on the cell line used (Cooper & Millar, 1997).
The SH-EPl-ha7 cell line used in these studies is no different with many cells not expressing
functional a7 nAChRs at the cell surface. However, I attempted to established [Ca2]; and
membranes potential assays in the SH-EPl-ha7 cell line using the same approach that was
successful for the SH-EPl-ha4p2 cell line.
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Figure 5.12
High Concentrations of the Nicotinic Antagonist d-TC Inhibited the (-)Nicotine-Evoked
Changes in Membrane Potential in SH-EPl-ha4p2 Cells. (-)Nicotine concentration-response
curves were generated in the absence (•) and presence of 10 pM (■), 30 pM (A) and 100 pM (•)
d-TC. The antagonist was preincubated for 10 min prior to the addition of (-)nicotine with the agonist
(10 nM) applied using the robotic microinjection system within the Flexstation \ Changes in
membrane potential were measured as changes in fluorescence with excitation and emission
wavelengths set to 535 nm and 560 nm, respectively. These data representing a typical experiment
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Soluble Human APi_42 Does Not Alter the (-)Nicotine Evoked Change in Membrane Potential in
SH-EPl-ha.4p2 Cells. Human Ap,.42 dissolved in (A) 5 % acetic acid, (B) 50/50 DMSO/Tris HC1 (pH
8.0), or MQ H20 was preincubated for 10 min with SH-EPl-ha4p2 cells and the membrane potential
sensitive dye (MD, U.K.). (-)Nicotine (10 nM) was applied using the robotic microinjection system
within the Flexstation® and changes in membrane potential measured as alterations in fluorescence.
Excitation and emission wavelengths were set to 535 nm and 560 nm, respectively with these data
representing a typical experiment performed in triplicate. Relative fluorescence units were calculated
by subtracting minimum from the maximum response.
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Figure 5.14
5% AA DMSO/Tris Agg
AP1-42 Vehicles Inhibit the (-)Nicotine Evoked Change in Membrane Potential in SH-EPl-ha4p2
Cells. Human Api_42 vehicles 5 % acetic acid (5% AA), 50/50 DMSO/Tris HC1 (pH 8.0)
(DMSO/Tris), and aggregated (Agg) were preincubated for 10 min with SH-EPl-ha4p2 nAChRs and
membrane potential sensitive dye (MD, U.K.). (-)Nicotine (10 nM) was applied using the robotic
microinjection system within the Flexstation'8 and changes in membrane potential were measured as
changes in fluorescence. Excitation and emission wavelengths were set to 535 nm and 560 nm,
respectively with these data representing a typical experiment performed in triplicate. Relative
fluorescence units were calculated by subtracting minimum from the maximum response. Vehicles
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Insoluble Human Ap)J(2 Does Not Alter the (-)Nicotinc Evoked Change in Membrane Potential
in SH-EPl-ha4P2 Cells. Human Ap^ was preaggregated for 48 h then preincubated for 10 min with
SH-EPl-ha4p2 cells and the membrane potential sensitive dye (MD, U.K.). (-)Nicotine (10 nM) was
applied using the robotic microinjection system within the Flexstation®' and changes in membrane
potential measured as changes in fluorescence. Excitation and emission wavelengths were set to 535
nnr and 560 nra, respectively with these data representing a typical experiment performed in triplicate.
Relative fluorescence units were calculated by subtracting minimum from the maximum response.
184
5.2.3.1 (-)Nicotine-Evoked [Ca2+]i Responses Were Absent in SH-EPl-hot7 Cells
To determine whether exposure to (-)nicotine could elict a [Ca2+]j response in SH-
EPl-ha7 cells, a plating density of 100,000 cells/well was used and the cells incubated
(37°C) overnight. This was shown to be the optimal density for SH-EPl-ha4p2 cells in the
previous section, giving full confluency and large fluorescence responses. (-)Nicotine (0.03
- 30 pM) failed to evoke any change in [Ca2+]j in the SH-EPl-ha7 cell line (Figure 5.16A).
In an attempt to maintain surface expression of the human a7 nAChR and therefore increase
responses, cells were grown in the presence ofMLA (concentration as described by Molinari
and colleagues (1998). However, using this treatment, (-)nicotine again failed to evoke a
change in [Ca2+]j response in these cells (Figure 5.16B). In the same set of studies and in
contrast to the lack of effect of human a7 nAChRs, (-)nicotine evoked a large increase in the
[Ca2+]j response in SH-EPl-ha4p2 cells (Figure 5.16C). No change in (-)nicotine evoked
[Ca2+]i response was observed in SH-EPl-host cells (Figure 5.16D).
5.2.3.2 (-)Nicotine Did Not Induce a Change in Membrane Potential in SH-EPl-ha7
Cells
Fitch and colleagues (2003) showed that membrane potential assays were
potentially more sensitive than calcium assays in detecting changes in ion flux through
nAChRs. As such, the membrane potential assay may be more likely to detect smaller
changes in ion flux through nAChRs, even though no change in [Ca2], was detected.
The ability of (-)nicotine to evoke a change in membrane potential was assessed in
SH-EPl-ha7 cells across a variety of cell densities (Figure 5.17). Although (-)nicotine (50
nM)was examined at a concentration just above the predicted IC50 of (-)nicotine at a7
nAChRs, the ligand failed to evoke a change in membrane potential in SH-EPl-ha7 cells
(Figure 5.17). Indeed, the small responses observed were no different from those observed
in SH-EPl-host cells.
The absence of any obvious (-)nicotine-induced change in [Ca2+]j or membrane
potential meant no subsequent gross plate-based fluorescent experiments were performed
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Lack of (-)Nicotine-Evoked Changes in Membrane Potential in SH-EPl-ha7 Cells. SH-EPl-ha7
cells were plated at increasing concentrations from 25,000 to 125,000 cells/well in a poly-D-lysine
coated 96-well plate were incubated overnight at 37°C. Following removal of media, membrane
potential sensitive fluorescence dye (Molecular Devices Ltd, UK) was added and the cells equilibrated
for 30 min at 22°C. (-)Nicotine (50 nM) was applied using the robotic microinjection system within
the Flexstation fluorescence plate reader (Molecular Devices) and changes in membrane potential
measured as changes in fluorescence, analysed in a Flexstation fluorescence plate reader. (Molecular
Devices, UK) with excitation and emission wavelengths set to 535 ran and 560 nm, respectively. Data
represent a typical experiment performed in triplicate with relative fluorescence units representing
maximum response - minimum response.
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5.3 Examination of Human a4p2 nAChR Electrophysiology
5.3.1 Nicotine-Induced Currents in a4p2 nAChR expressing SH-EP1 Cells
Whole cell current recording was used to characterise the pharmacology and re¬
confirm functional expression of a4p2 nAChR in the SH-EP1 stable cell line. Experiments
were performed using conventional whole cell recording in the voltage clamp mode at a VH
= -60 mV. Using potassium (K+) containing electrodes, repeated application of (-)nicotine
for 375 ms at intervals of 1 min induced an inward current (INic, Figure 5.18A). The (-
)nicotine concentration applied (10 pM) was below the predicted EC50 value for (-)nicotine
in SH-EPl-ha4p2 cells and was used in order to try and minimise receptor desensitisation.
The peak INjc showed "functional rundown", defined as a "loss of peak current amplitude
with each repeated application of agonist, with time" (Zhao et al., 2003; Figure 5.18A).
Zhao and colleagues (2003) recently demonstrated that the substitution of Tris
base and Tris diphosphate dibasic for KC1 in the recording pipette, produced a K+-free
pipette solution (while maintaining comparable concentrations of free Ca2+ and ATP), that
eliminated functional rundown of IN;C in SH-EPl-ha7 cells over a 12-15 min time interval.
Following the introduction of a K+-free internal solution to our whole cell recordings from
SH-EPl-ha4p2 cells, functional rundown was still observed when (-)nicotine was applied
every minute (Figure 5.18B). However, in agreement with Zhao and colleagues (2003), the
decay time constant (x) for acute desensitisation increased from 181 ms (n = 2) in the K+
containing electrode solution, to 322 ± 58 ms (n =3) when responses were recorded in a K+-
free solution. Increasing the (-)nicotine application interval to 3 min slowed but did not
abolish functional rundown (Figure 5.18B).
To allow direct comparison with the results published on the SH-EPl-ha4p2 cell
line by the Lukas laboratory, all subsequent experiments were performed with (-)nicotine
applied at 3 min intervals using identical K+-free internal and external solutions to those used
by Lukas' laboratories (Zhao et al., 2003; Wu et al., 2004).
5.3.2 Characterisation of the Pharmacological Properties of the Human a4p2
nAChR Using Whole Cell Patch Clamp Studies
A number of recent papers have reported a functional interaction between nAChRs
and P-amyloidi_42 (APi_42), the putatively toxic form of amyloid in Alzheimer's Disease
aetiology (Wang et al., 2000a; Wang et al., 2000b; Dineley et al., 2001; Liu et al., 2001;
Pettit et al., 2001; Tozaki et al., 2002; Dineley el al., 2002a; Grassi et al., 2003; Wu et al.,
























(-)Nicotine-Evoked Current Rundown in Human a4p2 nAChRs Stably Expressed in SH-EP1
Cells. Whole-cell current recording of human (X4P2 nAChR responses was measured as described in
the Materials and Methods using K+-containing electrodes and K+-free electrodes at a VH = -60 mV.
Cells were exposed to 10 pM (-)nicotine for 375 ms at 1 min (•) and 3 min (■) intervals. (A)
Recordings were made from 2 cells using K+-containing electrodes with the data points representing
the mean response. (B) Recordings were made from 3 cells using K+-free electrodes with the data
points representing the mean current only for reasons of visual clarity.
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pharmacological profile of this receptor was characterised using whole-cell voltage-clamp
recordings (VH = -60 mV) of SH-EPl-hcc4p2 cells.
Although nominally a stable cell line, peak current amplitude varied greatly
between individual cells and ranged from a few picoamperes to > 1 nA, at a (-)nicotine
concentration of 10 pM. Despite a maximal current of 3 nA being recorded, the mean
current amplitude generated following application of 10 pM (-)nicotine was 724 ± 182 pA at
a holding potential of -60 mV (n = 7). Cells were discarded if the initial response was below
100 pA.
In determining the half-effective concentration (EC50) of (-)nicotine in the SH-
EPl-ha4p2 cells, data collected over a range of (-)nicotine concentrations (0.3 - 300 pM),
was normalised to the maximal agonist response, prior to fitting with the empirical Hill
equation. The EC50 for (-)nicotine in the SH-EPl-ha4p2 cell line was 22.2 ± 2.2 pM (« = 3)
with a Hill coefficient of 1.99 ± 0.55 (n = 3; Figure 5.19A).
To examine inhibition of the human a4p2 nAChR, identical (-)nicotine
concentration response-curves were conducted in the presence and absence of the nicotinic
antagonist 10 pM d-tubocurarine (d-TC) with representative traces generated in individual
SH-EPl-ha4p2 cells shown in Figure 5.19 (A & B). In agreement with other published
studies (Harvey & Luetje, 1996; Palma et al, 1996), d-TC inhibited (-)nicotine evoked
currents (IN,C) at human a4p2 nAChRs, producing a rightward shift in the concentration-
response curve (Figure 5.19C). The EC50 value obtained for nicotine in the presence of 10
pM d-TC for nicotine was slightly (but not significantly) higher at 31.4 ± 7.8 pM with a
Hillslope of 2.27 ± 0.07 (n =3; Figure 5.19C).
Electrophysiological and pharmacological properties presented indicates that the
heterologously expressed ha4p2 nAChRs in the SH-EP1 cell line exhibited features
characteristic of this receptor subtype, validating the use of this stable cell line as an













(-)Nicotine Evoked-Currents in SH-EPI-IKX4P2 Cells and its Inhibition by the Nicotinic
Antagonist (/-Tubocurarine. Representative traces of a single cell in response to (-)nicotine (A)
alone or (B) in the presence of 10 uM d-TC. (C) The concentration-response relationship of (-
)nicotine with normalised peak current amplitude (ordinate; percentage of response in same cell to 300
pM (-)nicotine as a function of dose (abscissa in molar untils, log scale) of (-)nicotine in the absence
(EC50 = 22.2 ± 2.2, nH = 1.99 ± 0.54; n = 3) or presence (EC50 = 31.4 + 7.8, n„ = 2.27 ± 0.07; n =3) of
10 pM d-TC.
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5.3.3 Examination of the Effect of Human APi_42 on (-)Nicotine Evoked Currents in
SH-EPf-ha4p2 cells
Prior to examining the effect of human APi_42 on INic, initial control studies
examined the effect of switching between two separate reservoirs of drug-free bath solution
using similar conditions to that described in the previous section with a VH of -60 mV and
cells stimulated with 10 pM (-)nicotine for 375ms at 3 min intervals (total assay time was 66
mins). In brief, immediately following the third (-)nicotine stimulus, the flow from the
reservoir was switched to a continuous supply from another reservoir containing either the
compound of interest or drug-free bath solution and the cell stimulated a further 10 times
with (-)nicotine (10 pM) every 3 min. Directly after the 10th (-)nicotine (10 pM) stimulus
the perfusion tube was switched back to the original bath solution and the cell stimulated a
further 10 times with the same concentration of (-)nicotine. The entire protocol took 66
minutes.
Figure 5.20A shows a representative trace of INic generated in a single SH-EP1-
ha4p2 cell exposed to (-)nicotine (10 pM) with a non significant change in peak amplitude
observed after the switch to bath solution. Likewise, (-)nicotine-evoked responses generated
after the switch back to the original bath solution source, also showed a non-significant
decrease in peak amplitude (Figure 5.20B). The normalised peak current average from 3
individual SFI-EPl-ha4p2 cells was used as the control measure against which responses in
the presence of bath solution or drug were compared. Average INjc response traces obtained
during and after reservoir changes in bath solution are shown in Figure 5.20C.
To determine whether this decrease in INic was an artefact of switching reservoirs
or a consequence of the rundown described earlier, a direct assessment of the "switchover"
effect was performed. Following a single application of (-)nicotine (10 pM), the reservoir
either remained the same (no switch) or was switched to another reservoir containing drug-
free bath solution (Figure 5.21). Clear functional rundown was observed over the 15 minute
experimental interval regardless of whether reservoirs were changed during the experiment.
While conducting our studies investigating the interaction of APi.42 and
nAChRs, a number of other groups were publishing similar investigation, although the APi_42
used was from a range of species, suppliers, and vehicles (Wang et al., 2000a; Wang et al.,
2000b; Dineley et al., 2001; Liu et al., 2001; Pettit et al., 2001; Dineley et al., 2002; Tozaki
et al., 2002; Grassi et al., 2003; Wu et al., 2004). For example, Liu and colleagues (2001)
used Api_42 dissolved in 5 % acetic acid whereas Wang and colleagues (2000a,b, personal















Rundown of (-)Nicotine Induced Currents in SH-EPl-ha4p2 Cells. (A) Application of bath
solution from a fresh source induced a significant change in whole cell current induced by (-)nicotine
(10 |iM). (B) Further characterisation of the washout of (-)nicotine induced currents in the SH-EP1-
ha4p2 cell line. (C) Representative overlays of the 3 main currents; control (•), bath solution from
fresh source (•) and rundown (•). Traces are from a representative cell.
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Figure 5.21
Switchover Does Not Effect Rundown of (-)Nicotine Induced Currents in SH-EPl-ha4p2 Cells.
(-)Nicotine (10 pM) was applied every 3 min for 375 ms. Reservoirs supplying bath solution were
switched (•) or not switched (■) immediately following the first and third applications. Clear
functional rundown of ~30 % was observed over the 15 minute experimental interval (regardless of
whether reservoirs were changed during the experiment.
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In the next four sections (5.3.3.1 - 5.3.3.4), I will discuss the effect of human
A[31_42 resuspended in HEPES buffer, 5 % acetic acid, DMSO/Tris, and finally in water as a
water soluble acetate salt (Rpeptide APi.42).
5.3.3.1 Effect of Soluble Human APi.42 (Resuspended in 100 mM Hepes Buffer) on
(-)Nicotine-Evoked Currents in SH-EPl-ha4p2 Cells
The acute effects of human ApM2 on (-)nicotine-evoked current responses in SFI-
EP1 cells expressing the human a4p2 cells were examined. To avoid peptide aggregation
and maintain solubility, human APi_42 was resuspended in 100 mM HEPES buffer (pH 7.4)
before serial dilution in bath solution. In brief, each cell has its own internal control with
responses pre- and post-Ap^? treatment allowing for measurement of rundown. Figure
5.22, trace 1 shows the comparison between control response and the average response to 10
pM (-)nicotine in the presence of APi.42, while trace 2 compares the average response in the
presence of 100 nM Api_42 to the average response following drug washout. Finally Figure
5.22, trace three illustrates the rundown present in the cell. To control for any potential
vehicle effect, the HEPES buffer was also diluted in bath solution to the equivalent
concentration used for the 100 nM Api_42 solution.
Initial studies indicated that 100 nM human APi_42 significantly inhibited INic after
6 minutes of constant perfusion (Figure 5.22A). However, following a 10 min washout
period, the current amplitude in response to (-)nicotine was not restored (Figures 5.22C).
Somewhat surprisingly, the HEPES buffer control solution produced an inhibition of INic in
SH-EPl-ha4p2 cells equivalent to that of human Ap^ (Figures 5.22 - 5.24). Therefore,
these studies indicate the inhibition of IN;C by soluble Apt_42 (100 nM) in SH-EPl-ha4p2 cells
was in fact be due to a vehicle effect with this clearly illustrated in Figure 5.24.
Distinguishing a genuine drug inhibition response from functional rundown was
therefore clearly problematic when cells were sustained for such long periods of time (i.e. up
to 66 min). A shorter protocol (15 min) was therefore tried as the rundown during this
period is considerably less marked. Cells were stimulated once with (-)nicotine (10 pM)
before an immediate switch to human APi_42, vehicle, or bath solution for 6 min (2 further (-
















Effect of Soluble Human Ap^ (100 nM) Resuspended in HEPES (100 mM) on (-)Nicotine
Evoked Currents in SH-EPl-ha4p2 Cells. (A) Application of Ap[.42 produced a significant
reduction in the whole cell current induced by (-)nicotine (10 pM) (B) Further characterisation of the
current rundown by (-)nicotine application in the SH-EPl-ha4p2 cell line in the absence of Ap^2. (C)
Representative overlays of the 3 main currents; control (•), human Ap^i solubilised in HEPES (•)















Effect of the Api_42 HEPES Vehicle on (-)Nicotine Evoked Currents in SH-EPl-ha4p2 Cells. (A)
Application of HEPES (at a concentration used to dissolve 100 nM Ap.42) induced a significant
inhibition in the whole cell current induced by (-)nicotine (10 pM) equivalent to that induced by the
100 nM APi_42 solution (B) Further characterisation of the rundown of (-)nicotine induced currents in
the SH-EPl-ha4p2 cell line. (C) Representative overlays of the 3 main currents; control (•), HEPES





Summary of the Effect of Soluble P-Amyloid^ (100 nM) Resuspended in HEPES on (-)Nicotine
Evoked Currents in SH-EPl-ha4p2 Cells. Whole-cell recording of (-)nicotine-evoked currents in
SH-EPl-h a4p2 nAChR cells were measured as described in Materials and Methods, (-)nicotine (10
pM) was applied for 375 ms at 3 min intervals. Following the 3rd application of (-)nicotine, the cell
was constantly perfused for 30 min with (•) bath solution, (•) 100 nM Ap,.42 originally resuspended
in 100 mM Hepes buffer (pH 7.4), or (■) Hepes vehicle control, followed by a washout for a further
30 min. Peak amplitudes were normalised to the initial individual cell response to 10 pM Nic and
averaged recordings were made from 3 cells with the data points representing mean ± S.E.M. *
indicates significant inhibition of (-)nicotine evoked responses in SH-EPl-ha4p2 cells by human Api_
42 and vehicle (p < 0.05).
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returned to a drug-free bath solution. Consequently, this protocol allows for a 6 min
constant drug/vehicle perfusion before the 4th application of (-)nicotine and a 3 and 6 min
washout period before the 5th and 6th applications, respectively. Figure 5.25A illustrates the
15 min time-frame utilised in the following experiments and panel B-D explain how the data
is assessed using this protocol.
As with the longer protocol control experiments were performed using two sources
of the same bath solution to facilitate continual perfusion of the cell. Figure 5.26 shows that
even using the shorter 15 min protocol, functional rundown of approximately 25% was
observed across this time period (Figure 5.26). These responses represent the control data
against which all further Api_42, antagonist or vehicle responses will be compared.
To demonstrate that INjc in human a4p2 cells can be antagonised, the effect of the
antagonist d-TC was examined. At a concentration of 10 pM, J-tubocurarine significantly
inhibited the (-)nicotine-evoked response in SFI-EPl-ha4p2 cells by approximately 30 %,
consistent with its dose response curve shown earlier (Figures 5.19 & 5.27).
To determine whether the shorter protocol could identify an effect with P-
amyloid|_42, the peptide (300 nM) was prepared in HEPES buffer (100 mM, pH 7.4) and
serially diluted in bath solution. Representative traces of the effect of 300 nM Ap,_42 and the
HEPES buffer vehicle control are shown in Figures 4.28 and 4.29, respectively. Figure 5.28
clearly shows that, following repeated applications of (-)nicotine, internal cell rundown was
greater than the response generated by either the vehicle or Api_42 in vehicle. Therefore, 300
nM APi,42 had no inhibitory effect on the (-)nicotine induced current in SH-EPl-ha4p2 cells
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Response of Human (X4P2 nAChRs to (-)Nicotine While Under Constant Perfusion with Bath
Solution. Whole-cell recording from the human a4p2 nAChR cell line were measured as described in
Materials and Methods with (-)nicotine (10 pM) applied for 375 ms every 3 min. (A) Representative
trace of human a4p2 nAChR responses to 10 pM (-)nicotine in a single cell. (B) Representative
overlaid trace of the same cell shows clear functional rundown over the time course of the experiment.
(C) Peak currents were normalised to the peak response produced by the first application of 10 pM (-
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0.5 s
A Short Application of rf-Tubocurarine Inhibited (-)Nicotine Evoked Currents in SH-EPl-ha4p2
Cells. (-)Nicotine (10 pM) was applied for 375 ms at 3 min intervals. Immediately following the first
application of (-)nicotine, bath perfusion reservoir was switched to one supplying 10 pM d-TC.
Following 2 further applications of (-)nicotine (total d-TC application time was 6 min), the d-TC
perfusion reservoir was switched back to one containing bath solution and a further 3 applications of
(-)nicotine were applied (A) Representative trace of human oc4p2 nAChR responses to (-)nicotine (10
pM) in the presence and absence of 10 pM d-TC in a single cell (B) Peak currents were normalised
to the peak response produced by the first application of 10 pM (-)nicotine with recordings collected










Effect of Soluble Human APi^2 (300 nM) Resuspended in HEPES (100 mM) on (-)Nicotine
Evoked Currents in SH-EPl-ha4p2 Cells. (A) Application of human APi.42 produced a significant
reduction in the whole cell current induced by (-)nicotine (10 pM) (B) Further characterisation of the
current rundown by (-)nicotine application in the SH-EPl-ha4p2 cell line. (C) Representative
overlays of the 3 main currents; control (•), human Ap1_42 solubilised in HEPES (•) and rundown
(•) showing a significant difference between the 3 groups. Traces are from a representative cell.
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Figure 5.29









300 nM Hepes Vehicle
VVY
0.5 s
Effect of Ap]_42 (300 nM) HEPES Vehicle on (-)Nicotine Evoked Currents in SH-EPl-ha.4P2
Cells. Application of HEPES (at a concentration used to dissolve 300 nM Ap_42) induced a significant
inhibition in the whole cell current induced by (-)nicotine (10 pM) equivalent to that induced by the
100 nM APi_42 solution (B) Further characterisation of the rundown of (-)nicotine induced currents in
the SH-EPl-ha4p2 cell line. (C) Representative overlays of the 3 main currents; control (•), HEPES





Lack of Inhibition of INic in SH-EPl-ha4p2 Cells by Soluble Human Ap,_42 (300 nM) Prepared in
HEPES Vehicle. (-)Nicotine (10 |iM) was applied for 375 ms at 3 min intervals. Immediately
following the initial 10 uM application of (-)nicotine at time zero, bath solution perfusion was
changed to one supplying a continuous perfusate of either APi_42 solubilised in HEPES buffer (•) or
HEPES buffer at an equivalent concentration (•). After 2 further applications of (-)nicotine, the Ap,_
42/Vehicle perfusate was stopped (total application time was 6 min) and the bath solution perfusion
reinstated. Peak amplitude response for (A) 100 nM APi_42 prepared in HEPES buffer or (B) HEPES
buffer vehicle was normalised to the peak response produced by the initial application of (-)Nicotine.
(C) Summary of normalised peak recordings for INic in the presence and absence of 100 nM Ap^ or
HEPES buffer vehicle. Recordings were collected from 3 cells and data represent the mean + S.E.M.
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5.3.3.2 Effect of APi_42 Solubilised in 5% Acetic Acid on (-)Nicotine Evoked Currents
in SH-EPl-ha4p2 Cells
As with all human AP^ studies, each SH-EPl-ha4p2 cell examined has its own
internal control with responses pre- and post-human APi_42 treatment allowing for
measurement of rundown and was subsequently analysed as described in Figure 5.25. To
control for any potential vehicle effect, a 5 % acetic solution was also diluted in bath solution
to the equivalent concentration used for the 100 nM APj.42 solution.
Representative traces of 100 nM APi_42 dissolved in 5% acetic acid and its
equivalent concentration vehicle control are shown in Figures 5.31 and 5.32, respectively.
Again, with the effect of drug (Figure 5.31) and vehicle (Figure 5.32) being almost identical,
these figures clearly illustrate that the inhibition of INic by APi_42 is due to a vehicle response.
The mean data for 3 cells is summarised in Figure 5.33 and clearly shows the overlap
between vehicle and drug lines.
5.3.3.3 Effect of APi_42 Dissolved in 50/50 DMSO/Tris Buffer (-)Nicotine Evoked
Currents in SH-EPl-ha4p2 Cells
To produce non-fibrillar, soluble human APi.42, Wang and colleagues (2000a & b,
personal communication) dissolved the peptide in a 50/50 mixture of DMSO and Tris FIC1,
(pFl 8.0). Representative traces from a single cell, showing (-)nicotine evoked responses in
the presence and absence of human APi_42 is shown in Figure 5.34. After a 3 min constant
perfusion, Ap,_42 significantly inhibited INic by almost 30 % (n = 3; p < 0.05; Figure 5.34).
However, when the equivalent concentration ofDMSO/Tris buffer was examined, it too was
found to inhibit INic in SH-EPl-ha4p2 cells by an equivalent extent {n = 3; p < 0.05; Figure
5.35). The overall data is summarised in Figure 4.36, with human APi_42 and the DMSO/Tris
HC1 having a similar effect on the (-)nicotine evoked current in SH-EPl-ha4p2 cells.
Therefore, human Ap,_42 (100 nM) dissolved in 50/50 DMSO/Tris HC1 had no inhibitory












Effect of 100 nM APi^ Resuspended in 5% Acetic Acid on (-)Nicotine Evoked Currents in SH-
EPl-ha4p2 Cells. (A) Application of human Afh.42 produced a significant reduction in the whole cell
current induced by (-)nicotine (10 pM) (B) Further characterisation of the current rundown by (-
(nicotine application in the SH-EPl-ha4p2 cell line. (C) Representative overlays of the 3 main
currents; control (•), human Ap^i resuspended in 5 % acetic acid (•) and rundown (•) showing a














Effect of Aj3]_42 5% Acetic Acid Vehicle on (-)Nicotine Evoked Currents in SH-EPl-ha4p2 Cells.
Application of 5 % acetic acid (at a concentration used to dissolve 100 nM A(l42) induced a
significant inhibition in the whole cell current induced by (-)nicotine (10 pM) equivalent to that
induced by the 100 nM APi_42 solution (B) Further characterisation of the rundown of (-)nicotine
induced currents in the SH-EPl-ha4p2 cell line. (C) Representative overlays of the 3 main currents;
control (•), 5 % acetic acid vehicle (•) and rundown (•) showing a significant difference between









Lack of Inhibition of INic in SH-EPl-ha4p2 Cells by Soluble Human Ap^ (300 nM) Prepared in
5% Acetic Acid. (-)Nicotine (10 pM) was applied for 375 ms at 3 min intervals. Immediately
following the initial 10 pM application of (-)nicotine at time zero, bath solution perfusion was
changed to one supplying a continuous perfusate of either AP]_42 (in 5% acetic acid; •) or 5 % acetic
acid at an equivalent concentration (•). After 2 further applications of (-)nicotine, the Ap^/Vehicle
perfusate was stopped (total application time was 6 min) and the bath solution perfusion reinstated.
Peak amplitude response for (A) 100 nM AP^ prepared in 5% acetic acid or (B) 5 % acetic acid
vehicle was normalised to the peak response produced by the initial application of (-)nicotine. (C)
Summary of normalised peak recordings for INjC in the presence and absence of 100 nM Ap).42 or 5 %

















Effect of 100 nM Ap^ Resuspended in DMSO/Tris on (-)Nicotine Evoked Currents in SH-EP1-
ha4p2 Cells. (A) Application of human APi,42 produced a significant reduction in the whole cell
current induced by (-)nicotine (10 pM) (B) Further characterisation of the current rundown by (-
)nicotine application in the SH-EPl-ha4p2 cell line. (C) Representative overlays of the 3 main
currents; control (•), human AP]_42 resuspended in DMSO/Tris (•) and rundown (•) showing a













Effect of APi_42 DMSO/Tris Vehicle on (-)Nicotine Evoked Currents in SH-EPl-ha4p2 Cells.
Application of DMSO/Tris (at a concentration used to dissolve 100 nM Ap.42) induced a significant
inhibition in the whole cell current induced by (-)nicotine (10 pM) equivalent to that induced by the
100 nM APi_42 solution (B) Further characterisation of the rundown of (-)nicotine induced currents in
the SH-EPl-ha4p2 cell line. (C) Representative overlays of the 3 main currents; control (•),
DMSO/Tris vehicle (•) and rundown (•) showing a significant difference between the 3 groups.
Traces are from a representative cell.
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Figure 5.36
Lack of Inhibition of INic in SH-EPl-ha4p2 Cells by Soluble Human ApM2 (300 nM) Prepared in
DMSO/Tris. (-)Nicotine (10 pM) was applied for 375 ms at 3 min intervals. Immediately following
the initial 10 pM application of (-)nicotine at time zero, bath solution perfusion was changed to one
supplying a continuous perfusate of either ApM2 (in DMSO/Tris; •) or DMSO/Tris at an equivalent
concentration (•). After 2 further applications of (-)nicotine, the Ap^/Vehicle perfusate was
stopped (total application time was 6 min) and the bath solution perfusion reinstated. Peak amplitude
response for (A) 100 nM Ap,^2 prepared in DMSO/Tris or (B) DMSO/Tris vehicle was normalised to
the peak response produced by the initial application of (-)nicotine. (C) Summary of normalised peak
recordings for IN|C in the presence and absence of 100 nM APi.42 or DMSO/Tris vehicle. Recordings
were collected from 3 cells and data represent the mean ± S.E.M.
212
5.3.3.4 Effect of Rpeptide Human Ap(_42 Acetate salt on (-)Nicotine Evoked Currents
in SH-EPf -ha4p2 Cells
During the course of my studies, Wu and colleagues (2004) published a paper
showing the Rpeptide Ap,_42 (100 nM) inhibited human a4p2 nAChRs expressed in SH-EP1
cells. Therefore, the final human Ap|.42 solution utilised was a newly available APi_42
acetate salt (Rpeptide Ltd., USA) that was water soluble, potentially eliminating the
confounding vehicle effects. Representative traces from_single cells exposed to either 100 or
300 nM AP]_42 are shown in Figures 5.37 and 5.38. To ensure no inhibitory effect of vehicle,
an acetate salt solution equivalent to that used to dissolve 300 nM Rpeptide APi_42 was
examined. Vehicle alone had no inhibitory inhibitory effect on INic in SH-EPl-ha4p2 cells
(Figure 5.39). The effect of both Rpeptide human APi_42 (100 and 300 nM) and the
equivalent high concentration acetate vehicle are summarised in Figure 5.40, where you can
clearly see that neither concentration of APi„42 had any effect on (-)nicotine evoked currents











Effect of Rpeptide Human ApM2 Acetate Salt (100 nM) on (-)Nicotine Evoked Currents in SH-
EPI-IKX4P2 Cells. (A) Application of human A[V42 produced a significant reduction in the whole cell
current induced by (-)nicotine (10 pM) (B) Further characterisation of the current rundown by (-
(nicotine application in the SH-EPl-ha4p2 cell line. (C) Representative overlays of the 3 main
currents; control (•), Rpeptide human Api_42 (•) and rundown (•) showing a significant difference










Effect of Rpeptide Human Ap,^2 Acetate Salt (300 nM) on (-)Nicotine Evoked Currents in SH-
EPl-ha4p2 Cells. (A) Application of human Api_42 produced a significant reduction in the whole cell
current induced by (-)nicotine (10 pM) (B) Further characterisation of the current rundown by (-
)nicotine application in the SH-EPl-ha4P2 cell line. (C) Representative overlays of the 3 main
currents; control (•), Rpeptide human APi_42 (•) and rundown (•) showing a significant difference















Effect of APi_42 Acetate Vehicle on (-)Nicotine Evoked Currents in SH-EPl-h<X4p2 Cells.
Application of acetate vehicle (at a concentration used to dissolve 300 nM Ap_42) induced a significant
inhibition in the whole cell current induced by (-)nicotine (10 pM) equivalent to that induced by the
100 nM APi_42 solution (B) Further characterisation of the rundown of (-)nicotine induced currents in
the SH-EPl-hix^ cell line. (C) Representative overlays of the 3 main currents; control (•),
DMSO/Tris vehicle (•) and rundown (•) showing a significant difference between the 3 groups.
Traces are from a representative cell.
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Figure 5.40
Lack of Inhibition of INic in SH-EPl-hc^Pi Cells by APi^2 Rpeptide Acetate Salt. (-)Nicotine (10
pM) was applied for 375 ms at 3 min intervals. Immediately following the initial 10 pM application
of (-)nicotine at time zero, bath solution perfusion was changed to one supplying a continuous
perfusate of either (A) APi_42 (100 nM) or (B) Aff.42 (300 nM) or (C) acetate vehicle at an equivalent
concentration (•). After 2 further applications of (-)nicotine, the Ap^/Vehicle perfusate was
stopped (total application time was 6 min) and the bath solution perfusion reinstated. Peak amplitude
responses were normalised to the peak response produced by the initial application of (-)nicotine.
Recordings were collected from 3 cells and data represent the mean ± S.E.M.
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5.4 Examination of Human a7 nAChR Electrophysiology
The inability to detect changes in intracellular calcium and membrane potential of
SH-EPl-ha7 cells (detailed in the Section 5.2.3) may simply result from assay insensitivity
for these cells. As such, whole cell current recording was used to characterise the
pharmacology of the human a7 nAChR. As discussed above, electrophysiological analysis
of single cells allows more detailed investigation of the functional viability of receptors.
5.4.1 Characterisation of the Pharmacological Properties of the Human a7 nAChR
Using Whole Cell Patch Clamp Studies in SH-EPl-ha7 Cells
Electrophysiology experiments were performed using whole cell recording in a
voltage clamp mode at a holding potential (VM) of -60 mV. Although nominally a stable cell
line, application of (-)nicotine to SH-EPl-ha7 cells resulted in the absence of or low peak
current amplitudes of only a few picoamperes. Indeed, the majority of cells failed to exhibit
functional responses despite using both K+-free and KC-containing electrodes as discussed in
Section 5.3.1 (pg 189) for the human a4p2 nAChRs. To encourage functional surface
expression of the human a7 nAChR, Molinari and colleagues (1998) treated PIEK293 cells
with nicotinic agonists and antagonists. Pre-treatment of the SH-EPl-ha7 cells with a7
nAChR-specific antagonist MLA did not result in consistent, or indeed, increased functional
responses in these cells. However, treatment with MLA did allow completion of a full (-
)nicotine dose-response curve from which an EC5o of 43 pM was measured (Figure 5.41 A &
C).
5.4.2 Characterisation of the Pharmacological Properties of the Human a7 nAChR
Using Other Cell Lines
The lack of consistent functional responses obtainable from the SH-EPl-ha7 cell
line led me to look to other cell lines from which I might determine functional a7 nAChR
pharmacology. The rat pituitary cell line, GH4C1, in which the human a7 nAChR was over-
expressed, was obtained from the European Collection of Cell Cultures (ECACC) and
maintained in our laboratories (Section 2.2.2). Like the SH-EP1 cell line, GH4C1 cells do
not express any native a7 nAChRs and has been used by other groups to investigate a7
nAChR pharmacology (Quik et al., 1996; Sweileh et al., 2000). Unfortunately, peak current
responses in GH4C1 cells were also low and inconsistent, again reflecting the difficult of
expressing functional a7 nAChRs in neuronal cell lines. However, I did obtain a full (-
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)nicotine dose response profile with a (-)nicotine EC50 value of 53 pM, consistent with that
obtained from the SH-EPl-ha7 cells (Figure 5.4IB & C).
Finally, I conducted both electrophysiological and [3H]-MLA binding studies to
assess the potential of IMR32 cells for functional studies. Like SH-EP1 cells, IMR32 cells
are a neuroblastoma derived cell line but have been shown to express native a7 nAChRs
(Gotti et al., 1995). Only a small level of [3H]-MLA binding was observed in GH4C1 cells.
Consistent with the lack of [3H]-MLA binding in this cell line (Figure 5.4.2), no functional
responses were obtained from the IMR32 cells.
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Figure 5.41
(A) Nicotine^ (uM)3_ Hi 30 100 22P
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(-)Nicotine Evoked-Currents in SH-EP1 and GH4C1 Cells in Which the Human a7 nAChR was
Over-Expressed. Representative traces of a single cell in response to (-)nicotine in (A) SH-EPl-ha7
or (B) GH4C1 cells. (C) The concentration-response relationship of (-)nicotine with normalised peak
current amplitude (ordinate; percentage of response in same cell to 1 mM (-)nicotine as a function of
dose (abscissa in molar untils, log scale) of (-)nicotine in the SH-EPl-ha7 (•, EC50 = 43 pM, n = 9) or




SH-EPl-null SH-EPl-ha7 IMR32 SH-EPl-ha?
Cytomyx
Proportions of [3H]-MLA Binding in Various Cell Membrane Preparations. Membranes (~60
pg) prepared from SH-EPl-Null (SH-EP-host), SH-EPl-ha7, 1MR32, and SH-EP1 cells transiently
transfected with the human a7 nAChR (SH-EPl-ha7) were incubated with [3H]-MLA (2.5 nM) in a
total assay volume of 250 pi for 60 min at 22°C. ■ Total Binding whilst non-specific binding (■) was
determined in the presence of 10 pM rZ-tubocurarine.
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5.5.1 Co-Immunoprecipitation Analysis of Human a4p2 or ct7 nAChRs with Human
AP1-42
At the outset of my Ph.D, Wang and colleagues (2000a), presented some exciting
data showing the co-localisation and co-immunoprecipitation of human Afh.^ with the
human 0.7 nAChR. To confirm and extend these finding I examined whether human Api_42
could co-immunoprecipitate with either the human a4p2 or the a7 nAChRs. SH-EP1 cells
stably expressing either the human a4p2 or a7 nAChR were used in these studies and were
incubated with human Ap,.42 for 30 min, probed with the appropriate IP antibody and finally
analysed using western analysis. Initial experiments determined the ability of anti-a4, anti-
0,7, or anti-APi_42 antibodies to detect the presence of the a4, a7, or human APi_42,
respectively, on a Western blot. Finally, prior to their use in co-immunoprecipitation studies,
the ability of the anti-a4, anti-a7, and anti-APi_42 antibodies to detect immunoprecipitation of
their target was assessed.
5.5.1.1 Western Blot Analysis of the Human a4 nAChR Subunit
Lysates were prepared (see Methods Section 2.7.1) from SH-EPl-ha4p2 cells and
then subjected to Western blot analysis with a rat monoclonal anti-a4 nAChR antibody
(mAb299). No band was detected in lysates prepared from SH-EP1 cells indicating there
was no detectable native a4 nAChR subunits in the host cell line (Figure 5.43). In contrast, a
clear band at a molecular weight of 60 kDa was identified, consistent with the molecular
weight predicted from the amino acid sequence of the human a4 nAChR subunit (Figure
5.43; Elliott et ai, 1996).
5.5.1.1A Immunoprecipitation Analysis of the Human a4 nAChR Subunit
Lysates prepared from SH-EPl-ha4p2 cells were immunoprecipitated with the
anti-a4 nAChR subunit antibody HI33 (rabbit polyclonal). Following precipitation of the
antigen-Hl 33 complex using Protein G agarose, the complex was eluted and successfully
analysed by Western blot analysis using the anti-a4 nAChR subunit monoclonal antibody
mAb299 (mouse; Figure 5.44). Clear bands were observed at 60 kDa in both the control
lysate and in the sample which had been subjected to immunoprecipitation (Figure 5.44).
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Figure 5.43
Western Blot Analysis ofSH-EPl-ha.^ Cell Lysates with an Anti-a4 nAChR Subunit Antibody.
Solubilised SH-EPl-ha4P2 cells (30 (ig) and SH-EPl-Host cells (Ctrl, 30 fig) were subjected to SDS-
PAGE separation on NuPAGE® 4-12 % Bis-Tris Gels (Invitrogen, UK) before transferring to
nitrocellulose membranes for Western blot analysis. Membranes were blocked by a PBS buffer
containing 5 % skim milk powder and incubated overnight (4°C) with the anti-a4 nAChR subunit
antibody 299 (rat monoclonal, 1:1,000, Sigma). Following three 5 min washes in PBS buffer
containing 0.05 % Tween20 (PBST), horseradish peroxidase conjugated goat anti-rat conjugated IgG
secondary antibody (Santa Cruz Biotechnology, 1:1,000) was added to the reaction medium. After 1
h membranes were washed (3x5 min) in PSBT and visualised using ECL+ chemiluminescence kit





Immunoprecipitation of the Anti-a4 nAChR Subunit Antibodies in SH-EPl-ha4p2 cell lysates.
Solubilised SH-EPl-ha4P2 cell lysates (1 mg) were incubated overnight (4°C) with the anti-a4 nAChR
subunit antibody HI33 (Santa Cruz Biotechnology, 5 pg/ml) and protein G agarose beads (Sigma).
The sample was washed three times in NP Buffer (see Methods) and then sample buffer containing P-
mercaptoethanol (20 pl/sample) added. Samples were then subjected to electrophoretic separation on
NuPAGE® 4-12 % Bis-Tris Gels (Invitrogen, UK) before transfer to nitrocellulose membranes for
Western blot analysis. Membranes were blocked in a PBS buffer containing 5 % skimmed milk
powder and incubated overnight (4°C) with the rat anti-a4 nAChR subunit antibody 299 (Sigma,
1:1,000). Following three 5 min washes in PBS buffer containing 0.05 % Tween20 (PBST),
horseradish peroxidase conjugated goat anti-rat conjugated IgG secondary antibody (Santa Cruz
Biotechnology, 1:1,000) was added to the reaction medium. After 1 h membranes were washed (3x5
min) in PSBT and visualised using ECL' chemiluminescence kit (Amersham Biosciences, UK). The
control sample represents 30 pg of protein prior to addition of antibodies. A clear immunoreactive
band at 60 kDa can be observed in both the control (Ctrl; cell lysate) and immunoprecipitation (IP)
sample.
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5.5.1.2 Development of the Western Blot Analysis of the Human a7 nAChR subunit
To detect the human a7 nAChR subunit protein on a Western blot, lysates were
prepared from SH-EPl-ha7 cells and the choice of transfer membrane, blocking solution,
and primary antibody sequentially altered in an attempt to enhance the a7 nAChR protein
signal.
5.5.1.3A Transfer of Proteins from the Polyacrylamide Gel to Transfer Membrane
Nitrocellulose and polyvinylidene difluoride (PVDF) membranes constitute two of
the most popular transfer membranes. PVDF has a higher protein binding capacity and
lower background than nitrocellulose but requires pre-soaking in 100% methanol. This latter
step may interfere with the protein of interest causing degradation of sample.
The ability of three different anti-a7 nAChR subunit antibodies to detect a7
nAChR protein in Western blots was examined following transfer to either nitrocellulose or
PVDF membranes. Lysates were first separated using gel electrophoresis as described
before transfer to the membrane of choice. Using nitrocellose membranes, a clear protein
band was detected at 55 kDa, consistent with the molecular weight predicted from the amino
acid sequence of the human a7 nAChR (Peng et al., 1994b; Figures 5.45A & 5.45B).
Interestingly, this band was only detected using the anti-a7 nAChR antibodies M220 (mouse
monoclonal) and sc-5544 (rabbit polyclonal; Figure 5.45A). Weak or no immunoreactivity
was observed when the goat polyclonal anti-a7nAChR antibody sc-1447 was used (Figure
5.45A). In contrast to the former two antibodies which map to amino acids 380-400 (M220)
and 367-502 (sc-5544) of the a7 nAChR, the sc-1447 epitope maps to the C terminus of the
a7 nAChR and may not be suitable for use with the SH-EPl-ha7 cell line. When PVDF
membranes were used, the immunoreactive signal was weak or absent regardless of antibody
employed (Figure 5.45B). In the following Western blot experiments, I attempted to
optimise the signal of the anti-a7 nAChR antibody M220 using the nitrocellulose transfer
membrane.
5.5.1.3B Oxidation or Reduction of Samples
The rate-limiting step in Western blot analysis is often the ability of the primary
antibody to recognise the antigen epitope within the sample. If the epitope is located within
the protein of interest, the protein must be denatured to expose the epitope and enable the
antibody to bind. The most common method of protein denaturation is to heat the sample










Antibody M220 sc-5544 sc-1447 Ctrl
Effect of Transfer Membrane on the Detection of a7 nAChR Protein in Western Blot Analysis.
The ability of anti-a7 antibodies M220 (mouse monoclonal, Sigma, 1:1,000), sc-5544 (rabbit
polyclonal, Santa Cruz Biotechnology, 1:200), and sc-1447 (goat polyclonal, Santa Cruz
Bioctechnology, 1:100) to detect the a7 nAChR subunit was examined using Western blot analysis
and (A) nitrocellulose or (B) PVDF membranes for the transfer step (see Methods). Lysates were
prepared from SH-EPl-ha7 cells (30 pg) and subjected to Western analysis using the appropriate
primary and secondary antibodies (Table 2.1). The control sample (Ctrl) represents a sample (30 pg)
prepared from SH-EPl-ha4p2 cell membranes and probed with anti-a7 antibodies. Clear protein
bands were observed when the anti-a7 nAChR antibodies M220 or sc-5544 were utilised in
conjunction with nitrocellulose membranes. The immunoreactive signal using these antibodies and
PVDF membranes was weak (M220) or absent (sc-5544). In contrast, weak (A) or no (B)
immunoreactive signal was observed using sc-1447 and either nitrocellulose or PVDF membranes.
No immunoreactivity was present in control samples.
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reducing agents such as dithiothreitol (DTT) or (3-mercaptoethanol are often used to break
any disulphide bonds present within the protein.
According to the information provided by the supplier (Sigma, M220), the anti-a7
nAChR M220 only recognises the denatured form of the human a7 nAChR. As such, all the
SH-EPl-ha7 lysates examined were heated at 95°C for 10 min prior to sample loading on the
gel. However, care must also be taken when adding reducing agents to your sample as they
can potentially destroy the epitope recognised by the primary antibody. The effect of the
reducing agent DTT on the intensity of the a7 nAChR protein band was examined by
preparing samples in the absence or presence of DTT (0.1 M) prior to Western blot analysis.
The intensity of the immunoreactive signal did not alter despite inclusion of DTT in the
sample buffer (Figure 5.46). Therefore, as a precautionary measure only, DTT continued to
be included in the sample buffer.
5.5.1.3C Extraction Buffers
Care must be taken when choosing a detergent to solubilise the membrane
preparations used in Western blotting. Detergents work by mimicking the lipid bilayer
environment, with the wide range available broadly classified into three categories including
ionic, non-ionic, and zwitterionic. Ionic detergents are usually positively (cationic), or
negatively (anionic) charged and include sodium dodecyl sulphate (SDS), an anionic
detergent which is commonly incorporated into many running buffers. Non-ionic detergents
such as Triton X-100 contain uncharged hydrophilic head groups and are generally better
suited for breaking lipid-lipid and lipid-protein interactions rather than protein-protein
interactions (Bhairi, 2001). In contrast zwitterionic detergents such as 3-[(3-
Cholamidopropyl)dimethylammonio]-l-propanesulfonate (CHAPS) exhibit properties of
both ionic and non-ionic detergents. These latter detergents lack a net charge, conductivity,
and electrophoretic mobility and are efficient at breaking protein-protein interactions (Bhairi,
2001).
The zwitterionic detergent CHAPS and the non-ionic detergent Triton X-100 were
used to solubilise membranes from SH-EPl-ha7 cells, to determine what effect this had on
the signal intensity. By maximising the solubilisation process, the protein yield should
increase and thereby enhance the 55 kDa immunoreactive signal. A weak protein band was
observed at 55 kDa when utilising the CHAPS detergent (Extraction BufferCHAPs, (EBChaps)
Figure 5.47), whereas a stronger immunoreactive signal was present when using Triton X-








Effect of the Reducing Agent DTT on the Signal Intensity of the a7 nAChR Protein in Western
blots. Lysates (SH-EPl-ha7 cells) were prepared in sample buffer in the (A) presence or (B) absence
of reducing agent dithiothreitol (0.1 M DTT). Following electrophoresis using NuPAGE® Bis-Tris
polyacrylamide gels, samples were transferred to nitrocellulose membranes and blocked using PBS
buffer containing 5 % semi-skimmed milk. Membranes were probed using the anti-a7 nAChR subunit
antibody M220 (mouse monoclonal, Sigma, 1:1,000) and horseradish peroxidase conjugated rat anti-
mouse conjugated IgG secondary antibody (Sigma, 1:10,000) were subsequently visualised using
ECL1 chemiluminescence kit (Amersham Biosciences, UK). Clear protein bands at 55 kDa were
observed under both (A) reducing and (B) non-reducing conditions. Control (Ctrl) lysates are samples









Effect of Detergents on the Signal Intensity of the a7 nAChR Protein in Western blots. Lysates
(SH-EPl-hay cells, 1 mg) were solubilised in extraction buffer containing (A) the zwitterion detergent
CHAPS (EBchaps) or (B) the non-ionic detergent Triton X-100 (EBTrit0n), prior to analysis by Western
blotting. Membranes probed using the anti-a7 nAChR subunit antibody M220 (mouse monoclonal,
Sigma, 1:1,000) and horseradish peroxidase conjugated rat anti-mouse conjugated IgG secondary
antibody (Sigma, 1:10,000) were subsequently visualised using ECLf chemiluminescence kit
(Amersham Biosciences, UK.). A clear protein band at 55 kDa was only observed when using EBTrilon-
Control (Ctrl) lysates are samples prepared from SH-EPl-ha4(32 cell membranes and probed with anti-
ay antibody M220.
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Western blot studies were performed using Triton X-100 as the detergent of choice in the
extraction buffer.
5.5.1.3D Summary ofWestern Blot Analysis of the Human a7 nAChR Subunit
SH-EPl-ha7 cells were solubilised in lysate buffer containing the detergent Triton
X-100, with the resulting protein then prepared in sample buffer containing the reducing
agent DTT and heated (95°C, 10 min) to denature the protein. Following separation on a
NuPAGE® 4 - 12 % Bis-Tris polyacrylamide gel, proteins were transferred to a
nitrocellulose membrane, prior to incubation (overnight) with the monoclonal mouse anti-a7
nAChR antibody M220 (primary antibody; 1:1,000), followed by addition of the secondary
horse radish peroxidase conjugated goat anti-mouse conjugated IgG (A2004, 1:10,000,
Sigma). This protocol resulted in a clear protein band being observed at 55 kDa (Figure
5.48).
5.5.1.3E Immunoprecipitation Analysis of the Human a7 nAChR subunit
Immunoprecipitation is generally used to concentrate an antigen in situations
where it may have been otherwise undetectable using standard Western blotting techniques
on a gel. Our target protein (the a7 nAChR subunit) is detectable as a -55 kDa protein band
which is identical to that of the 55 kDa immunoglobulin (Ig) heavy chain. As a consequence,
the choice of IP and primary antibodies is critical as any manifestation of the Ig heavy chain
is likely to obscure the presence of the a7 nAChR band. To avoid this problem and
demonstrate that any 55 kDa protein detected represents the a7 nAChR subunit protein, I
utilised antibodies derived from different species. SH-EPl-ha7 cell lysates were
immunoprecipitated with the anti-a7 nAChR antibody sc-5544 (rabbit polyclonal; 1:200) and,
following separation of the antigen-sc-5544 complex with Protein G agarose, the complex
was eluted and analysed by Western blot analysis using M220 (mouse monoclonal, 1:1,000)
as the primary antibody. Although the human a7 nAChR subunit protein could be detected
in the original lysate, no immunoreactive signal was observed at 55 kDa, indicating the
protein has not immunoprecipitated (Figure 5.49A). This experiment was repeated on at
least 5 further occasions with the same result on every occasion (data not shown). When the
inverse experiment was performed where lysates were immunoprecipitated with M220




55 kDa - ► |
a7 Ctrl
Western Blot Analysis of a7 nAChR Protein Conducted Under Optimal Conditions Using the
Anti-ay nAChR Subunit Antibody M220. SH-EPl-ha7 cells (30 pg) and SH-EPl-ha4p2 cells (Ctrl,
30 pg), solubilised in EBTriton and prepared in sample buffer containing DTT (0.1 M), were subjected
to SDS-PAGE separation on NuPAGE"; 4-12 % Bis-Tris Gels before transferring to nitrocellulose
membranes for Western blot analysis. Membranes were blocked in a PBS buffer containing 5 %
skimmed milk powder and incubated overnight (4°C) with the primary anti-a7 nAChR antibody M220
(mouse monoclonal, Sigma, 1:1,000). Following three 5 min washes in PBS buffer containing 0.05 %
Tween 20 (PBST), horseradish peroxidase conjugated rat anti-mouse conjugated IgG secondary
antibody (Sigma, 1:10,000) was added to the reaction medium. Following incubation (1 h, 22°C),
membranes were washed (3x5 min) in PSBT and visualised using ECL+ chemiluminescence kit
(Amersham Biosciences, UK). Although no immunoreactive band was visible in the control SH-EP1-
ha4p2 sample, a strong band was detected in the a7 nAChR sample.
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Figure 5.49
(A) IP: sc-5544, WB: M220
55 kDa t
Ctrl IP
(B) IP: M220, WB: sc-5544
55 kDa —►
Ctrl IP
Immunoprecipitation of a7 nAChR Subunit from SH-EPl-ha7 Cell Lysates. Lysates were
immunoprecipitated (see Methods for full details) with anti-a7 nAChR antibodies (A) sc-5544 (rabbit)
or (B) M220 (mouse) and Western blotted with a second anti-a7 nAChR antibody (i.e. (A) M220 (B)
sc-5544). The control sample represents 30 pg of protein prior to addition of antibodies (positive
control). Membranes were visualised using ECL+ chemiluminescence kit (Amersham Biosciences,
UK). Although a clear immunoreactive band at 55 kDa can be observed in the control samples, no
immunoreactivity was observed in the immunoprecipitated samples.
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5.5.1.4 Western Blot Analysis of Human Api_42
The ability of the anti-human APi_42 antibody 171609 (polyclonal rabbit,
Calbiochem® U.K.) and 4G8 (monoclonal mouse, Rpeptide, U.S.A.) to detect APi_42 was
assessed using Western blotting. A control ("spiked") solution of 10 pg/ml APi_42
(Rpeptide) was prepared in sample buffer (containing DTT) and loaded onto a NuPAGE®
Bis-Tris polyacrylamide gel. Following transfer to a nitrocellulose membrane, the samples
were incubated with primary antibodies 171609 or 4G8, then appropriate secondary
antibodies prior to analysis by chemiluminescence. Using the polyclonal antibody 171609,
there was a clear protein band observed at 3 kDa (Figure 5.50), consistent with previous
studies examining Ap,.42 with molecular weight ranging from 3-10 kDa which are dependent
on its fibrillar state (Ida et al., 1996; Roher et al., 1996; Wang et al., 2000a). In addition,
lysate samples were prepared from Chinese Hamster Ovary (CHO) cells in which the human
amyloid precursor protein (APP) had been over-expressed (Pahlsson & Spitalnik, 1996) and
analysed using Western blotting. The anti-human A(3i.42 antibody 171609 again detected a 3
kDa band in CHO-APP cells, consistent with previous the spiked sample (Figure 5.50) and
with previous reports (Sun et al., 2002; Arbel et al., 2005). In contrast, no band was seen
when the anti-human APi_42 4G8 monoclonal antibody was utilised. All subsequent Western
blotting experiments used the anti-APi_42 antibody 171609 as the primary antibody.
5.5.1.4A Immunoprecipitation Analysis of Human APi_42
A "spiked" solution of Ap,_42 (100 nM, Rpeptide) was immunoprecipitated using
the 4G8 anti-APi_42 antibody (mouse monoclonal; 1:500) and then analysed by Western
blotting with the rabbit polyclonal antibody, 171609 (1:500). Although faint, a distinct 3
kDa band was identified in the original "spiked" sample and in the APi_42 immunoprecipitate
indicating the procedure has been successful (Figure 5.51).
5.5.1.5 Co-Immunoprecipitation Analysis of the Human a4 nAChR Subunit and
Human Ap^
Co-immunoprecipitation is most commonly used to identify a target protein and
other molecules that interact with it. To determine whether the human a4 nAChR subunit
and human Api_42, co-immunoprecipitate, whole cell lysates from SH-EPl-ha4p2 cells were
incubated with 100 nM APi_42 for 1 h, prior to solubilisation. The subsequent cell lysate was
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Figure 5.50
(A) Anti AP1-42 Antibody 171609
Ap,_42 CHO-APP Ctrl
(B) Anti-Api.42 Antibody 4G8
3 kDa —►
Apui2 CHO-APP Ctrl
Western Blot Analysis of Human Ap^ with Anti-Human APi_42 Antibodies 171609 and 4G8.
Human AP1.42 (100 nM in 1 ml EBTriton), CHO-APP cells (30 (_ig) and SH-EPl-ha4p2 cells (Ctrl, 30
|ig) were subjected to SDS-PAGE separation on NuPAGE® 4-12 % Bis-Tris Gels (Invitrogen, UK)
before transferring to nitrocellulose membranes for Western analysis. Membranes were blocked in a
PBS buffer (see Methods) containing 5 % skimmed milk powder and incubated with either anti-
human AP1.42 antibody (A) 171609 (polyclonal rabbit; Calbiochem; 1:500) or (B) 4G8 (monoclonal
mouse, Rpeptide, 1:500) overnight at 4°C. Following three 5 min washes in PBS buffer containing
0.05 % Twcen 20 (PBST), horseradish peroxidase conjugated goat anti-mouse IgG was added to the
171609 preparation (Sigma, 1:10,000) or horseradish peroxidase conjugated goat anti-rabbit
conjugated IgG secondary antibody (Sigma, 1:10,000) to the 4G8 preparation. After incubation at
room temperature (1 h), membranes were washed (3x5 min) in PSBr and visualised using ECL+
chemiluminescence kit (Amersham Biosciences, UK). A clear protein band (3 kDa) was observed in
the spiked human AP|.42 with both antibodies. In contrast, human APi.42 (3 kDa) was only detected in
CHO-APP cells when anti-human Apl.42 antibody 171609 was used. Human AP|.42 was not detected





Immunoprecipitation of Human Ap,_42 Using the Anti-Human APi_42 Antibodies 4G8 and
171609. APi_42 (100 nM final concentration in 1 ml EBTriton) was incubated overnight with anti-
human AP]_42 antibody 4G8 (Rpeptide, 1:500) and protein G agarose beads (Sigma). Samples were
then subjected to electrophoretic separation on NuPAGE® 4-12 % Bis-Tris Gels (Invitrogen, UK)
before transfer to nitrocellulose membranes for Western blot analysis. Membranes were probed using
the anti-human Ap|_42 antibody 171609 (Calbiochem, 1:500) and an anti-mouse horseradish
peroxidase conjugated secondary (Sigma, 1:10,000) before visualisation using the ECL+
chemiluminescence kit (Amersham Biosciences, UK). The control sample (Ctrl) represents 5 pi of
the original spiked human APi.42 sample solution. A clear immunoreactive band at 3 kDa can be
observed in both the control and immunoprecipitation (IP) samples.
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immunoprecipitated with the 4G8 anti-human Api_42 antibody and samples separated by
electrophoresis using NuPAGE® Bis-Tris polyacrylamide gels. Following transfer to
nitrocellulose membranes, proteins were stained for a4 nAChR subunit immunoreactivity
using the anti-a4 antibody mAb299. For the co-immunoprecipitation to be considered
successful, a band at 60 kDa must be detected in the immunoprecipitate sample lane. A clear
band was detected at 60 kDa (molecular weight of a4 nAChR subunit) in the original lysate
sample, however despite multiple attempts no signal was detected at the same molecular
weight in the immunoprecipitated sample (Figure 5.52).
5.5.1.6 Co-Immunoprecipitation Analysis of the Human a7 nAChR Subunit and
Human APi_42
Co-immunoprecipitation analysis of the human a7 nAChR and human ApM2 was
not carried out as immunoprecipitation of the human a7 nAChR from the SH-EPl-ha7 cell
lysate was unsuccessful (see 5.5.1.3E, pg 230).
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Figure 5.52
Human APi_42 Does Not Co-immunoprecipitate with the Human a4 nAChR Subunit. Lysate (1
mg solubilised SH-EPl-ha4p2 cell protein) spiked with human APi_42 (final concentration 100 nM in 1
ml EBTriton) was incubated overnight with the anti-APi_42 antibody 4G8 (Rpeptide, 1:500) and protein
G agarose beads (Sigma). Samples were then separated on NuPAGE® Bis-Tris Gels (Invitrogen, UK)
before transferring to nitrocellulose membranes for western analysis. Membranes were probed with
the anti-a4 nAChR antibody 299 (rat monoclonal, Sigma, 1:1,000) overnight and horseradish
peroxidase conjugated goat anti-rat conjugated IgG secondary antibody (Santa Cruz Biotechnology,
1:1,000). Following a 1 h incubation with the secondary antibody, membranes were washed (3x5
min) in PSB buffer containing 0.05 % Tween 20 and visualised using ECL+ chemiluminescence kit
(Amersham Biosciences). The control sample represents 30 pg solubilised SH-EPl-ha4p2 cells
spiked with human APi_42, prior to addition of any antibodies. Although a clear protein band was
observed in the control sample (60 kDa), no such immunoreactivity was observed in the IP sample.
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5.6 DISCUSSION
In Chapter 3, Section 3.7.2 (pg 117), radioligand binding assays were used to show
the lack of an interaction between soluble and insoluble APi_42 with the rodent and human
a4p2 and a2 nAChRs. However, standard radioligand binding assays do not assess how the
conformation and the regulation of the channel contribute to the function of the channel. For
instance, many receptors require the binding of multiple ligands before channels opening
(Chang & Weiss, 1999). Fluorescence based calcium and membrane potential assays and
whole-cell patch clamp electrophysiology have been performed to examine the
pharmacological and biophysical properties of human a4p2 and a7 nAChRs expressed in SH-
EP1 cells and their interaction with soluble and insoluble human APi_42. In addition, any
protein-protein interaction have been assessed by examining whether human nAChRs co-
immunoprecipitate with human APi_42.
5.6.1 Characterisation of Human a4p2 nAChRs Using an Intracellular Calcium
Assay
Interest in fluorescence based assays for the assessment of receptors/channels has
grown substantially over the past few years (Manning & Sontheimer, 1999; Villarroya et al.,
1999; Chavez-Noriega et al., 2000). Furthermore, these assays avoid many of the safety
issues associated with assays like the 86Rb efflux assay (Chavez-Noriega et al., 2000). The
development of high-throughput screening has led to simpler, less labour-intensive (in
comparison to electrophysiology) fluorescence-based assays with enhanced reproducibility
(Dooley et al., 1998; Lin et al., 1999; Manning & Sontheimer, 1999; Whiteaker et al., 2001;
Baxter et al., 2002; Fitch et al., 2003; Hodder et al., 2004; Whitaker, 2004). The most widely
used fluorescent probes for examining the function of nAChRs are the calcium chelating dyes
Fluo® and Fura® (Grynkiewicz et al., 1985; Minta et al., 1989; Gee et al., 2000). In the
current study the Molecular Devices (U.K.) calcium plus assay kit was utilised. This kit uses
a proprietary dye similar in nature to the Fluo-3 and Fluo-4 intensity dyes but also
incorporates a secondary dye to mask background fluorescence due to unloaded and extruded
dye (Fitch et al., 2003). The masking dye enhances reproducibility by eliminating the need
for washing out of extracellular dye, minimising variability due to cell detachment.
Alterations in [Ca2+]j are observed as a change in fluorescence intensity that is captured by
the FlexStation fluorometric plate reader (Molecular Devices, U.K.).
It is well documented that nAChR function is modulated by external Ca2r
concentration with a number of electrophysiological studies showing maximal potentiation
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of nAChR responses when external Ca2+ concentrations are between 2-20 mM (Mulle et al.,
1992; Vernino et al., 1992; Buisson et al., 1996; Sabey et al., 1999; Chavez-Noriega et al.,
2000). In agreement with these earlier observations, the [Ca2+]j response elicited by 10 pM
(-)nicotine in SH-EPl-ha4p2 cells was considerably enhanced when the external Ca2+
concentration was increased to 20 mM (Mulle et al., 1992; Vernino et al., 1992; Buisson et
al., 1996; Chavez-Noriega et al., 2000). However, this concentration of Ca2~ is much higher
than found physiologically (Benninger el al., 1980; Avoli et al., 1996). Therefore, to keep
the external [Ca2+] physiologically relevant as well as comparable with previous studies
(Mulle et al., 1992; Vernino et al., 1992; Buisson et al., 1996; Chavez-Noriega et al., 2000),
all subsequent experiments were performed with an additional 2.5 mM external Ca2+, which
itself increased the (-)nicotine evoked response in [Ca2+]j by > 300%.
In the [Ca2+]j assay, EC50/IC50 values for nAChR ligands (-)nicotine, cytisine,
(±)epibatidine, MLA, and d-TC (Figures 5.3 (pg 168) & 5.4 (pg 170)) were consistent with
those determined by others using the Molecular Devices calcium assay (Fitch et al., 2003),
the 86Rb efflux assay (Marks et al., 1993; Gopalakrishnan et al., 1996; Eaton et al., 2003;
Gentry et al., 2003), or a Fluo-3 fluorescence based calcium assay (Chavez-Noriega et al.,
2000). Indeed, the (-)nicotine EC50 value determined in the current study (22.9 pM) was
slightly higher than Chavez-Noriega and colleagues (2000) of 3.5 pM determined using
human a4p2 nAChRs expressed in HEK293 cells, but lower than the EC50 value of 32 pM
determined by Gentry and colleagues (2003) using SH-EPl-ha4p2 cells in a 86Rb efflux
assay. Furthermore, the (-)nicotine EC50 value of 22.8 nM determined using the calcium
assay is not significantly different to that determined using the fluorescence-based membrane
potential assay (EC50 = 19.5 nM, Chapter 5, Section 5.2). Therefore, high affinity nAChR
agonists such as (-)nicotine and (±)epibatidine evoke large alterations in [Ca2+]j, while the a7
nAChR antagonist MLA exhibits low potency. Together these results indicate that the SH-
EPl-ha4p2 cells express a4p2 nAChRs with classic pharmacology.
5.6.2 Human Ap,_42 Does Not Alter (-)Nicotine Evoked |Ca2+)j Responses in SH-EP1-
ha4p2 Cells to (-)Nicotine
To my knowledge, this is the first study to assess whether human a4p2 nAChRs
interact with human APi_42 using (-)nicotine evoked [Ca2+]j responses. In agreement with
data from ['HJ-cytisine binding assays (Chapter 3, Section 3.7.2, pg 117), neither soluble nor
insoluble human APi_42 inhibited the (-)nicotine evoked [Ca2+]j responses in SH-EPl-ha4p2
cells (Figures 5.42 - 5.44). Although 10 pM APi.42 dissolved in 5 % acetic acid did cause an
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inhibition of the (-)nicotine evoked [Ca2+]j response, an equivalent inhibition was also caused
by vehicle alone. Furthermore, a similar observation was made with AfSi.42 dissolved in
HEPES, as it appeared to inhibit the cytisine (but not (-)nicotine)-evoked [Ca2+]j response
(Figure 5.5, pg 171). However, again the level of inhibition was not significantly different
from that induced by vehicle. Although HEPES, a calcium-buffering solution has been used
as a weak ligand in nAChR structure studies (Brejc et al., 2001; Artali et al., 2005) it was
surprisingly to find it was such a potent inhibitor of (-)nicotine evoked responses at human
a4p2 nAChRs. Yet this finding was not restricted to the [Ca2+]i assay but was also observed
when using other functional techniques discussed below. Therefore, no evidence has been
presented to confirm human APi.42 inhibits nAChR agonist evoked currents in SH-EPl-ha4p2
cells.
5.6.3 Human APi_42 Does Not Alter Membrane Potential of SH-EPl-ha4p2 Cells
Although functional characterisation of nAChR pharmacology using [Ca2+]; assays
is relatively well documented, less characterisation of the use of the fluorescent membrane
potential sensitive dyes has been performed. Membrane potential sensitive dyes such as
DiBAC(3)(4) have been used for a number of years, however, these have several limitations
including a slow onset of response and multistep preparation (de Poorter & Keltjens, 2001;
Baxter et al., 2002; Wolff et al., 2003). In a recent publication, Fitch and colleagues (2003)
used the new Molecular Devices membrane potential-sensitive dye and suggested the FLll'R
membrane potential assay (Molecular Devices, U.K.) provided a more sensitive measure of
nAChR function when compared to the [Ca2+]; assay. These authors showed that they could
detect agonist evoked changes in membrane potential even in those cell lines with little or no
demonstrable [Ca2+]j response (Fitch et al., 2003). Although the establishment of a functional
assay (see later discussion) for human a7 nAChRs proved challenging, the membrane
potential assay was established using the SH-EPl-ha4p2 cell line.
In agreement with Fitch and colleagues (2003), using SH-EPl-ha4p2 cells I showed
that the membrane potential assay provided comparable data to that obtained in previous
[Ca2+]j (Chavez-Noriega et al., 2000) or in 86Rb efflux assays (Marks et al., 1993;
Gopalakrishnan et al., 1996; Eaton et al., 2003; Gentry et al., 2003). In general, agonist
affinities were not significantly different than those obtained in the calcium fluorescence
assay. However, the EC50 value obtained for (±)epibatidine (0.56 ±0.11 nM) in the
membrane potential assay was significantly lower than the EC50 of 1.04 ± 0.11 nM detected
in the calcium fluorescence assay (p < 0.01) whilst the EC50 for cytisine was also significantly
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lower in the membrane potential assay (EC50 = 3.09 ± 0.83 pM, n = 3). These findings may
reflect differences in a4(32 nAChR expression in various cell types. For example, in the
current study human a4p2 nAChRs were expressed in the SH-EP1 cell line while Fitch and
colleagues (2003) used human a4p2 nAChRs expressed in K-177 cells and rat a4p2 nAChRs
expressed in KXa4p2R2 cells.
All agonists examined in the human a4p2 nAChR membrane potential assay, with
the exception of cytisine (Figure 5.10, pg 178), produced a concentration-dependent increase
in fluorescence, with a Hillslope close to unity. Although some researchers (including
ourselves) have shown that [2H]-cytisine binds to a single site (Chapter 3, Section 3.4.2, pg
65; Gopalakrishnan et al., 1997; Sabey et al., 1999), two-site binding has been observed for
cytisine in electrophysiological experiments (Buisson et al., 1996). The antagonist potency
for MLA (415 nM, Figure 5.11, pg 179) determined using the membrane potential assay is
slightly lower than that determined using the 86Rb efflux assay (6.6 pM, Chavez-Noriega et
al., 2000), electrophysiology (1.5 pM, Buisson et al., 1996), or indeed using the calcium plus
assay (875 nM). Furthermore, an additional 2.5 mM external Ca2+ decreased depolarisation
of SFI-EPl-ha4p2 cells in the membrane potential assay (Figure 5.9, pg 177) whereas (-
)nicotine evoked changes in [Ca2+]i response were increased in the presence of higher
external Ca2+ concentrations (Figure 5.2, pg 167).
In my hands, the membrane potential assay appeared to provide a highly sensitive
alterative to measure human a4p2 nAChR functional response with comparable data to
calcium assays and 86Rb efflux studies (Marks et al., 1993; Chavez-Noriega et al., 2000;
Eaton et al., 2003; Fitch et al., 2003; Gentry et al., 2003). However, in agreement with the
calcium assay observations, neither soluble nor insoluble human APi_42 inhibited (-)nicotine
evoked changes in membrane potential (Figures 5.13 - 5.15) in SH-EPl-ha4p2 cells.
5.6.4. Whole Cell Patch Clamp Electrophysiological Analysis of Human a4p2
nAChRs
Although the calcium and membrane potential assays proved to be useful tools for
assessing the functional interaction of compounds with receptors, electrophysiological
analysis of single cells allows more detailed investigation of the functional viability of
receptors in cells and tissues and avoid some of the difficulties such as ligand penetration and
sensitivity issues surrounding cell-based plate dye assays. Patch clamp electrophysiological
recording was first described by Bert Sakmann and Erwin Neher in 1978 for which they
subsequently received the Nobel Prize in Medicine or Physiology in 1991. This technique
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revolutionised the discipline of physiology, allowing the study of the behaviour of single ion
channels or currents in small cells or macro-patches. I have successfully established a
protocol to assess the functional viability of human CX4P2 nAChRs expressed in SH-EP1 cells
using whole cell patch clamp electrophysiology and have subsequently characterised the
pharmacological properties of this channel prior to assessing the effects of P-amyloid.
As expected, and in agreement with previous studies using rat and human a4p2
nAChRs (Sudweeks & Yakel, 2000; Wu et al., 2004), an inward current was detected
following application of (-)nicotine to the SH-EP l-ha4p2 cells with the agonist log
concentration-response profde showing a simple, sigmoidal shape (Figure 5.19, pg 191). The
EC50 value for (-)nicotine (22 pM) at human a4p2 nAChRs was slightly higher than in other
studies using this receptor expressed in SH-EP1 cells (3.2 pM, Wu et al., 2004) or human
embryonic kidney cells (HEK293; 1.6 pM, Buisson et al., 1996), perhaps reflecting the
presence of rundown in the current study. In addition, the nAChR antagonist d-TC inhibited
(-)nicotine evoked responses, with 10 pM d-TC producing a rightward shift in the (-)nicotine
concentration-response curve and a change in (-)nicotine EC50 from 22.2 ± 2.2 to 31.4 ± 7.8
pM (Figure 5.19, pg 191).
When (-)nicotine was applied at 3 min intervals to cells in which cc4p2 nAChRs
have been heterologously expressed, the current underwent "rundown", declining in
amplitude with each successive application of agonist (Figure 5.18). This phenomenon is not
exclusive to ha4p2 nAChRs with rundown reported for a7 nAChRs when expressed in SH-
EP1 cells (Zhao et al., 2003). Nor is it restricted to the SH-EP1 cell line with rundown
reported in P2X receptors expressed in HEK293 cells (Surprenant et a/., 2000), voltage-gated
Ca2+ current responses in dissociated thalamic neurons (Huguenard & Prince, 1994), and
GABAA-induced currents in dissociated neurons (Kapur et al., 1999). Attempts were made to
minimise rundown in order to avoid compromising an accurate evaluation of ligand
concentration-response relationships. Indeed, Zhao and colleagues (2003) showed the use of
a K+-free pipette solution completely abolished rundown of (-)nicotine-induced currents in
the SH-EP l-ha7 cell line. Furthermore Wu and colleagues (2004) working on cells
expressing the ha4p2 nAChR, minimised rundown by using the same pipette solutions as that
described by Zhao and colleagues (2003). Although the pipette and bath solutions were
identical to those described above, no reduction in functional rundown of the (-)nicotine
evoked currents in SH-EP l-ha4p2 cells was observed. However, increasing the time between
(-)nicotine applications combined with the K+-free pipette solution reduced rundown to a
level where measurements could be taken within the initial 15 minutes of recording. Because
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assay conditions were kept as close as possible to those of Wu and colleagues (2004) / Zhao
and colleagues (2003) it is difficult to explain the differences in cellular rundown. However,
it is possible that the design of our application system resulted in a higher likelihood of cell
desensitisation rather than rundown. Indeed, a fundamental difference in the assay procedure
used by Zhao and colleagues (2003) and Wu and colleagues (2004) and the present
experiments is that the former used a U-tube delivery system and we used an eight-barrel
manifold with a single outlet. This could result in a small amount of deadspace between the
single outlet tube and therefore, potentially small variations in applied drug concentrations.
I have demonstrated that the SH-EPl-ha4p2 nAChR cell line expresses functional
human a4p2 nAChRs with appropriate pharmacology and, as such, demonstrated that it is a
viable model to study the potential interaction of human APi_42 on human a4p2 nAChR
function.
5.6.5. Human Ap^ Does Not Inhibit (-)Nicotine Evoked Currents in SH-EPI-ha4p2
Cells
Although several reports have now indicate that Ap inhibits a7 nAChRs (Wang et
al., 2000a; Wang et al., 2000b; Dineley et al., 2001; Liu et al., 2001; Pettit et al., 2001;
Tozaki et al., 2002; Dineley et al., 2002a; Grassi et al., 2003) there is considerably less data
on the effects ofAp on non-a7 nAChR subtypes (Pettit et al., 2001; Tozaki et al., 2002; Fu &
Jhamandas, 2003; Wu et al., 2004). Pettit and colleagues (2001) suggested that APi„42
inhibits carbachol-induced currents in rat hippocampal slices, currents that are composed of
contributions from the activation of non-a7 nAChRs and recorded in the presence of atropine
to block muscarinic AChR responses. This data was supported by Fu and Jhamandas (2003)
who observed that Ap activated non-a7 nAChR subtypes in rat basal forebrain membranes,
where the predominant nAChR subunit is the a4 nAChR (Perry et al., 2002). Direct evidence
for an interaction between a4p2 nAChR and Ap,_42 specifically was presented by Tozaki and
colleagues (2002) who showed Api_42 induced inhibition of ACh-induced currents at rat a4p2
nAChRs following expression in Xenopus oocytes. Furthermore, Wu and colleagues (2004)
recently demonstrated that APi_42 inhibited ACh and (-)nicotine-evoked currents in the same
SH-EP1 cell line used in the current studies. All of the above mentioned studies used a range
of different vehicles to dissolve APi_42 and assess its potential interaction with both the rat
and human a4p2 nAChRs. In direct contrast to these four studies, I could find no evidence
that human APi_42 inhibits (-)nicotine evoked currents in SFI-EPl-ha4p2 cells. Indeed,
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Rpeptide APi_42 (100 nM or 300 nM) did not inhibit (-)nicotine evoked currents in SH-EP1-
ha4p2 cells despite assay conditions (e.g. pipette and external solutions, cell line, Ap,.42
supplier, etc) being kept identical to those used by Wu and colleagues (2004)(Figures 5.37 &
5.40). P-Amyloidi.42 was preincubated with SH-EPl-ha4p2 cells therefore it is unlikely the
lack of inhibition in the current study could be explained by APi_42 not having adequate time
to reach its binding site on the nAChR. Indeed, the time allowed for preincubation (6 min) is
consistent with other studies (Tozaki et al., 2002; Wu et al., 2004). Furthermore, it is
unlikely that the choice in delivery system (U-tube or eight barrel manifold) would
significantly affect the end result as no difference in the slope of the (-)nicotine evoked
responses was observed (Chapter 4, Section 5.3.3). As stated in Section 5.6.4, the EC50 value
for (-)nicotine at the a4p2 nAChR was slightly higher to that obtained in other studies
(Buisson et al., 1996; Papke et al., 2000; Wu et al., 2004) possibly reflecting the difficulty of
obtaining estimates of ECjo in the presence of rundown. However, both this study and that by
Wu and colleagues (2004) used EC25 to assess the effect of APi_42 on (-)nicotine evoked
currents in SH-EPl-ha4p2 cells.
It is important to note that only Liu and colleagues (2001) and ourselves present
control vehicle data for nAChR and Ap studies. Vehicle effects with solutions such as 5 %
acetic acid and 50/50 DMSO/Tris HC1 are not unexpected (Figures 5.32 and 5.35,
respectively). However, although HEPES, a calcium-buffering solution has been used as a
weak ligand in nAChR structure studies (Artali et al., 2005; Brejc et al., 2002) it was
surprisingly to find it was such a potent inhibitor of (-)nicotine evoked responses at human
a4p2 nAChRs (Figures 5.23 and 5.29). This finding does not appear to be an artefact of pH as
APi_42 samples were always adjusted to pH 7.4. The lack of control AP vehicle data
presented in other studies (Wang et al., 2000a; Wang el al., 2000b; Pettit et al., 2001; Tozaki
et al., 2002; Dineley et al., 2002a; Fu & Jhamandas, 2003; Grassi et al., 2003; Wu et al.,
2004; Lamb et al., 2005) may simply reflect that these researchers found no evidence of
inhibition by their respective vehicles and, as such, chose not to present these results.
However, the current study found significant and equivalent inhibition of (-)nicotine evoked
currents by APi.42 and its vehicle, emphasising the necessity of presenting experimental
controls, even when using seemingly innocuous solutions such as HEPES.
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5.6.6 The Human a4 and a7 nAChR Subunits Do Not Co-Immunoprecipitate with
Human Api_42
The lack of a direct functional interaction between the nAChR subtypes, a4p2 and
a7 and APi_42 does not exclude the possibility of a more indirect interaction between these
receptors and the peptide. Indeed, previous studies have reported co-localisation and co-
immunoprecipitation of nAChRs and APi_42 (Wang et al., 2000a; Nagele et al., 2002).
Consequently, studies were performed to determine whether the human a4p? and a7 nAChRs
co-immunoprecipitate with human APi_42.
Western analysis revealed clear protein bands at 60, 55, and 3 kDa using anti-a4,
anti-a7, and anti-APi_42 antibodies, respectively (Figures 5.43, 5.48, & 5.50). Furthermore,
successful immunoprecipitation of anti-a4 and anti-Ap,_42 antibodies (but not anti-a7
antibodies) has also been demonstrated (Figures 5.44 & 5.51). The a4 protein band at 60 kDa
is consistent with the molecular weight predicted by the amino acid sequence (Elliott et al.,
1996) and comparable with previous studies who observed protein bands between 52 kDa
(Guan et al., 2000; Wu et al., 2004) and 70 kDa (Elliott et al., 1996; Burghaus et al., 2003).
Likewise, the 55 kDa protein band detected is consistent with the predicted amino acid
sequence for the a7 nAChR subunit (Peng et al., 1994b) and comparable with previous
studies analyses of a7 nAChR subunit western blots (Schoepfer et al., 1990; Gotti et al.,
1994; Orr-Urtreger et al., 1997; Burghaus et al., 2003; Williams et al., 2005). Finally, P-
amyloidi_42 ranges in its molecular weight from 3-10 kDa depending on the presence of
monomers, dimers, and other aggregates (Mak et al., 1994; Wiltfang et al., 1997; Fay et al.,
1998; Wang et al., 2000a; Walsh et al., 2002a; Walsh et al., 2002b). As such, the protein
band detected at 3 kDa is consistent with a mainly monomeric solution (Wiltfang et al., 1997;
Fay et al., 1998; Walsh et al., 2002a).
Regardless of extensive optimisation of a7 nAChR Western blots,
immunoprecipitation of anti-a7 nAChR antibodies proved unsuccessful and hence, co-
immunoprecipitation of the human a7 nAChR could not be performed. Although both the
anti-a7 nAChR antibodies examined in the immunoprecipitation were successfully used in
Western blot experiments, the possibility remains that one or the other is not suitable for
immunoprecipitation studies. Indeed, the antigen epitope may not be available to bind the
anti-a7 nAChR immunoprecipitation antibody or the immunoprecipitation antibody itself
may bind too weakly to be carried through the immunoprecipitation procedure. Furthermore,
although many reports have demonstrated Western analysis of the a7 nAChR in rodent and
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chick brain extracts using monoclonal antibodies from clones 306 and 319 (Schoepfer et al.,
1990; Orr-Urtreger et al., 1997; Dineley et al., 2001; Fabian-Fine et al., 2001) many of these
reports have used non-commerical antibodies. Reference must also be made to a recent study
in which the commercially available anti-017 nAChR antibodies used in the current study were
shown to recognise multiple protein bands on a Western blot (Herber et al., 2004). As such,
care must be taken when choosing the appropriate antibody for both the immunoprecipitation
and Western blot analysis. Moreover, the current study may be limited by use of
commercially available antibodies only and their questioned specificity for the a7 nAChR
(Flerber et al., 2004).
Co-immunoprecipitation is most commonly used to identify a target protein and
any other molecules that interact with it. Despite multiple attempts, there is no evidence that
the human a4 nAChR subunit and human Ap^ co-immunoprecipitate.
5.6.7 Functional Human a7 nAChRs are not Stably Expressed in the SH-EPl-ha7
Cell Line
The failure to demonstrate a functional interaction between the a7 nAChR and APi_
42 using fluorescence based assays or whole cell patch clamp, was possibly a result of the lack
of consistent expression of functional human a7 nAChRs in the SH-EP1 cell line. Indeed, a7
nAChRs are notoriously difficult to express in mammalian cell lines (Cooper & Millar,
1997). Pharmacological, electrophysiological, and biochemical techniques have been utilised
by ourselves and others to examine the over-expression of the a7 nAChR in SH-SY5Y
(Puchacz et al., 1994), GFI4C1 (Quik et al., 1996; Blumenthal et al., 1997; Cooper & Millar,
1997), PC12 (Blumenthal et al., 1997; Cooper & Millar, 1997; Rangwala et al., 1997), and
SH-EP1 cell lines (Peng et al., 1999; Zhao et al., 2003) with varying degrees of success.
Certainly, we have successfully characterised [?H]-MLA binding to the human a7 nAChR
(over-expressed in SH-EPl-ha7 cells or GH4C1) in Chapter 3, Section 3.5 and Chapter 4,
Section 5.4, respectively. We have successfully characterised ligand binding to the human a7
nAChR over-expressed in the SH-EPl-ha7, GFI4C1, and IMR32 cells (Chapter 3, Section
3.5). However, the binding of a radioligand to a receptor does not require it to be fully
assembled. Indeed, the a7 nAChR can exist in various states of assembly including trimers,
tetramers, pentamers, as well as aggregates of the subunits (Nicke et al., 2004).
The reasons for inadequate heterologous expression of the a7 nAChR are poorly
understood although it appears that expression is host-cell dependent (Cooper & Millar, 1997;
Sweileh et al., 2000). The SH-EP1 cell line stably expressing the human a7 nAChR was first
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reported in the late 1990's (Peng et al., 1999). However, other reports have indicated that the
problems associated with a7 nAChR expression in other cell lines (Puchacz et al., 1994; Quik
et al., 1996; Blumenthal et al., 1997; Cooper & Millar, 1997; Rangwala et al., 1997; Rakhilin
et al., 1999) are also present in the SH-EPl-ha7 cell line (Dunckley et al., 2003; Schroeder et
al., 2003). Moreover, personal communication with Dr R. J. Lukas, whose laboratory
developed the SH-EPl-ha7 cell line (Peng et al., 1999), suggests not all SH-EPl-ha7 cells
have currents and that surface expression is erratic from passage to passage. Considerable
research has focussed on finding methods that increase cell surface expression including
altering cell culture conditions (Molinari et al., 1998; Schroeder et al., 2003; Zhao et al.,
2003), generation of a7 nAChR chimeras with the 5-hydroxytryptamine type-3 (5HT3)
receptor (Eisele et al., 1993; Papke et al., 2004), and site directed mutagenesis (Chen et al.,
1998; Dineley & Patrick, 2000; Dunckley et al., 2003).
To form functional nAChRs at the cell surface, the a7 nAChR must undergo
protein folding and assembly in the endoplasmic reticulum (ER) and gain complex
carbohydrates in the Golgi apparatus before subsequent trafficking to the cell surface (Nicke
et al., 2004). Recently, the ric-3 gene was identified as a requirement for maturation of
nAChRs in Caenorhabditis elegans (Halevi et al., 2002). Subsequently, identified as a
member of a conserved gene family (Halevi et al., 2003), its human equivalent is known as
hric3 (Williams et al., 2005). Although, ric-3 was originally thought to be directly involved
in a7 nAChR trafficking (Halevi et al., 2002; Halevi et al., 2003), co-expression of hric-3
with the human a7 nAChR indicates that ric-3 facilitates the correct folding and assembly of
a7 nAChR subunits in the ER (Williams et al., 2005). Furthermore, ric-3 has been shown to
promote trafficking of the 5HT3 receptor perhaps partially explaining the success of the a7
nAChR-5HT3 chimera (Eisele et al., 1993; Papke et al., 2004; Castillo et al., 2005; Cheng et
al., 2005) and has recently been shown to significantly enhance levels of functional a4(32
nAChRs expressed in mammalian cell lines (Lansdell et al., 2005).
Although our laboratory has had intennittent functional expression of human a7
nAChRs expressed in the SH-EP1 cell line, my studies found no evidence for functional
stably expressed human a7 nAChRs in the SH-EPl-ha7 cell line, despite the use of calcium
and membrane potential fluorescence assays and whole cell patch clamp electrophysiology.
Furthermore, although others have shown that pre-treatment of SH-EPl-ha7 cells with low-
concentrations of the a7 nAChR specific antagonist MLA enhances surface expression
(Molinari et al., 1998; Zhao et al., 2003), this finding was not replicated in the current study
(Chapter 4, Section 5.4). Studies employing transient transfections or cell lines expressing
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native a7 nAChRs also generally failed to result in high enough receptor numbers to be
detected by any of the above functional methods. However, some limited data was obtained
from human a7 nAChRs expressed in the GH4C1 cell line (Chapter 4, Section 5.4).
There are a number of factors associated with low functional expression. These
include the presence of mRNA but no protein formation, receptors are simply not surface
expressed, or surface expression of an incorrectly folded a7 nAChR. Experiments performed
by our laboratory have determined the presence of both a7 nAChR mRNA and protein in the
SH-EPl-ha7 cell line and as such replication of these studies has not been performed in the
current study. Therefore, the most likely explanation for the discrepancies between our
results and the a7 nAChR-mediated currents detected by the Lukas laboratories (Peng et al.,
1999; Schroeder et al., 2003; Zhao et al., 2003; Peng et al., 2005) may be due to fluctuations
in ric-3 and a7 nAChR expression within the SH-EPl-ha7 cell line. Further study is required
to assess the exact relationship between a7 nAChRs and ric-3 expression in the SH-EPl-ha7
cell line.
4.7 CONCLUSIONS
In order to pharmacologically characterise the human a4p2 and a7 nAChRs, I have
established 3 separate functional assays; the calcium plus assay, the membrane potential
assay, and whole cell electrophysiology of SH-EPl-ha4p2 cells. These assays have verified
that SH-EPl-ha4p2 cells are a useful tool to study the function of the human a4p2 nAChR.
Furthermore, I have confirmed that the membrane potential assay determines ligand affinities
at a4p2 nAChRs that are comparable with or more sensitive than those obtained using the
calcium plus assay. Despite the successful development of these assays, I could find no
evidence of a direct interaction between the human a4p2 nAChR and human APi_42.
Unfortunately, measurement of functional a7 nAChR responses was hampered by the lack of
consistent functional expression of these receptors in the SH-EPl-ha7 cell line. In addition,
the human a4 subunit did not co-immunoprecipitate with human Api_42 and although a clear
a7 nAChR protein band was detected using Western blot analysis, the protein was not
detected by immuno- or co-immunoprecipitated.
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6.0 Overall Conclusions
Research into Alzheimer's Disease has focused upon the cholinergic hypothesis
(where loss of the cholinergic system precedes that of other neurotransmitter systems) and
the Ap hypothesis (where Ap is critically responsible for the neurodegeneration observed in
AD brains), both of which have been examined separately in many respects. In the last 10
years, some of the research linking the two theories was mainly circumstantial such as (-
)nicotine being shown to protect cultured rat cortical neurons against Ap-induced toxicity
(Kihara et al., 1997, 1998). It is six years since two pivotal papers were published by Wang
and colleagues (2000a,b) directly linking the cholinergic and amyloid hypotheses by
showing that Ap,.42 bound with picomolar affinity to the a7 nAChR. Subsequent to these
studies, a substantial body of literature has appeared indicating a direct and indirect
interaction of Ap with the a4p2 and a7 nAChRs in AD aetiology (Dineley et al., 2001;
2002a,b; Guan et al., 2001; Liu et al., 2001; Pettit et al., 2001; Shimohama & Kihara, 2001;
Apelt et al., 2002; Bednar et al., 2002; Nordberg et al., 2002; Tozaki et al., 2002; Fu &
Jhamandas, 2003; Grassi et al., 2003; Klingner et al., 2003; Flellstrom-Lindahl et al., 2004;
Martin et al., 2004; Wu et al., 2004; de Fiebre & de Fiebre, 2005; Lamb et al., 2005)
although concerns with both of these hypotheses remain. These include whether it is the
soluble or insoluble forms of Ap,.42 that is neurotoxic (Walsh et al., 1997, 2002a,b; Teplow
et al., 1998; Conway et al., 2000; Bitan et al., 2003; Blanchard et al., 2003; Oddo et al.,
2003; Billings et al., 2005; Crowther et al., 2005), and with which nAChR (or indeed both)
AP, _42 may interact. In light of the work by Wang and colleagues (2000a,b), to date, the
majority of papers initially published focused on the interaction of (soluble) Ap,_42 and the
a7 nAChR (Dineley et al., 2001, 2002a; Kihara et al., 2001; Liu et al., 2001; Pettit et al.,
2001; Tozaki et al., 2002; Grassi et al., 2003). However, it is clear that more studies are now
examining the possibility of an interaction between the a4p2 nAChR and Ap,_42 (Kihara et
al., 1998; Guan et al., 2001; Liu et al., 2001; Tozaki et al., 2002; Dineley et al., 2002a; Fu &
Jhamandas, 2003; Grassi et al., 2003). It is interesting to note that no single study has
systematically compared the effects of soluble and insoluble forms of Ap,_42 at either nAChR
subtype, choosing instead to examine a single soluble form of Ap,_42 per study.
In the current study, I have attempted to address the type of nAChR involved in
any potential interaction with Ap,_42. In addition to examining a variety of different vehicles
that promote formation of both soluble and insoluble (aggregated) forms of Ap,_42. To do
this, radioligand binding assays ([JFI]-epibatidine, ['Hj-cytisine, [3H]-MLA, and [JH]-aBgTx
binding assays) were established to characterise the pharmacology of rodent and human ot4p2
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and a7 nAChRs. Furthermore, the degree of (3-sheet aggregation was assessed in a range of
vehicles using a thioflavin T assay and the functional interaction between human a4p2 and a7
nAChRs over-expressed in the SH-EP1 cell line and human Api_42 explored using an array of
functional assays (intracellular calcium and membrane potential fluorescence assays, and
whole-cell patch clamp electrophysiology). The co-localisation of human A(3i_42 with the
human a4(32 and a7 nAChRs using co-immunoprecipitation was also examined.
Using these approaches several conclusions can be drawm. (1) A range of
pharmacological ([3H]-epibatidine, [3H]-cytisine, [TIJ-MLA, & [3H]aBgTx binding assays)
and functional assays (calcium and membrane potential fluorescence assays and whole-cell
patch-clamp electrophysiology) with which to study human, rat, and mouse a4p2 and a7
nAChRs were successfully introduced. (2) Nicotinic agonists were shown to exhibit a higher
affinity for human a7 nAChRs compared to their rat a7 counterpart. In contrast, no species
difference was evident for agonists at rat and human a4p2 nAChRs. (3) The a7 nAChR
antagonists [3H]-aBgTx and [3H]-MLA bind to different number of binding sites on the a7
nAChR. (4) A thioflavin T assay was established to assess the state of aggregation of APi_42
that occurred in a range of vehicles and when serially diluted in three different assay buffers.
(5) I have also shown that the human a4p2 nAChR and human AP]_42 do not co-
immunoprecipitate. (6) Furthermore, as part of an on-going collaboration within our group,
the (/H]-cytisine and [3H]-MLA binding assays were used to characterise a4p2 and a7
nAChR pharmacology in a7 nAChR-transgenic mice. Aspects of this data has been included
in a published paper (Young et al., 2004) and in one paper currently accepted for European
Journal ofPsychopharmacology. (7) Finally, despite the successful development of a range
of pharmacological and functional assays, no evidence could be presented to show a direct
interaction between the human a4p2 or a7 nAChRs and human APi_42. Furthermore, using
the radioligand binding assays, no interaction between rat a4p2 and a7 nAChRs and rat Ap^
42 was observed. Whilst these results have been extensively discussed in previous sections
(3.9 and 4.6), I will further discuss the observation that the human nAChRs (a4p2 and a7), do
not interact with human APi_42 in the context of on-going literature.
Radioligand binding assays do not assess the overall conformation of the receptor
and it is possible that the lack of interaction observed between the human a4p2 and a7
nAChRs and human APi_42 using radioligand binding assays (Section 3.9.4) does not reflect
either the binding of APi.42 to the receptor or the suitability of the receptor for Ap,_42
binding. However, despite the use of functional assays (calcium and membrane potential
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fluorescent assays and the more conventional whole-cell patch clamp electrophysiology), no
functional interaction between the nAChRs and Ap|.42 was observed.
This lack of interaction between the Api_42 and the nAChRs shown in these studies
may simply be because these receptors and APi„42 do not interact directly with each other.
However, at least two other options exist. There may have been no interaction because (1)
APi_42 itself may not have been in a form that does not interact with these nAChRs or (2) in
the case of the human a7 nAChR, the expression of this receptor in the SH-EP1 cell line was
not stable enough to allow sensitive measurements of functional interaction between this
receptor and Api_42. As there is less reported evidence to suggest a direct interaction
between the a4p2 nAChR and Ap^? (Guan et al., 2000; Liu et al., 2001; Tozaki et al., 2002;
Dineley et al., 2002a; Fu & Jhamandas, 2003; Grassi et al., 2003), it is perhaps possible that
no such interaction actually exists, option one remains a viable reason for the lack of
interaction between the a4p2 nAChR and the peptide in the current study. However, in light
of the growing body of published work in favour of a direct interaction between the a7
nAChR and APj_42, these latter two theories will be examined in more detail.
6.1 Determination of APi_42 P-Sheet Aggregation
As discussed in previous sections (1.3.2.2 and 4.3), there is still no consensus on
which form of APi_42 is neurotoxic (Walsh et al., 1997; 2002a; Teplow et al., 1998; Conway
et al., 2000; Bitan et al., 2003). The examination of Ap^ is complicated because it can
spontaneously aggregate in vitro (Selkoe, 1994; Lendon et al., 1997; Lamb et al., 1999), in
addition to the peptide being present in multiple conformations in vivo including monomers,
oligomers, protofibrils, and mature fibrils (Conroy et al., 1992; Walsh et al., 1997, 2002a;
Teplow et al., 1998; Bitan et al., 2003). To address the issue of multiple conformations and
therefore potentially different responses, human APi_42 was resuspended in a number of
different vehicles to produce soluble, non-fibrillar solutions (Calbiochem Ap,_42 in 5 %
acetic acid, 50/50 DMSO/Tris, or HEPES buffer, or Rpeptide acetate salt in MilliQ water)
and aggregated, fibrillar solutions (Mg2+-free, K+-free PBS at 37°C for 49 h, Calbiochem
APi„42). Indeed, to my knowledge, this is the first study to compare the solubility of the APi.
42 in a range of vehicles and what effect serial dilution had on the composition of the
solution. As expected, once resuspended and serially diluted, none of the APm2 solutions
used in this study (with the exception of the aggregated APi.42) exhibited P-sheet aggregation
despite the use of AP;.42 concentrations ranging from picomolar to millimolar (Section
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3.7.1). Furthermore, none of the APi.42 solutions examined inhibited [3H]-cytisine or [3H]-
MLA binding (Section 3.9.4) or any of the nAChR responses in the functional assay panel
(Sections 4.2.1.4, 4.2.3.2, and 4.3.3). It is interesting to note that Grassi and colleagues
(2003) suggest that there is batch to batch variation between different lots of Ap|.42.
Although a systematic study of APi_42 from different lots was performed, in the current study
the human (or rat) AP)_42 used was purchased from Calbiochem for all soluble APi_42
solutions, and these Ap,_42 samples did cover a range of lot numbers. Furthermore, in some
electrophysiological experiments AP)_42 from Sigma® (U.K.) was used with the same null
result (data not shown) as well as from Ap,.42 from Rpeptide®. Therefore, because I used
vehicles used in previous studies (Wang et al., 2000a,b; Liu et al., 2001; Pettit et al., 2001;
Grassi et al., 2003), and unless each batch lot of APi_42 examined was non-viable, it is
unlikely that the observed lack of interaction between the nAChRs and APi_42 in the current
study is the result of the form of Api_42.
6.2 Expression of nAChRs in the SFI-EP1 Cell Line
The successful binding of [3FI]-cytisine and [3H]-MLA to SH-EPl-ha4p2 and SH-
EPl-ha7 membrane preparations, respectively, does not necessarily prove that the receptors
are correctly inserted into the plasma membrane of the SH-EP1 cells. Therefore, it was
critical to perform functional studies to assess the interaction of both nicotinic compounds
and Ap,_42 with these receptors. In the current study, expression of functional human a4p2
nAChRs was confirmed in the SH-EPl-ha4p2 cell line (Sections 4.2.1.3, 4.2.2.3 and 4.3.2)
allowing analysis of any interaction between this receptor subtype and human APi_42 to be
performed. Flowever, no evidence could be provided to show that ApM2 interacted with
human a4p2 nAChRs over-expressed in the SH-EP1 cell line (Sections 4.2.1.4, 4.2.3.2, and
4.3). In contrast, functional expression of the human a7 nAChRs in the SH-EPl-ha7 cell line
was notably intermittently present in some batches of cells and absent in others. Indeed,
problems with expression of the a7 nAChR in neuronal cell lines has already been discussed
(Section 4.6.7). Therefore, the inability to perfonn analysis of any functional interaction
between the human a7 nAChR and human APi_42 may have been compromised. As such,
until functional expression of the human a7 in the SH-EP1 cell line has been consistently
stabilised, I cannot conclusively state that there is no functional interaction between the
human a7 nAChR and human Ap,_42. Likewise, the lack of functional stability may have
affected the co-localisation studies by interfering with the anti-human a7 nAChR antibodies.
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The discovery of the ric-3 gene and its role in the translocation of correctly folded a7
nAChRs to the cell surface has implications for any future studies of a7 nAChR expression
in cell lines. Indeed, any future studies of human a7 nAChRs and human APi.42 need to
include an examination of ric-3 levels in the SH-EPl-ha7 cell line passage to passage and
perhaps co-expression of the ric-3 and a7 nAChR genes to help promote cell surface
expression in the SH-EP1 cell line.
6.3 Recent Publications on the nAChR and APi^2 Interaction
In addition to my own research, recent publications analysing the interaction
between nAChRs and ApM2 only serve to increase the debate. Although Wang and
colleagues (2000a,b) showed Api_42 inhibited [125I]-aBgTx and [3H]-MLA binding to human
a7 nAChRs with picomolar affinity, this finding was not replicated by de Fiebre and de
Fiebre (2005) nor by Dr. R. J. Lukas (personal communication). Furthermore, while Pym
and colleagues (2005) expressed a number of different human nAChRs in Xenopus oocytes
and observed APi_42 antagonised responses at a7 nAChRs, Lamb and colleagues (2005)
found APi_42 preferentially inhibited non-a7 nAChRs in rat hippocampal CA1 interneurons.
The story has recently become even more complicated following a recent publication by Eric
Synder and colleagues (2005). It is well known that N-methyl-D-aspartate glutamate
(NMDA) and a7 nAChRs have potential roles in learning and memory, the disturbance of
which is common in many AD patients (Dineley et al., 2001; D'Angelo et al., 2005). Synder
and colleagues (2005) have brought these observations together by showing a significant
decrease in NMDA1 receptor surface expression on neurons cultured from mice bearing the
APPSWC gene. Moreover, this decrease could be partially inhibited by pre-treatment with the
a7 nAChR antagonists aBgTx and MLA (Snyder et al., 2005). As such, this paper widens
the debate further, implicating an indirect, but critical role for an interaction between APi_42
and the a7 nAChR in learning and memory.
In conclusion, I have successfully developed both pharmacological and functional
assays to study rat and human a4p2 and a7 nAChRs pharmacology whilst some of these
assays have also been used to study these receptors in brain membranes from wildtype and
a7 nAChR transgenic mice. Furthermore, I have studied the interaction of the human a4p2
and a7 nAChRs with APi_42, resuspended in several different vehicles to promote or inhibit
P-sheet aggregation. Flowever, despite this extensive array of experiments, I could find no
253
evidence to support the hypothesis that the human cx4p2 and a7 subtypes directly interact with
human Api.42.
6.4 Future Studies
In order to thoroughly investigate any potential interaction between APi_42 and the
a7 nAChRs, it is necessary to have access to a cell line in which the a7 nAChR is expressed
functionally.
It is well documented that the a7 nAChR is notoriously difficult to express in
mammalian cell lines (Cooper & Millar, 1997). Indeed, in the current studies functional
expression of the a7 nAChR in the SH-EP1 cell line was weak or absent, although other
groups have reported successful expression (Peng et al., 2005). Recent studies have
identified the gene ric-3 gene to be a requirement for maturation of nAChRs (Halevi et al.,
2002) with subsequent studies indicating that this gene facilitates the correct folding and
assembly of the a7 nAChR in the endoplasmic reticulum (Williams et al., 2005). It would be
interesting to re-examine the SH-EPl-ha7 nAChR cell line as a potential tool for functional
a7 nAChR expression, by examining to what extent the ric-3 gene is present in the cell line
whether its expression in the SH-EPl-ha7 cell line alters through passages. Indeed, it would
also be interesting to examine whether co-expression of ric-3 and the a7 nAChR would
produce a more stable functional cell line.
In addition I would like to examine other models of AD. As mentioned
previously, the a7 nAChR-null mice data presented in this thesis is part of an on-going
collaboration within our Institute (Fujisawa Institute of Neuroscience in Edinburgh, now
Astellas Centre for Neuroscience in Edinburgh). We are cross-breeding the a7 nAChR-null
mice with mice in which the human APPSWC gene has been over-expressed. We hope that this
double-transgenic model will allow a full in vivo assessment of any nAChR/APi_42
interaction. As such, a4p2 and a7 nAChR pharmacology will be assessed in mice over-
expressing the APPSWC gene only and in a7 nAChR-null mice expressing the APPswe gene
(double transgenic). A further potential model of interest is Caenorhabiditis elegans. Dr
Christopher Link (University of Colorado, U.S.A.) has successfully expressed human APP in
C. elegans, leading to substantial amyloid deposit within the animal (Link, 1995). In
contrast to rodent models where amyloid deposition may take many weeks or months,
amyloid deposition in C. elegans is visible within days of transfection and may be assessed
using the p-sheet specific dye thioflavin S and confocal imaging (Link, 1995; Fay et al.,
254
1998; Link et ai, 2001). As such, this animal may represent a new and novel method of
assessing the effect of nicotinic agonists and antagonists on Ap deposition.
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